

```
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS 22:CLASS
23:CLASS
```

26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 37:CLASS  
38:CLASS 39:CLASS 40:CLASS 42:CLASS 43:CLASS 44:Atom 45:CLASS 46:Atom 47:Atom 48:Atom  
49:Atom 50:CLASS 51:CLASS 54:CLASS 55:CLASS 56:Atom 57:Atom 58:Atom 59:CLASS 60:CLASS  
61:CLASS 62:CLASS 65:CLASS 66:CLASS 67:CLASS 68:CLASS 71:CLASS 72:CLASS 73:Atom  
76:CLASS 77:CLASS 78:Atom 86:CLASS 87:CLASS 88:CLASS

Generic attributes :

73:  
Saturation : Saturated  
78:  
Saturation : Saturated  
86:  
Saturation : Saturated  
Number of Carbon Atoms : less than 7  
88:  
Saturation : Saturated  
Number of Carbon Atoms : less than 7

Element Count :

Node 73: Limited  
N,N1

Node 78: Limited  
N,N1

10/568,367

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840


L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10568367 (amd).str



chain nodes :

19 20 22 23 26 27 28 29 30 31 32 37 38 39 40 42 43 45 50 51 54  
55 59 60 61 62 65 66 67 68 71 72 73 76 77 78 86 87 88

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 46 47 48 49 56  
57 58

chain bonds :

2-20 3-22 4-23 6-19 7-39 8-38 9-37 10-42 11-20 12-40 15-19 26-27 28-29  
30-31 30-32 45-47 50-51 54-55 55-57 59-60 60-61 61-62 65-66 66-67 67-68  
71-72 72-73 76-77 76-78 87-88



```

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18 46-47 46-49 47-48 48-49 56-57 56-58 57-58
exact/norm bonds :
2-20 3-22 4-23 6-19 7-39 8-38 9-37 10-42 11-20 12-40 15-19 26-27 28-29
30-31 30-32 45-47 59-60 60-61 65-66 66-67 72-73 76-77 76-78 87-88
exact bonds :
46-47 46-49 47-48 48-49 50-51 54-55 55-57 56-57 56-58 57-58 61-62 67-68
71-72
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14 13-18
14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 7 : 13 : 46 : 56 :

```

G1:H,Cl,Br,F,I

G2:H, [\*1], [\*2], [\*3]

G3:H,CH3

G4:CF3,CN, [\*3], [\*4], [\*5], [\*6], [\*7], [\*8], [\*9], [\*10], [\*11], [\*12]

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS
20:CLASS 22:CLASS 23:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS
31:CLASS 32:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 42:CLASS 43:CLASS
44:Atom 45:CLASS 46:Atom 47:Atom 48:Atom 49:Atom 50:CLASS 51:CLASS 54:CLASS
55:CLASS 56:Atom 57:Atom 58:Atom 59:CLASS 60:CLASS 61:CLASS 62:CLASS
65:CLASS 66:CLASS 67:CLASS 68:CLASS 71:CLASS 72:CLASS 73:Atom 76:CLASS
77:CLASS 78:Atom 86:CLASS 87:CLASS 88:CLASS
Generic attributes :
73:
Saturation           : Saturated
78:
Saturation           : Saturated
86:
Saturation           : Saturated
Number of Carbon Atoms : less than 7
88:
Saturation           : Saturated
Number of Carbon Atoms : less than 7

```

Element Count :  
Node 73: Limited  
N,N1

Node 78: Limited  
N,N1

L3           STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4    QUE L3 AND L1 NOT L2

=> d 14

L4 HAS NO ANSWERS

L1               SCR 1840

L2               SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3               STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -   AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

L4               QUE   L3 AND L1 NOT L2

=> s 14 sss sam

SAMPLE SEARCH INITIATED 11:49:30 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -       1389 TO ITERATE

100.0% PROCESSED       1389 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:   ONLINE   \*\*COMPLETE\*\*

BATCH   \*\*COMPLETE\*\*

PROJECTED ITERATIONS:       25545 TO       30015

PROJECTED ANSWERS:           768 TO       1712

L5               50 SEA SSS SAM L3 AND L1 NOT L2

=> => s 14 sss ful

FULL SEARCH INITIATED 11:51:18 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -       28174 TO ITERATE

100.0% PROCESSED       28174 ITERATIONS

1153 ANSWERS

SEARCH TIME: 00.00.02

L6               1153 SEA SSS FUL L3 AND L1 NOT L2

=> => s 16

L7               64 L6

=> d 16 1-64 bib,ab,hitstr

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> d 17 1-64 bib,ab,hitstr

L7 ANSWER 1 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:1167788 CAPLUS  
 TI Process for the identification of novel enzyme interacting compounds  
 IN Drewes, Gerard; Kuester, Bernhard; Kruse, Ulrich; Hopf, Carsten; Eberhard, Dirk; Bantscheff, Marcus; Reader, Valerie; Raida, Manfred; Middlemiss, David  
 PA Germany  
 SO U.S. Pat. Appl. Publ., 202pp., Cont.-in-part of Appl. No. PCT/EP2006/062984.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20090238808	A1	20090924	US 2007-2222	20071214
	EP 1734367	A1	20061220	EP 2005-12722	20050614
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	WO 2006134056	A1	20061221	WO 2006-EP62984	20060607
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2005-12722	A	20050614		
	US 2005-711399P	P	20050825		
	US 2006-782170P	P	20060314		
	WO 2006-EP62984	A2	20060607		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The present invention relates to methods for the characterization of enzymes or of enzyme-compound complexes, wherein the enzyme is obtained from a protein preparation with the help of at least one broad spectrum ligand immobilized on a solid support and wherein the enzyme is characterized by mass spectrometry. These methods are useful for the screening of non-immobilized compound libraries, selectivity profiling of lead compds. and mechanism of action studies in living cells.

IT 916603-07-1P  
 RL: ARU (Analytical role, unclassified); BUU (Biological use, unclassified); PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (process for identification of novel enzyme interacting compds.)

RN 916603-07-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[4-(aminomethyl)phenyl]-5-fluoro-N4-phenyl- (CA INDEX NAME)



IT 916603-12-8P  
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP  
 (Preparation); RACT (Reactant or reagent)  
 (process for identification of novel enzyme interacting compds.)  
 RN 916603-12-8 CAPLUS  
 CN Carbamic acid, N-[[4-[[5-fluoro-4-(phenylamino)-2-  
 pyrimidinyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX  
 NAME)



L7 ANSWER 2 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:1138168 CAPLUS  
 DN 151:381387  
 TI Preparation of N-(pyrimidinylaminophenyl) sulfonamides as ZAP-70 inhibitors  
 IN Major, Jeremy; Harrison, Richard John; Ramsden, Nigel; Middlemiss, David; Kruse, Ulrich; Drewes, Gerard  
 PA Cellzome Limited, UK  
 SO PCT Int. Appl., 210pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009112490	A1	20090917	WO 2009-EP52789	20090310
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	EP 2008-152568	A	20080311		
	US 2008-138822P	P	20081218		
AB	The title compds. I [R1-R3 = H, halo, CN, etc.; R4-R7, R41 = H, halo, CN, etc.; R8 = H, F, Cl, Br, CN, etc.; R9 = H, (un)substituted alkyl, cycloalkyl, cycloalkylmethyl], useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunol., inflammatory, autoimmune, allergic disorders, and immunol.-mediated diseases, were prepared E.g., a multi-step synthesis of II, starting from 2,4-dichloro-5-fluoropyrimidine and o-phenylenediamine, was given. In general, compds. I are effective for the inhibition of ZAP-70, with an IC50 of <10 µM. The invention also relates to pharmaceutical compns. including compds. I, the preparation of such compds. as well as the use as medicaments.				
IT	1187341-55-4P		1187341-58-7P,		
	N-[2-[[5-Fluoro-2-(3,5-dimethylphenylamino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide		1187341-64-5P,		
	N-[2-[[5-Fluoro-2-(3,5-bis(trifluoromethyl)phenylamino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide		1187341-65-6P,		
	N-[2-[[5-Fluoro-2-(4-trifluoromethylphenylamino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide		1187341-66-7P,		
	N-[2-[[5-Fluoro-2-(4-chloro-3-methoxyphenylamino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide		1187341-67-8P,		
	N-[2-[[5-Fluoro-2-(4-methyl-3-nitrophenylamino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide		1187341-70-3P,		
	N-[2-[[2-(3-Ethoxyphenylamino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide		1187341-71-4P,		
	N-[2-[[2-(3-Acetylphenylamino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide		1187341-77-0P,		
	N-[2-[[2-(3-Chloro-4-methoxyphenylamino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide		1187341-86-1P,		

N-[2-[[2-((3-(Difluoromethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187341-87-2P,  
N-[2-[[2-((4-(Difluoromethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187341-88-3P,  
N-[2-[[2-((4-(Trifluoromethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187341-90-7P,  
N-[2-[[2-((3-(Trifluoromethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187341-92-9P,  
N-[2-[[2-((3-(1,1,2,2-Tetrafluoroethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187341-96-3P,  
N-[2-[[2-((4-Methoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187341-98-5P,  
N-[2-[[2-((3,4-Dimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187341-99-6P,  
N-[2-[[2-((3,5-Dimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-00-2P,  
N-[2-[[2-((3-Methoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-01-3P,  
N-[4-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]thiophene-3-sulfonamide 1187342-03-5P,  
N-[4-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]thiophene-2-sulfonamide 1187342-04-6P,  
N-[4-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]pyridine-3-sulfonamide 1187342-05-7P,  
N-[4-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-1-methyl-1H-imidazole-4-sulfonamide 1187342-06-8P,  
N-[4-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-phenylmethanesulfonamide 1187342-07-9P,  
N-[4-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]benzenesulfonamide 1187342-08-0P,  
N-[4-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-2,2,2-trifluoroethanesulfonamide 1187342-10-4P,  
N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-2,2,2-trifluoroethanesulfonamide 1187342-11-5P,  
N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]benzenesulfonamide 1187342-12-6P,  
N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-phenylmethanesulfonamide 1187342-13-7P,  
N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]thiophene-3-sulfonamide 1187342-15-9P,  
N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]thiophene-2-sulfonamide 1187342-16-0P,  
N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-1-methyl-1H-imidazole-4-sulfonamide 1187342-17-1P,  
N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]pyridine-3-sulfonamide 1187342-19-3P,  
N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]pyridine-2-sulfonamide 1187342-20-6P,  
N-[3-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]thiophene-2-sulfonamide 1187342-21-7P,  
N-[3-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]thiophene-3-sulfonamide 1187342-22-8P,  
N-[3-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-1-methyl-1H-imidazole-4-sulfonamide 1187342-23-9P,  
N-[3-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]pyridine-2-sulfonamide 1187342-24-0P,  
N-[3-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-

fluoropyrimidin-4-yl]amino]phenyl]pyridine-3-sulfonamide  
1187342-26-2P, N-[3-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-  
fluoropyrimidin-4-yl]amino]phenyl]benzenesulfonamide  
1187342-27-3P, N-[3-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-  
fluoropyrimidin-4-yl]amino]phenyl]-2,2,2-trifluoroethanesulfonamide  
1187342-28-4P, N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-  
fluoropyrimidin-4-yl]amino]phenyl]-2-dimethylaminoethanesulfonamide  
1187342-29-5P, N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-  
fluoropyrimidin-4-yl]amino]phenyl]-2-methylaminoethanesulfonamide  
1187342-30-8P, N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-  
fluoropyrimidin-4-yl]amino]phenyl]-2-(morpholin-4-yl)ethanesulfonamide  
1187342-31-9P, N-[3-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-  
fluoropyrimidin-4-yl]amino]phenyl]-2-methylaminoethanesulfonamide  
1187342-33-1P, N-[3-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-  
fluoropyrimidin-4-yl]amino]phenyl]-2-dimethylaminoethanesulfonamide  
1187342-37-5P, N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)pyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-39-7P,  
N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-bromopyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-40-0P,  
N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]-N-methylmethanesulfonamide 1187342-41-1P,  
N-[2-[[2-((3,5-Dimethylphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-  
N-methylmethanesulfonamide 1187342-42-2P,  
N-[2-[[2-((3-Methoxy-4-methylphenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-44-4P,  
N-[2-[[2-((3,4-Dimethoxy-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)-5-  
fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide  
1187342-45-5P, N-[2-[[2-((3,5-Dimethoxy-4-(2-(pyrrolidin-1-  
yl)ethoxy)phenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-48-8P,  
N-[2-[[2-((3-(2-Morpholinoethoxy)phenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-50-2P,  
N-[2-[[2-((3-(2-Hydroxyethoxy)phenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-51-3P,  
N-[2-[[2-((3-(2-Piperidinoethoxy)phenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-52-4P,  
N-[2-[[2-((3-(Methylcarbamoyl)phenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-53-5P,  
N-[2-[[2-((3-(Diethylcarbamoyl)phenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-55-7P,  
N-[2-[[2-((3-((Pyrrolidin-1-yl)carbonyl)phenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-56-8P,  
N-[2-[[2-((3-(Cyclopropylcarbamoyl)phenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-57-9P,  
N-[2-[[2-((3-(Dimethylcarbamoyl)phenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-60-4P,  
N-[2-[[2-((4-(2-Morpholinoethoxy)phenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-61-5P,  
N-[2-[[2-((4-(2-Piperidinoethoxy)phenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-62-6P,  
N-[2-[[2-((3-Methoxy-4-(pyrrolidin-1-yl)phenyl)amino)-5-fluoropyrimidin-4-  
yl]amino]phenyl]methanesulfonamide 1187342-64-8P,  
N-[2-[[2-((4-(2-(4-Methylpiperazin-1-yl)ethoxy)phenyl)amino)-5-  
fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide  
1187342-65-9P, N-[2-[[2-((4-(3-Piperidinopropoxy)phenyl)amino)-5-  
fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide  
1187342-66-0P, N-[2-[[2-((4-(3-(4-Methylpiperazin-1-

yl)propoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-67-1P,  
N-[2-[[2-((4-(3-(Pyrrolidin-1-yl)propoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-70-6P,  
N-[2-[[2-((3-Methoxy-5-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-71-7P,  
N-[2-[[2-((3-(2-(Pyrrolidin-1-yl)ethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-73-9P,  
N-[2-[[2-((4-(2-(Pyrrolidin-1-yl)ethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-74-0P,  
N-[2-[[2-((3-((1-Methylpiperidin-2-yl)methoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-75-1P,  
N-[2-[[2-((3-((1-Methylpiperidin-3-yl)methoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-77-3P,  
N-[2-[[2-((3-(Carboxymethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-79-5P,  
1187342-81-9P, N-[2-[[2-((3-((Ethylcarbonyl)methoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-83-1P,  
N-[2-[[2-((3-(Difluoromethoxy)phenyl)amino)-5-bromopyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-85-3P,  
N-[2-[[2-((3-Methoxy-4-methylphenyl)amino)-5-bromopyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-87-5P,  
N-[2-[[2-((3,5-Dimethoxyphenyl)amino)-5-bromopyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-88-6P,  
N-[2-[[2-((4-Methoxyphenyl)amino)-5-bromopyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-89-7P,  
N-[2-[[2-((3,4-Dimethoxyphenyl)amino)-5-bromopyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187342-91-1P,  
N-[2-[[2-((4-Methoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-N-methylmethanesulfonamide 1187342-92-2P,  
N-[2-[[2-((3,4-Dimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-N-methylmethanesulfonamide 1187342-93-3P,  
N-[2-[[2-((4-(2-Piperidinoethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-N-methylmethanesulfonamide 1187342-95-5P,  
N-[2-[[2-((4-(2-Morpholinoethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-N-methylmethanesulfonamide 1187343-11-8P,  
N-[2-[[2-((3-(2-Hydroxyethoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-12-9P,  
N-[2-[[2-((3-(2-Piperidinoethoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-13-0P,  
N-[2-[[2-((4-Methoxy-3-(2-piperidinoethoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-15-2P,  
N-[2-[[2-((3-(2-Diethylaminoethoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-16-3P,  
N-[2-[[2-((4-(2-Diethylaminoethoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-18-5P,  
N-[2-[[2-((3-((Piperidin-4-yl)methoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-20-9P,  
N-[2-[[2-((3-(2-(2-Oxopyrrolidin-1-yl)ethoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-21-0P,  
N-[2-[[2-((3-(2-(Pyrrolidin-2-yl)ethoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-23-2P,  
N-[2-[[2-((3-(2-(Piperazin-1-yl)ethoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-24-3P,



N-[2-[[2-((3-(3-Piperidinopropoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-26-5P,  
 N-[2-[[2-((3-(3-(4-Methylpiperazin-1-yl)propoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-27-6P,  
 N-[2-[[2-((4-(3-(4-Methylpiperazin-1-yl)propoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-28-7P,  
 N-[2-[[2-((3,4-Dimethoxy-5-isobutoxyphenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-30-1P,  
 N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-31-2P,  
 N-[2-[[2-((4-Methoxyphenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-32-3P,  
 N-[2-[[2-((3-(2-(Pyrrolidin-1-yl)ethoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-33-4P,  
 N-[2-[[2-((3-Methoxy-4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-35-6P 1187343-36-7P 1187343-38-9P 1187343-39-0P,  
 N-[2-[[2-((3-((1-Methylpiperidin-2-yl)methoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-40-3P,  
 N-[2-[[2-((3-((1-Methylpiperidin-3-yl)methoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-41-4P,  
 N-[2-[[2-((3-((1,4-Dimethylpiperazin-2-yl)methoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-42-5P,  
 N-[2-[[2-((4-(Carboxymethyl)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-43-6P 1187343-44-7P,  
 N-[2-[[2-((3-((Diethylcarbamoyl)methoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-46-9P,  
 N-[2-[[2-((3-((Ethylcarbamoyl)methoxy)phenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187343-49-2P,  
 N-[2-[[2-((3,4,5-Trimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-N-ethylmethanesulfonamide 1187343-50-5P,  
 N-[2-[[2-((3,5-Dimethylphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-N-ethylmethanesulfonamide 1187343-52-7P,  
 N-[2-[[2-((4-Methoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-N-ethylmethanesulfonamide 1187343-53-8P,  
 N-[2-[[2-((3,4-Dimethoxyphenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-N-ethylmethanesulfonamide 1187343-54-9P,  
 N-[2-[[2-((4-(2-Piperidinoethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-N-ethylmethanesulfonamide 1187343-55-0P,  
 N-[2-[[2-((4-(2-Morpholinoethoxy)phenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]-N-ethylmethanesulfonamide 1187344-03-1P,  
 N-[2-[[2-((4-Cyanophenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187344-08-6P,  
 N-[2-[[2-((3-Cyanophenyl)amino)-5-fluoropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187344-14-4P,  
 N-[2-[[2-((4-Cyanophenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide 1187344-15-5P,  
 N-[2-[[2-((3-Cyanophenyl)amino)-5-chloropyrimidin-4-yl]amino]phenyl]methanesulfonamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-(pyrimidinylaminophenyl) sulfonamides as ZAP-70 kinase

inhibitors useful in treatment and prevention of ZAP-70-mediated diseases)


RN 1187341-55-4 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-58-7 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(3,5-dimethylphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-64-5 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[[3,5-bis(trifluoromethyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-65-6 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-66-7 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(4-chloro-3-methoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-67-8 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[(4-methyl-3-nitrophenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-70-3 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(3-ethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-71-4 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(3-acetylphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-77-0 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(3-chloro-4-methoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-86-1 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[[3-(difluoromethoxy)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-87-2 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[[4-(difluoromethoxy)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-88-3 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-90-7 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[3-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-92-9 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[3-(1,1,2,2-tetrafluoroethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-96-3 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-98-5 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(3,4-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187341-99-6 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(3,5-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-00-2 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-01-3 CAPLUS

CN 3-Thiophenesulfonamide, N-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187342-03-5 CAPLUS


CN 2-Thiophenesulfonamide, N-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)






RN 1187342-04-6 CAPLUS

CN 3-Pyridinesulfonamide, N-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-05-7 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-1-methyl- (CA INDEX NAME)




RN 1187342-06-8 CAPLUS

CN Benzenemethanesulfonamide, N-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-07-9 CAPLUS

CN Benzenesulfonamide, N-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-08-0 CAPLUS

CN Ethanesulfonamide, 2,2,2-trifluoro-N-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-10-4 CAPLUS

CN Ethanesulfonamide, 2,2,2-trifluoro-N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-11-5 CAPLUS

CN Benzenesulfonamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-12-6 CAPLUS

CN Benzenemethanesulfonamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-13-7 CAPLUS

CN 3-Thiophenesulfonamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-15-9 CAPLUS

CN 2-Thiophenesulfonamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-16-0 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-1-methyl- (CA INDEX NAME)




RN 1187342-17-1 CAPLUS

CN 3-Pyridinesulfonamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-19-3 CAPLUS

CN 2-Pyridinesulfonamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-20-6 CAPLUS

CN 2-Thiophenesulfonamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-21-7 CAPLUS

CN 3-Thiophenesulfonamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-22-8 CAPLUS

CN 1H-Imidazole-4-sulfonamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-1-methyl- (CA INDEX NAME)




RN 1187342-23-9 CAPLUS

CN 2-Pyridinesulfonamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-24-0 CAPLUS

CN 3-Pyridinesulfonamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-26-2 CAPLUS

CN Benzenesulfonamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-27-3 CAPLUS

CN Ethanesulfonamide, 2,2,2-trifluoro-N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-28-4 CAPLUS

CN Ethanesulfonamide, 2-(dimethylamino)-N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-29-5 CAPLUS

CN Ethanesulfonamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-2-(methylamino)- (CA INDEX NAME)




RN 1187342-30-8 CAPLUS

CN 4-Morpholineethanesulfonamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187342-31-9 CAPLUS


CN Ethanesulfonamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-2-(methylamino)- (CA INDEX NAME)



RN 1187342-33-1 CAPLUS


CN Ethanesulfonamide, 2-(dimethylamino)-N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)






RN 1187342-37-5 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-39-7 CAPLUS

CN Methanesulfonamide, N-[2-[[5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-40-0 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N-methyl- (CA INDEX NAME)




RN 1187342-41-1 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(3,5-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]-N-methyl- (CA INDEX NAME)




RN 1187342-42-2 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[(3-methoxy-4-methylphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-44-4 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[[3,4-dimethoxy-5-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-45-5 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[[3,5-dimethoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-48-8 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-50-2 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[3-(2-hydroxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-51-3 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-52-4 CAPLUS

CN Benzamide, 3-[[5-fluoro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1187342-53-5 CAPLUS


CN Benzamide, N,N-diethyl-3-[[5-fluoro-4-[[2-  
[(methanesulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX  
NAME)



RN 1187342-55-7 CAPLUS  
CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[3-(1-  
pyrrolidinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX  
NAME)




RN 1187342-56-8 CAPLUS  
CN Benzamide, N-cyclopropyl-3-[[5-fluoro-4-[[2-  
[(methanesulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX  
NAME)




RN 1187342-57-9 CAPLUS

CN Benzamide, 3-[[5-fluoro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1187342-60-4 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-61-5 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[4-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-62-6 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[3-methoxy-4-(1-pyrrolidinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-64-8 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187342-65-9 CAPLUS


CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[4-[3-(1-piperidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187342-66-0 CAPLUS


CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

NAME )




RN 1187342-67-1 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[4-[3-(1-pyrrolidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187342-70-6 CAPLUS


CN	Methanesulfonamide, N-[2-[[5-fluoro-2-[[3-methoxy-5-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]-	(CA INDEX NAME)
----	--	-----------------




RN 1187342-71-7 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)







RN 1187342-73-9 CAPLUS  
 CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187342-74-0 CAPLUS  
 CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[3-[(1-methyl-2-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-75-1 CAPLUS  
 CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187342-77-3 CAPLUS

CN Acetic acid, 2-[3-[[5-fluoro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)




RN 1187342-79-5 CAPLUS

CN Acetamide, N,N-diethyl-2-[3-[[5-fluoro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1187342-78-4


CMF C23 H27 F N6 O4 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 1187342-81-9 CAPLUS

CN Acetamide, N-ethyl-2-[3-[[5-fluoro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)




RN 1187342-83-1 CAPLUS

CN Methanesulfonamide, N-[2-[[5-bromo-2-[[3-(difluoromethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-85-3 CAPLUS

CN Methanesulfonamide, N-[2-[[5-bromo-2-[(3-methoxy-4-methylphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-87-5 CAPLUS

CN Methanesulfonamide, N-[2-[[5-bromo-2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-88-6 CAPLUS

CN Methanesulfonamide, N-[2-[[5-bromo-2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-89-7 CAPLUS

CN Methanesulfonamide, N-[2-[[5-bromo-2-[(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187342-91-1 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N-methyl- (CA INDEX NAME)




RN 1187342-92-2 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(3,4-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]-N-methyl- (CA INDEX NAME)




RN 1187342-93-3 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[4-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]-N-methyl-  
(CA INDEX NAME)




RN 1187342-95-5 CAPLUS

CN Methanesulfonamide, N-[2-[[5-fluoro-2-[[4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]-N-methyl-  
(CA INDEX NAME)




RN 1187343-11-8 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-(2-hydroxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187343-12-9 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187343-13-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




RN 1187343-15-2 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-[2-(diethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187343-16-3 CAPLUS


CN Methanesulfonamide, N-[2-[[5-chloro-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187343-18-5 CAPLUS


CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-(4-piperidinylmethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)






RN 1187343-20-9 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-[2-(2-oxo-1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187343-21-0 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-[2-(2-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187343-23-2 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-[2-(1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187343-24-3 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-[3-(1-piperidinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187343-26-5 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187343-27-6 CAPLUS


CN Methanesulfonamide, N-[2-[[5-chloro-2-[[4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187343-28-7 CAPLUS  
 CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3,4-dimethoxy-5-(2-methylpropoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187343-30-1 CAPLUS  
 CN Methanesulfonamide, N-[2-[[5-chloro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187343-31-2 CAPLUS  
 CN Methanesulfonamide, N-[2-[[5-chloro-2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187343-32-3 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187343-33-4 CAPLUS


CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-methoxy-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187343-35-6 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-methoxy-4-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]-, hydrochloride (1:?) (CA INDEX NAME)


10/568,367



●x HCl

RN 1187343-36-7 CAPLUS


CN Acetic acid, 2-[4-[[5-chloro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-, 1-methylethyl ester, hydrochloride (1:?) (CA INDEX NAME)



●x HCl


RN 1187343-38-9 CAPLUS

CN Acetic acid, 2-[4-[[5-fluoro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-, ethyl ester, hydrochloride (1:?) (CA INDEX NAME)




RN 1187343-39-0 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-[(1-methyl-2-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187343-40-3 CAPLUS


CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187343-41-4 CAPLUS


CN Methanesulfonamide, N-[2-[[5-chloro-2-[[3-[(1,4-dimethyl-2-piperazinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

10/568,367




RN 1187343-42-5 CAPLUS

CN Benzeneacetic acid, 4-[[5-chloro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1187343-43-6 CAPLUS

CN Acetic acid, 2-[3-[[5-chloro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-, hydrochloride (1:?) (CA INDEX NAME)




●<sub>x</sub> HCl

RN 1187343-44-7 CAPLUS  
 CN Acetamide, 2-[3-[[5-chloro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-N,N-diethyl- (CA INDEX NAME)




RN 1187343-46-9 CAPLUS  
 CN Acetamide, 2-[3-[[5-chloro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)




RN 1187343-49-2 CAPLUS  
 CN Methanesulfonamide, N-ethyl-N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)






RN 1187343-50-5 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(3,5-dimethylphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]-N-ethyl- (CA INDEX NAME)




RN 1187343-52-7 CAPLUS

CN Methanesulfonamide, N-ethyl-N-[2-[[5-fluoro-2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187343-53-8 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(3,4-dimethoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]-N-ethyl- (CA INDEX NAME)




RN 1187343-54-9 CAPLUS

CN Methanesulfonamide, N-ethyl-N-[2-[[5-fluoro-2-[[4-[2-(1-piperidinyloxy)]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187343-55-0 CAPLUS

CN Methanesulfonamide, N-ethyl-N-[2-[[5-fluoro-2-[[4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187344-03-1 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(4-cyanophenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187344-08-6 CAPLUS

CN Methanesulfonamide, N-[2-[[2-[(3-cyanophenyl)amino]-5-fluoro-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187344-14-4 CAPLUS

CN Methanesulfonamide, N-[2-[[5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1187344-15-5 CAPLUS  
 CN Methanesulfonamide, N-[2-[[5-chloro-2-[(3-cyanophenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



IT 1187344-56-4P, 2-(3-((5-Fluoro-4-((2-((methylsulfonyl)amino)phenyl)amino)pyrimidin-2-yl)amino)phenoxy)acetic acid ethyl ester 1187344-66-6P,  
 N-(2-((5-Chloro-2-((3-((1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide 1187344-68-8P, N-(2-((5-Chloro-2-((3-(2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide 1187344-70-2P,  
 N-(2-((5-Chloro-2-((3-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)methanesulfonamide trifluoroacetate 1187344-75-7P,  
 2-(4-((5-Chloro-4-((2-((methylsulfonyl)amino)phenyl)amino)pyrimidin-2-yl)amino)phenyl)acetic acid ethyl ester 1187344-77-9P,  
 2-(3-((5-Chloro-4-((2-((methylsulfonyl)amino)phenyl)amino)pyrimidin-2-yl)amino)phenoxy)acetic acid ethyl ester  
 RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of N-(pyrimidinylaminophenyl) sulfonamides as ZAP-70 kinase inhibitors useful in treatment and prevention of ZAP-70-mediated diseases)


RN 1187344-56-4 CAPLUS

CN Acetic acid, 2-[3-[[5-fluoro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-, ethyl ester (CA INDEX NAME)



RN 1187344-66-6 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[3-[[5-chloro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1187344-68-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[2-[3-[[5-chloro-4-[[2-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


10/568,367



RN 1187344-70-2 CAPLUS  
 CN 1-Piperazinecarboxylic acid, 4-[2-[3-[[5-chloro-4-[[2-  
 [(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]ethyl]-,  
 1,1-dimethylethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 1187344-69-9  
 CMF C28 H36 Cl N7 O5 S




CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 1187344-75-7 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED



RN 1187344-77-9 CAPLUS

CN Acetic acid, 2-[3-[[5-chloro-4-[[2-[(methanesulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]phenoxy]-, ethyl ester (CA INDEX NAME)



IT 1187344-44-0P, N-[2-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]ethanesulfonamide


1187344-45-1P, N-[3-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]ethanesulfonamide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-(pyrimidinylaminophenyl) sulfonamides as ZAP-70 kinase inhibitors useful in treatment and prevention of ZAP-70-mediated diseases)


RN 1187344-44-0 CAPLUS

CN Ethenesulfonamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1187344-45-1 CAPLUS

CN Ethenesulfonamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 3 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:1130268 CAPLUS  
 DN 151:381385  
 TI Preparation of 5-fluoro-4N-phenyl-4-pyrimidinamine compounds and their use  
 as inhibitors of IgE and/or IgG receptor signaling cascades  
 IN Singh, Rajinder; Argade, Ankush; Payan, Donald; Molineaux, Susan; Holland,  
 Sacha J.; Clough, Jeffrey; Keim, Holger; Bhamidipati, Somasekhar; Sylvain,  
 Catherine; Li, Hui; Rossi, Alexander B.  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO U.S., 259pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 7589200	B2	20090915	US 2004-911684	20040803
	US 20050209230	A1	20050922		
	US 20040029902	A1	20040212	US 2003-355543	20030131
	US 7557210	B2	20090707		
	ZA 2005000775	A	20080625	ZA 2005-775	20030729
	US 20050038243	A1	20050217	US 2004-858343	20040601
	US 7060827	B2	20060613		
	ZA 2004005979	A	20070425	ZA 2004-5979	20040727
	US 20060025410	A1	20060202	US 2005-149105	20050608
	US 7329672	B2	20080212		
	US 20060035916	A1	20060216	US 2005-148746	20050608
	US 7329671	B2	20080212		
	US 20060058292	A1	20060316	US 2005-149418	20050608
	US 7332484	B2	20080219		
	US 20060135543	A1	20060622	US 2005-299207	20051208
	US 7435814	B2	20081014		
	US 20070225321	A1	20070927	US 2006-539013	20061005
	US 20070293520	A1	20071220	US 2006-539018	20061005
	US 7498435	B2	20090303		
	US 20070293521	A1	20071220	US 2006-539029	20061005
	US 20070293522	A1	20071220	US 2006-539041	20061005
	US 20070293523	A1	20071220	US 2006-539049	20061005
	US 20070293524	A1	20071220	US 2006-539054	20061005
	US 7485724	B2	20090203		
	US 20080039622	A1	20080214	US 2007-782581	20070724
	US 7550460	B2	20090623		
	US 20090082567	A1	20090326	US 2008-199705	20080827
	US 20090171085	A1	20090702	US 2008-268235	20081110
	US 20090156622	A1	20090618	US 2008-273357	20081118
	AU 2008252053	A1	20090108	AU 2008-252053	20081203
	US 20090171086	A1	20090702	US 2009-363537	20090130
PRAI	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-399673P	P	20020729		
	US 2002-434277P	P	20021217		
	US 2003-355543	A1	20030131		
	AU 2003-208931	A3	20030131		
	US 2004-858343	A3	20040601		
	US 2005-149418	A1	20050608		
	US 2006-539041	A1	20061005		
	US 2006-539054	A3	20061005		

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides 2,4-pyrimidinediamine compds. of formula I that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators; intermediates and methods of synthesizing the compds. and methods of using the compds. in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation

and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. Compds. of formula I wherein R4 is substituted phenyl; LG is a leaving group; and salts, hydrates, solvates, N-oxides and prodrugs thereof, are claimed. Example compound II was prepared by nucleophilic aromatic substitution reaction of 2,4-dichloropyrimidine with 4-ethoxyaniline. All the invention compds. were evaluated for their inhibitory activity fo IgE and/or IgG receptor signaling cascades (some data given).


IT 575484-54-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-phenyl(fluoro)pyrimidinamine compds. as IgE and/or IgG receptor signaling cascade inhibitors useful in the treatment of diseases)

RN 575484-54-7 CAPLUS

CN Benzamide, 3-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)  
 RE.CNT 361 THERE ARE 361 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:1015029 CAPLUS  
 DN 151:280249  
 TI Treatment of acne vulgaris, rosacea and rhinophym with inhibitors of the  
 fibroblast growth factor receptor 2 and insulin-like growth factor 1  
 receptor signal pathways  
 IN Melnik, Bodo  
 PA Germany  
 SO PCT Int. Appl., 39pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009101199	A2	20090820	WO 2009-EP51749	20090216
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI EP 2008-101654 A 20080215  
 EP 2008-154022 A 20080403  
 US 2008-123294P P 20080407  
 EP 2008-164431 A 20080916  
 EP 2008-168765 A 20081110

AB A composition for the treatment of acne vulgaris, rosacea and/or rhinophym comprises at least one inhibitor of the FGFR2 signal pathway and/or IGF1R signal pathway. Also claimed is a bovine milk or a product of bovine milk having a reduced content of hormones, especially progesterone and growth factors, like IGF-1 and IGF-2, FGF1, and FGF2, or having a modified casein which has a reduced influence on IGF-1 levels. Further, use of Metforming for the prevention of adenocarcinomas, cardiovascular diseases and neurodegenerative diseases, is also presented.

IT 761437-28-9


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(as inhibitor of IGF1R tyrosine kinase, as inhibitor of IGF-1 receptor signal pathway; acne vulgaris, rosacea and rhinophym treatment with inhibitors of fibroblast growth factor receptor 2 and insulin-like receptor 1 signal pathways)

RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/568,367



L7 ANSWER 5 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:798948 CAPLUS  
 DN 151:101194  
 TI Preparation of pyrimidinylaminophenyl sulfamide derivatives as ZAP-70 inhibitors  
 IN Harrison, Richard John; Major, Jeremy; Middlemiss, David; Ramsden, Nigel; Kruse, Ulrich; Drewes, Gerard  
 PA Cellzome Limited, UK  
 SO PCT Int. Appl., 75pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009080638	A2	20090702	WO 2008-EP67682	20081217
	WO 2009080638	A3	20091001		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	EP 2007-150227	A	20071220		


OS MARPAT 151:101194

AB Title compds. I [X = (un)substituted phenyl; R1, R2 and R3 independently = H, halo, CN, (un)substituted alkyl, alkenyl, alkynyl, etc.; R8 = H, F, Cl, Br, CN, CH, CH2F, etc.; R9 = H, (un)substituted alkyl, cycloalkyl, cycloalkylmethyl, alkyl, cycloalkyl, cycloalkylmethyl, etc.; ], and pharmaceutically acceptable salts, prodrugs or metabolites, are prepared and disclosed. The invention compds. are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunol., inflammatory, autoimmune, allergic disorders, and immuno logically-mediated diseases. The invention also relates to pharmaceutical compns. including said compds., the preparation of such compds. as well as the use as medicaments. E.g., II was prepared by sulfonation of N'-(3-aminophenyl)-5-fluoro-N-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine (preparation given) with dimethylaminosulfonyl chloride. The compds. of the invention were tested in the ZAP-70 kinobeads assay, e.g., II exhibited IC50 value of < 1  $\mu$ M.

IT 1166389-24-7P, N-[3-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N',N'-dimethylsulfamide  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrimidinylaminophenyl sulfamide derivs. as ZAP-70 inhibitors)

RN 1166389-24-7 CAPLUS

CN Sulfamide, N'-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N,N-dimethyl- (CA INDEX NAME)



IT 1166389-21-4P, N-[3-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]sulfamide  
 1166389-25-8P, N-[3-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-cyclopropylmethylsulfamide 1166389-26-9P,  
 N-[3-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-phenylsulfamide 1166389-27-0P,  
 N-[3-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-benzylsulfamide 1166389-28-1P,  
 N-[3-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-isopropylsulfamide 1166389-29-2P,  
 N-[3-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-ethylsulfamide 1166389-30-5P,  
 N-[3-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-(2-methoxyethyl)sulfamide 1166389-31-6P,  
 N-[3-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-methylsulfamide 1166389-32-7P,  
 N-[2-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]sulfamide 1166389-33-8P,  
 N-[2-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N',N'-dimethylsulfamide 1166389-34-9P,  
 N-[2-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-cyclopropylmethylsulfamide 1166389-35-0P,  
 N-[2-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-isopropylsulfamide 1166389-36-1P,  
 N-[2-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-benzylsulfamide 1166389-37-2P,  
 N-[2-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-(2-methoxyethyl)sulfamide 1166389-38-3P,  
 N-[4-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N',N'-dimethylsulfamide 1166389-39-4P,  
 N-[4-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-ethylsulfamide 1166389-40-7P,  
 N-[4-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-cyclopropylmethylsulfamide 1166389-41-8P,  
 N-[4-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-phenylsulfamide 1166389-42-9P,  
 N-[4-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-isopropylsulfamide 1166389-43-0P,  
 N-[4-[[5-Fluoro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]-N'-(2-methoxyethyl)sulfamide 1166389-44-1P,  
 N-[2-[[2-[(3,4,5-Trimethoxyphenyl)amino]pyrimidin-4-yl]amino]phenyl]sulfamide 1166389-47-4P,  
 N-[2-[[5-Bromo-2-(4-methoxyphenylamino)pyrimidin-4-yl]amino]phenyl]sulfamide 1166389-49-6P,  
 N-[2-[[5-Fluoro-2-(4-methoxyphenylamino)pyrimidin-4-


yl]amino]phenyl]sulfamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidinylaminophenyl sulfamide derivs. as ZAP-70 inhibitors)


RN 1166389-21-4 CAPLUS

CN Sulfamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1166389-25-8 CAPLUS

CN Sulfamide, N-(cyclopropylmethyl)-N'-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1166389-26-9 CAPLUS

CN Sulfamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N'-phenyl- (CA INDEX NAME)




RN 1166389-27-0 CAPLUS

CN Sulfamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N'-(phenylmethyl)- (CA INDEX NAME)




RN 1166389-28-1 CAPLUS

CN Sulfamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N'-(1-methylethyl)- (CA INDEX NAME)




RN 1166389-29-2 CAPLUS

CN Sulfamide, N-ethyl-N'-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 1166389-30-5 CAPLUS


CN Sulfamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N'-(2-methoxyethyl)- (CA INDEX NAME)



RN 1166389-31-6 CAPLUS




CN Sulfamide, N-[3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N'-methyl- (CA INDEX NAME)




RN 1166389-32-7 CAPLUS

CN Sulfamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1166389-33-8 CAPLUS

CN Sulfamide, N'-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N,N-dimethyl- (CA INDEX NAME)




RN 1166389-34-9 CAPLUS

CN Sulfamide, N-(cyclopropylmethyl)-N'-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1166389-35-0 CAPLUS

CN Sulfamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N'-(1-methylethyl)- (CA INDEX NAME)




RN 1166389-36-1 CAPLUS

CN Sulfamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N'-(phenylmethyl)- (CA INDEX NAME)




RN 1166389-37-2 CAPLUS

CN Sulfamide, N-[2-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N'-(2-methoxyethyl)- (CA INDEX NAME)




RN 1166389-38-3 CAPLUS

CN Sulfamide, N'-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N,N-dimethyl- (CA INDEX NAME)




RN 1166389-39-4 CAPLUS

CN Sulfamide, N-ethyl-N'-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1166389-40-7 CAPLUS


CN Sulfamide, N-(cyclopropylmethyl)-N'-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1166389-41-8 CAPLUS  
 CN Sulfamide, N-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N'-phenyl- (CA INDEX NAME)



RN 1166389-42-9 CAPLUS  
 CN Sulfamide, N-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N'-(1-methylethyl)- (CA INDEX NAME)




RN 1166389-43-0 CAPLUS  
 CN Sulfamide, N-[4-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]-N'-(2-methoxyethyl)- (CA INDEX NAME)




RN 1166389-44-1 CAPLUS  
 CN Sulfamide, N-[2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)

10/568,367




RN 1166389-47-4 CAPLUS

CN Sulfamide, N-[2-[[5-bromo-2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 1166389-49-6 CAPLUS

CN Sulfamide, N-[2-[[5-fluoro-2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



L7 ANSWER 6 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:514975 CAPLUS  
 DN 151:520  
 TI A Class of 2,4-Bisanilinopyrimidine Aurora A Inhibitors with Unusually  
 High Selectivity against Aurora B  
 AU Aliagas-Martin, Ignacio; Burdick, Dan; Corson, Laura; Dotson, Jennafer;  
 Drummond, Jason; Fields, Carter; Huang, Oscar W.; Hunsaker, Thomas;  
 Kleinheinz, Tracy; Krueger, Elaine; Liang, Jun; Moffat, John; Phillips,  
 Gail; Pulk, Rebecca; Rawson, Thomas E.; Ultsch, Mark; Walker, Leslie;  
 Wiesmann, Christian; Zhang, Birong; Zhu, Bing-Yan; Cochran, Andrea G.  
 CS Departments of Small Molecule Drug Discovery, Cell Regulation,  
 Translational Oncology and Protein Engineering, Genentech Inc., South San  
 Francisco, CA, 94080, USA  
 SO Journal of Medicinal Chemistry (2009), 52(10), 3300-3307  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB The two major Aurora kinases carry out critical functions at distinct mitotic  
 stages. Selective inhibitors of these kinases, as well as pan-Aurora  
 inhibitors, show antitumor efficacy and are now under clin. investigation.  
 However, the ATP-binding sites of Aurora A and Aurora B are virtually  
 identical, and the structural basis for selective inhibition has therefore  
 not been clear. We report here a class of bisanilinopyrimidine Aurora A  
 inhibitors with excellent selectivity for Aurora A over Aurora B, both in  
 enzymic assays and in cellular phenotypic assays. Crystal structures of  
 two of the inhibitors in complex with Aurora A implicate a single amino  
 acid difference in Aurora B as responsible for poor inhibitory activity  
 against this enzyme. Mutation of this residue in Aurora B (E161T) or  
 Aurora A (T217E) is sufficient to swap the inhibition profile, suggesting  
 that this difference might be exploited more generally to achieve high  
 selectivity for Aurora A.  
 IT 1158838-43-7P 1158838-45-9P  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN  
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);  
 PREP (Preparation); USES (Uses)  
 (bisanilinopyrimidine Aurora A inhibitors with high selectivity)  
 RN 1158838-43-7 CAPLUS  
 CN Benzamide, 4-[[2-[[4-[2-(4-acetyl-1-piperazinyl)-2-oxoethyl]phenyl]amino]-  
 5-fluoro-4-pyrimidinyl]amino]-N-(2-chlorophenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1158838-45-9 CAPLUS  
 CN Benzamide, N-(2-chlorophenyl)-4-[[2-[[4-[2-(4-ethyl-1-piperazinyl)-2-oxoethyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



IT 1158838-42-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (bisanilinopyrimidine Aurora A inhibitors with high selectivity)  
 RN 1158838-42-6 CAPLUS  
 CN Benzeneacetic acid, 4-[[4-[[4-[[2-  
 chlorophenyl)amino]carbonyl]phenyl]amino]-5-fluoro-2-pyrimidinyl]amino]-  
 (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 7 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:448699 CAPLUS  
 DN 150:423212  
 TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor  
 modulators for treatment of autoimmune diseases  
 IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Clough, Jeffrey; Keim,  
 Holger; Bhamidipati, Somasekhar; Sylvain, Catherine; Li, Hui  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO U.S., 300pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7517886	B2	20090414	US 2003-631029	20030729
	US 20070060603	A1	20070315		
	CA 2492325	A1	20040219	CA 2003-2492325	20030729
	WO 2004014382	A1	20040219	WO 2003-US24087	20030729
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				
	PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,				
	TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,				
	FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,				
	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003265336	A1	20040225	AU 2003-265336	20030729
	AU 2003265336	B2	20080619		
	EP 1534286	A1	20050601	EP 2003-784871	20030729
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013059	A	20050705	BR 2003-13059	20030729
	CN 1678321	A	20051005	CN 2003-821120	20030729
	JP 2006514989	T	20060518	JP 2005-506142	20030729
	NZ 537752	A	20061222	NZ 2003-537752	20030729
	ZA 2005000775	A	20080625	ZA 2005-775	20030729
	CN 101514191	A	20090826	CN 2009-10006771	20030729
	SE 2005000203	A	20050329	SE 2005-203	20050127
	NO 2005001069	A	20050228	NO 2005-1069	20050228
	IN 2005KN00302	A	20060421	IN 2005-KN302	20050228
	US 20060135543	A1	20060622	US 2005-299207	20051208
	US 7435814	B2	20081014		
	US 20070299095	A1	20071227	US 2006-539101	20061005
	US 20080039622	A1	20080214	US 2007-782581	20070724
	US 7550460	B2	20090623		
	US 20090082567	A1	20090326	US 2008-199705	20080827
	US 20090156622	A1	20090618	US 2008-273357	20081118
	AU 2008252053	A1	20090108	AU 2008-252053	20081203
PRAI	US 2002-399673P	P	20020729		
	US 2003-443949P	P	20030131		
	US 2003-452339P	P	20030306		
	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-434277P	P	20021217		

AU 2003-208931	A3	20030131
US 2003-355543	A1	20030131
CN 2003-821120	A3	20030729
US 2003-631029	A	20030729
WO 2003-US24087	W	20030729
US 2004-858343	A3	20040601
US 2005-149418	A1	20050608
US 2006-539041	A1	20061005
US 2006-539054	A3	20061005

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Title compds. I [wherein L1 and L2 = independently a bond; R2, R4 = independently (un)substituted Ph, 5-15 membered heteroaryl; ; R5 = CN, NC, NO2, F, (per)haloalkyl, (per)haloalkoxy, COCF3, etc.; R6 = H; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5  $\mu$ M and 4.4  $\mu$ M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. Specific examples of autoimmune diseases that can be treated or prevented with I and their pharmaceutical compns. include rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis (no data).


IT 575484-54-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)

RN 575484-54-7 CAPLUS

CN Benzamide, 3-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

10/568,367

RE.CNT 277 THERE ARE 277 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2009:293033 CAPLUS

DN 150:306669

TI Pyrimidine derivatives as IGF-1R and ALK inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases

IN Marsilje, Thomas H.; Lu, Wenshuo; Chen, Bei; He, Xiaohui; Bursulaya, Badry; Lee, Christian Cho-Hua; Gray, Nathanael S.

PA IRM LLC, Bermuda

SO PCT Int. Appl., 92pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009032668	A2	20090312	WO 2008-US74392	20080827
	WO 2009032668	A3	20090924		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2007-966449P	P	20070828		
	US 2008-75556P	P	20080625		

OS MARPAT 150:306669

AB The invention provides pyrimidine derivs. of formula I and their pharmaceutical compns. thereof, and methods for using such compds. Pyrimidine derivs. of formula I may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or anaplastic lymphoma kinase (ALK). Compds. of formula I wherein R1a is H, halo, OR8, NRR8, SR8, (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, C2-6 alkenyl, (un)substituted C2-6 alkynyl, etc.; R1b is H and NH2; R3 and R4 are independently H, COR7 and (halo)C1-6 alkyl; each of R5-R7 is independently (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, halo, NO2, CN, OR8, etc.; two adjacent R5 may taken together with the carbon atom attached to form (un)substituted 9- to 14-membered ring; R7-R9 are independently (CR2)0-4-Y, (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy, (un)substituted C2-6 alkenyl and (un)substituted C2-6 alkynyl; R7 and R8 may be H; R is H and C1-6 alkyl; Y is (un)substituted C3-12 (hetero)cyclic ring, (un)substituted C6-10 aryl, (un)substituted C5-10 heteroaryl and heterocyclic ring; m is 1-4; n is 0-4; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by N-arylation of 4'-amino-5'-fluoro-N,2'-dimethylbiphenyl-4-carboxamide with 2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine. All the invention compds. were evaluated for their kinase inhibitory activity. From the assay, it was determined that some of the tested compds. exhibited the IC50 value of < 1 nM.

IT 1129409-51-3P 1129409-53-5P 1129409-55-7P


1129409-56-8P      1129409-58-0P      1129409-59-1P  
 1129409-60-4P      1129409-62-6P      1129409-63-7P  
 1129409-64-8P      1129409-65-9P      1129409-66-0P  
 1129409-67-1P      1129409-68-2P      1129409-70-6P  
 1129409-71-7P      1129409-73-9P      1129409-74-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. as IGF-1R and ALK inhibitors useful in treatment of diseases)


RN 1129409-51-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(cyclopropylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-N,2'-dimethyl- (CA INDEX NAME)




RN 1129409-53-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[5-methoxy-2-methyl-3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1129409-55-7 CAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(cyclopropylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-hydroxy-N,2'-dimethyl- (CA INDEX NAME)




RN 1129409-56-8 CAPLUS  
 CN Benzamide, 2-[[2-[[4'-(aminocarbonyl)-5-fluoro-2-methyl[1,1'-biphenyl]-4-yl]amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)



RN 1129409-58-0 CAPLUS  
 CN [1,1'-Biphenyl]-2,4'-dicarboxamide, 4-[[4-[[2-(aminocarbonyl)phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-5-methoxy-N2,N4'-dimethyl- (CA INDEX NAME)




RN 1129409-59-1 CAPLUS  
 CN [1,1'-Biphenyl]-2,4'-dicarboxamide, 4-[[4-[[2-(aminocarbonyl)phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-5-methoxy-N4'-methyl-N2-4-piperidinyl- (CA INDEX NAME)




RN 1129409-60-4 CAPLUS

CN [1,1'-Biphenyl]-2,4'-dicarboxamide,  
4-[[4-[[2-(aminocarbonyl)phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-5-  
methoxy-N4'-methyl-N2-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 1129409-62-6 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid,  
4-[[4-[[2-(aminocarbonyl)phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-5-  
methoxy-4'-[(methyamino)carbonyl]-, methyl ester (CA INDEX NAME)



RN 1129409-63-7 CAPLUS


CN [1,1'-Biphenyl]-2,4'-dicarboxamide,  
4-[[4-[[2-(aminocarbonyl)phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-5-  
methoxy-N4'-methyl-N2-4-morpholinyl- (CA INDEX NAME)



RN 1129409-64-8 CAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[4-[[2-(aminocarbonyl)phenyl]amino]-5-  
chloro-2-pyrimidinyl]amino]-5'-methoxy-N-methyl-2'-[(4-methyl-1-  
piperazinyl)carbonyl]- (CA INDEX NAME)






RN 1129409-65-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[4-[[2-(aminocarbonyl)phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-5'-methoxy-N-methyl-2'-(4-morpholinylcarbonyl)- (CA INDEX NAME)



RN 1129409-66-0 CAPLUS


CN [1,1'-Biphenyl]-2,4'-dicarboxamide, 4-[[4-[[2-(aminocarbonyl)phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-N2-cyclopentyl-5-methoxy-N4'-methyl- (CA INDEX NAME)



RN 1129409-67-1 CAPLUS

CN [1,1'-Biphenyl]-2,4'-dicarboxamide,  
4-[[4-[[2-(aminocarbonyl)phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-5-  
methoxy-N4'-methyl-N2-(3S)-3-pyrrolidinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1129409-68-2 CAPLUS


CN [1,1'-Biphenyl]-2,4'-dicarboxamide,  
4-[[4-[[2-(aminocarbonyl)phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-5-  
methoxy-N4'-methyl-N2-(3R)-3-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 1129409-70-6 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[4-[[2-(aminocarbonyl)phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-5'-methoxy-N,2'-dimethyl- (CA INDEX NAME)




RN 1129409-71-7 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-fluoro-N,2'-dimethyl- (CA INDEX NAME)




RN 1129409-73-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[4-[[2-[[2-(2-aminoethyl)amino]carbonyl]phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-5'-fluoro-N,2'-dimethyl- (CA INDEX NAME)




RN 1129409-74-0 CAPLUS


CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(2-hydroxyethyl)amino]carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-fluoro-N,2'-dimethyl- (CA INDEX NAME)



L7 ANSWER 9 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:277182 CAPLUS  
 DN 150:413026  
 TI SVM Model for Virtual Screening of Lck Inhibitors  
 AU Liew, Chin Y.; Ma, Xiao H.; Liu, Xianghui; Yap, Chun W.  
 CS Pharmaceutical Data Exploration Laboratory, Department of Pharmacy,  
 National University of Singapore, Singapore  
 SO Journal of Chemical Information and Modeling (2009), 49(4), 877-885  
 CODEN: JCISD8; ISSN: 1549-9596  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB Lymphocyte-specific protein tyrosine kinase (Lck) inhibitors have  
 treatment potential for autoimmune diseases and transplant rejection. A  
 support vector machine (SVM) model trained with 820 pos. compds. (Lck  
 inhibitors) and 70 neg. compds. (Lck noninhibitors) combined with 65 142  
 generated putative negatives was developed for predicting compds. with a  
 Lck inhibitory activity of  $IC_{50} \leq 10 \mu M$ . The SVM model, with an  
 estimated sensitivity of greater than 83% and specificity of greater than 99%,  
 was used to screen 168 014 compds. in the MDDR and was found to have a  
 yield of 45.8% and a false pos. rate of 0.52%. The model was also able to  
 identify novel Lck inhibitors and distinguish inhibitors from structurally  
 similar noninhibitors at a false pos. rate of 0.27%. To the best of our  
 knowledge, the SVM model developed in this work is the first model with a  
 broad applicability domain and low false pos. rate, which makes it very  
 suitable for the virtual screening of chemical libraries for Lck inhibitors.  
 IT 191728-29-7 944795-12-4 944795-18-0  
 944795-19-1 944795-20-4  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (SVM model for virtual screening of Lck inhibitors)  
 RN 191728-29-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-phenyl-N2-(3,4,5-trimethoxyphenyl)- (CA INDEX  
 NAME)




RN 944795-12-4 CAPLUS  
 CN Benzamide, 3-[[4-[(2-methylphenyl)amino]-2-pyrimidinyl]amino]- (CA INDEX  
 NAME)




RN 944795-18-0 CAPLUS

CN Benzamide, 3-[[2-[[3-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-4-methyl- (CA INDEX NAME)




RN 944795-19-1 CAPLUS

CN Benzamide, 3-[[2-[[3-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N,4-trimethyl- (CA INDEX NAME)



RN 944795-20-4 CAPLUS

CN Benzamide, 3-[[4-[[2-methyl-5-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)


RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:39051 CAPLUS  
 DN 150:89997  
 TI Inhibition of focal adhesion kinase as a potential therapeutic strategy  
 for imatinib-resistant gastrointestinal stromal tumor  
 AU Sakurama, Kazufumi; Noma, Kazuhiro; Takaoka, Munenori; Tomono, Yasuko;  
 Watanabe, Nobuyuki; Hatakeyama, Shinji; Ohmori, Osamu; Hirota, Seiichi;  
 Motoki, Takayuki; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Haisa, Minoru;  
 Matsuoka, Junji; Tanaka, Noriaki; Naomoto, Yoshio  
 CS Department of Gastroenterological Surgery, Transplant, and Surgical  
 Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical  
 Sciences, Graduate School of Medicine, Dentistry, and Pharmaceutical  
 Sciences, Okayama University Okayama 700-9558, Japan  
 SO Molecular Cancer Therapeutics (2009), 8(1), 127-134  
 CODEN: MCTOCF; ISSN: 1535-7163  
 PB American Association for Cancer Research  
 DT Journal  
 LA English  
 AB Focal adhesion kinase (FAK) is often up-regulated in a variety of  
 malignancies, including gastrointestinal stromal tumor (GIST), and its  
 overexpression seems to be associated with tumor progressiveness and poor  
 prognosis. GIST is well known to have a mutation to c-KIT; thus, a  
 specific c-KIT inhibitor (imatinib) is recognized as the first-line  
 chemotherapy for GIST, although a certain type of c-KIT mutation reveals a  
 resistance to imatinib due to as yet uncertain mol. mechanisms. To assess  
 the c-KIT mutation-related variation of cellular responses to imatinib,  
 murine lymphocyte-derived Ba/F3 cells, which are stably transduced with  
 different types of c-KIT mutation, were treated with either imatinib or a  
 FAK inhibitor (TAE226), and their antitumor effects were determined in vitro  
 and in vivo. A mutation at exon 11 (KITdel559-560) displayed a high  
 sensitivity to imatinib, whereas that at exon 17 (KIT820Tyr) showed a  
 significant resistance to imatinib in vitro and in vivo. KIT820Tyr cells  
 appeared to maintain the activities of FAK and AKT under the imatinib  
 treatment, suggesting that FAK might play a role in cell survival in  
 imatinib-resistant cells. When FAK activity in those cells was inhibited  
 by TAE226, cell growth was equally suppressed and the cells underwent  
 apoptosis regardless of the c-KIT mutation types. Oral administration of  
 TAE226 significantly diminished tumor growth in nude mice bearing  
 KIT820Tyr xenografts. In summary, c-KIT mutation at exon 17 displayed a  
 resistance to imatinib with maintained activations of FAK and subsequent  
 survival signals. Targeting FAK could be a potential therapeutic strategy  
 for imatinib-resistant GISTs.  
 IT 761437-28-9  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (inhibition of focal adhesion kinase with TAE226 as a potential  
 therapeutic strategy for imatinib-resistant gastrointestinal stromal  
 tumor)  
 RN 761437-28-9 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-  
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




10/568,367



RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 11 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:36532 CAPLUS  
 DN 150:555130  
 TI TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells  
 AU Wang, Zhi Gang; Fukazawa, Takuya; Nishikawa, Toshio; Watanabe, Nobuyuki; Sakurama, Kazufumi; Motoki, Takayuki; Takaoka, Munenori; Hatakeyama, Shinji; Omori, Osamu; Ohara, Toshiaki; Tanabe, Shunsuke; Fujiwara, Yasuhiro; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Tanaka, Noriaki; Naomoto, Yoshio  
 CS College of Life Science, The Key Laboratory of Mammal Reproductive Biology and Biotechnology, Ministry of Education, Inner Mongolia University, Huhhot, 010021, Peop. Rep. China  
 SO Oncology Reports (2008), 20(6), 1473-1477  
 CODEN: OCRPEW; ISSN: 1021-335X  
 PB Oncology Reports  
 DT Journal  
 LA English  
 AB Esophageal cancer is one of the most aggressive cancers in the world. Novel preventive and therapeutic strategies tend to target the key mols. involved in the signaling transduction pathways for cell growth. It is known that FAK and mTOR are important controllers of cell growth. TAE226, a novel small mol. compound, is a potent ATP competitive inhibitor of FAK and IGF-IR. TAE226 can block FAK and IGF-IR signaling pathways. The purpose of this study was to explore the inhibitory effects on mTOR signaling and the mechanism of cell growth suppression by TAE226. We examined the expression of mTOR and S6 in esophageal cancer cells (SEG-1) and normal esophageal epithelial cells (KOB-13) and the efficacy of TAE226 against SEG-1 cells. MTOR and S6 were overexpressed in SEG-1 cells compared with KOB-13 cells. TAE226 inhibited the expression of mTOR, Akt, p70S6K and S6 as well as the phosphorylation of mTOR (Ser2448), Akt (Ser473), p70S6K (Thr389) and S6 (Ser240/244). As a result, TAE226 induced a dose-dependent decrease in cell growth (number) and damage in the cell shape. Together, these data show that TAE226 has potent inhibitory effects on mTOR signaling and esophageal cancer cell growth indicating that TAE226 has potential application in esophageal cancer treatment.  
 IT 761437-28-9  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (TAE226, dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells)  
 RN 761437-28-9 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




10/568,367

OSC.G	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT	29	THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:13898 CAPLUS  
 DN 150:182730  
 TI Identification of novel CDK2 inhibitors by QSAR and virtual screening procedures  
 AU Babu, Padavala Ajay; Smiles, Dondapati Jesse; Narasu, Mangamoori Laxmi; Srinivas, Kolli  
 CS Centre for Biotechnology, Jawaharlal Nehru Technological University, Hyderabad, 500072, India  
 SO QSAR & Combinatorial Science (2008), 27(11-12), 1362-1373  
 CODEN: QCSSAU; ISSN: 1611-020X  
 PB Wiley-VCH Verlag GmbH & Co. KGaA  
 DT Journal  
 LA English  
 AB Quant. Structure - Activity Relationship (QSAR) studies were carried out on a set of 46 imidazo[1,2-a]pyridines, imidazo[1,2-b]pyridazines and 2,4-bis anilino pyrimidines, and nitroso-6-aminopyrimidine and 2,6-diaminopyrimidine inhibitors of CDK2 (Cyclin-dependent Kinase2) using a multiple regression procedure. The activity contributions of these compds. were determined from regression equation and the validation procedures such as external set cross-validation  $r^2$ , (R2cv.ext) and the regression of observed activities against predicted activities and vice versa for validation set were described to analyze the predictive ability of the QSAR model. An accurate and reliable QSAR model involving five descriptors was chosen based on the FIT Kubinyi function which defines the statistical quality of the model. The proposed model due to its high predictive ability was utilized to screen similar repertoire of compds. reported in the literature, and the biol. activities are estimated. The screening study clearly demonstrated that the strategy presented shall be used as an alternative to the time-consuming expts. as the model tolerated a variety of structural modifications signifying its potential for drug design studies.  
 IT 260044-97-1 280578-83-8 280578-93-0  
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (identification of novel CDK2 inhibitors by QSAR and virtual screening procedures)  
 RN 260044-97-1 CAPLUS  
 CN 2-Propanol, 1-(dimethylamino)-3-[4-[[4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)




RN 280578-83-8 CAPLUS  
 CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)- (CA INDEX NAME)




RN 280578-93-0 CAPLUS

CN 2-Propanol, 1-[4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)- (CA INDEX NAME)



RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 13 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:1477507 CAPLUS  
 DN 151:26548  
 TI Crystal structures of the FAK kinase in complex with TAE 226 and related  
 bis-anilino pyrimidine inhibitors reveal a helical DFG conformation  
 AU Lietha, Daniel; Eck, Michael J.  
 CS Department of Biological Chemistry and Molecular Pharmacology, Harvard  
 Medical School, Boston, MA, USA  
 SO PLoS One (2008), 3(11), No pp. given  
 CODEN: POLNCL; ISSN: 1932-6203  
 URL: <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0003800>  
 PB Public Library of Science  
 DT Journal; (online computer file)  
 LA English  
 AB Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase required for  
 cell migration, proliferation and survival. FAK overexpression has been  
 documented in diverse human cancers and is associated with a poor clin.  
 outcome. Recently, a novel bis-anilino pyrimidine inhibitor, TAE 226, was  
 reported to efficiently inhibit FAK signaling, arrest tumor growth and  
 invasion, and prolong the life of mice with glioma or ovarian tumor  
 implants. Here, the authors describe the crystal structures of FAK kinase  
 bound to TAE 226 and to 3 related bis-anilino pyrimidine compds. TAE 226  
 induced a conformation of the N-terminal portion of the kinase activation  
 loop that was only observed in FAK, but was distinct from the conformation in  
 both the active and inactive states of the kinase. This conformation  
 appeared to require a Gly residue immediately N-terminal to the "DFG  
 motif", which adopted a helical conformation stabilized by interactions  
 with TAE 226. The presence of a Gly residue in this position contributed  
 to the specificity of TAE 226 and related compds. for FAK. This work  
 highlights the fact that kinases can access conformational space that is  
 not necessarily utilized for their native catalytic regulation, and that  
 such conformations can explain and be exploited for inhibitor specificity.  
 IT 761437-28-9D, complexes with FAK kinase 878159-63-8D  
 , AZW 592, complexes with FAK kinase  
 RL: BSU (Biological study, unclassified); DMA (Drug mechanism of action);  
 PEP (Physical, engineering or chemical process); PRP (Properties); BIOL  
 (Biological study); PROC (Process)  
 (crystal structures of FAK kinase in complex with TAE 226 and related  
 bis-anilinopyrimidine inhibitors reveal a helical DFG conformation)  
 RN 761437-28-9 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-  
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 878159-63-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 14 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:1360637 CAPLUS  
 DN 149:553338  
 TI Genetic polymorphisms associated with an increased risk of  
 neurodegenerative disease and their detection and diagnostic and  
 prophylactic use  
 IN Grupe, Andrew; Li, Yonghong  
 PA Applera Corporation, USA  
 SO PCT Int. Appl., 137pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008137110	A1	20081113	WO 2008-US5734	20080501
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 20080286796 A1 20081120 US 2008-151163 20080501 PRAI US 2007-927864P P 20070503				

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention is based on the discovery of genetic polymorphisms that are associated with neurodegenerative disease, particularly Alzheimer's disease and Parkinson's disease. In particular, the present invention relates to nucleic acid mols. containing the polymorphisms, variant proteins encoded by such nucleic acid mols., reagents for detecting the polymorphic nucleic acid mols. and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. An anal. of genetic polymorphisms surrounding the NEDD9 gene is reported. Expression of the NEDD9 gene is lower in the hippocampus of Alzheimer's disease patients than in controls. A number of polymorphisms around the gene were shown to be associated with an increased risk of Alzheimer's disease.

IT 761437-28-9, NVP-TAE-226


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (in treatment of Alzheimer's disease; genetic polymorphisms associated with increased risk of neurodegenerative disease and their detection and diagnostic and prophylactic use)

RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



10/568,367



RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:1186991 CAPLUS  
 DN 149:425967  
 TI Pyrimidinediamine derivatives as JAK kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases  
 IN Li, Hui; Taylor, Vanessa; Bhamidipati, Somasekhar; Ramphal, John; Tso, Kin; Sran, Arvinder; Keim, Holger; Markovtsov, Vadim; Carroll, David; Thota, Sambaiah; Argade, Ankush; Clough, Jeffrey Wayne; Singh, Rajinder  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 240pp., which  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008118822	A1	20081002	WO 2008-US57930	20080321
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20080279867	A1	20081113	US 2008-53382	20080321
PRAI	US 2007-896823P	P	20070323		
	US 2007-910749P	P	20070409		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 149:425967

AB The invention encompasses compds. of formula I and the compns. and methods using these compds. in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful. Compds. of formula I wherein A and B are independently (hetero)aryl; when A is monocyclic, then p and q are independently 0-3; when A is multiple ring, then p and q are independently 0-5; X is (un)substituted alkyl, OH, (un)substituted alkoxy, (un)substituted amino, carboxyl, etc.; W is SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>, -alk-SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub> and NR<sub>4</sub>SO<sub>2</sub>R<sub>5</sub>; alk is (un)substituted (un)branched C<sub>1</sub>-6 alkylene; R<sub>1</sub> is H and C<sub>1</sub>-3 alkyl; each R<sub>2</sub> is independently (un)substituted alkyl, (un)substituted alkoxy, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkenyl, etc.; R<sub>4</sub> or R<sub>5</sub> and one of R<sub>2</sub> taken together with the intervening atoms attached to form (un)substituted heterocyclic fused to ring A; each R<sub>3</sub> is independently (un)substituted alkyl, (un)substituted alkoxy, (un)substituted alkenyl, (un)substituted alkynyl, alkynyloxy, etc.; R<sub>4</sub> is H, (un)substituted alkyl, (un)substituted cycloalkyl, (un)substituted heterocyclyl, (un)substituted (hetero)aryl, etc.; R<sub>5</sub> is H, (un)substituted alkyl, (un)substituted amino, (un)substituted cycloalkyl, (un)substituted heterocyclyl, (un)substituted (hetero)aryl, etc.; R<sub>4</sub>R<sub>5</sub> taken together with the intervening atoms attached to form (un)substituted heterocyclyl; provided that when W is SO<sub>2</sub>NR<sub>4</sub>R<sub>5</sub>, then W is not attached to an atom adjacent to the atom of ring A

that is bound to N4 of pyrimidine, A is not chromanyl; and their solvates, prodrugs and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multi-step procedure (procedure given). All the invention compds. were evaluated for their JAK kinase inhibitory activity. From the assay, it was determined that II exhibited an IC<sub>50</sub> value of 0.08797  $\mu$ M.


IT 1065078-71-8P 1065078-77-4P 1065078-78-5P  
1065078-91-2P 1065078-93-4P 1065079-05-1P  
1065079-07-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidinediamine derivs. as JAK kinase inhibitors useful in the treatment of diseases)


RN 1065078-71-8 CAPLUS

CN Benzenesulfonamide, 3-[[5-fluoro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 1065078-77-4 CAPLUS

CN Benzenesulfonamide, 3-[[5-fluoro-2-[(4-methoxy-3,5-dimethylphenyl)amino]-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 1065078-78-5 CAPLUS

CN Benzenesulfonamide, 4-[[5-fluoro-2-[(4-methoxy-3,5-dimethylphenyl)amino]-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 1065078-91-2 CAPLUS

CN Benzenesulfonamide, 3-[[5-chloro-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 1065078-93-4 CAPLUS

CN Benzenesulfonamide, 3-[[5-chloro-2-[(4-methoxy-3,5-dimethylphenyl)amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1065079-05-1 CAPLUS

CN Benzenesulfonamide, 3-[[5-chloro-2-[[3,5-dimethyl-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 1065079-07-3 CAPLUS

CN Benzenesulfonamide, 3-[[5-chloro-2-[[3-methyl-4-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)

Absolute stereochemistry.

10/568,367



OSC.G	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:1155852 CAPLUS  
 DN 149:394705  
 TI Dianilinopyrimidine derivs. for treatment of diseases associated with  
 inappropriate Weel kinase activity  
 IN Reid, Paul; Drewry, David Harold; Deanda, Felix, Jr.; Linn, James Andrew  
 PA Smithkline Beecham Corporation, USA  
 SO PCT Int. Appl., 33pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008115738	A1	20080925	WO 2008-US56591	20080312
	W:		AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW		
	RW:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		

PRAI US 2007-895893P P 20070320

OS MARPAT 149:394705

AB The present invention relates to dianilinopyrimidine derivs., compns. and medicaments containing the same, as well as processes for the preparation and use

of such compds., compns. and medicaments. Such dianilinopyrimidine derivs. are useful in the treatment of diseases associated with inappropriate Weel kinase activity.


IT 1042434-43-4P 1042434-44-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(dianilinopyrimidine derivs. for treatment of diseases associated with inappropriate Weel kinase activity such as cancer)


RN 1042434-43-4 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)



RN 1042434-44-5 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[4-(1H-1,2,4-triazol-1-ylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:1011397 CAPLUS

DN 149:283063

TI 2, 4-Dianilinopyrimidine derivatives, preparation thereof as drugs, pharmaceutical compositions, and use as IKK inhibitors

IN Bosch, Michael; Bouaboula, Monsif; Casellas, Pierre; Nguefack, Jean-Flaubert; Tonnerre, Bernard; Wagnon, Jean

PA Sanofi-Aventis, Fr.

SO PCT Int. Appl., 83pp.

CODEN: PIXXD2


DT Patent

LA French

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008099072	A2	20080821	WO 2008-FR1	20080102
	WO 2008099072	A3	20081113		
	W:				
	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	FR 2911137	A1	20080711	FR 2007-63	20070105
	FR 2911137	B1	20090220		
	CA 2672955	A1	20080821	CA 2008-2672955	20080102
	EP 2104673	A2	20090930	EP 2008-750460	20080102
	R:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				
PRAI	FR 2007-63	A	20070105		
	WO 2008-FR1	W	20080102		
OS	MARPAT 149:283063				
AB	The invention discloses compds. I [one of R2-R4 = halo, CF3 while the other two are H, halo, alkyl, (halo-substituted) alkoxy; R1 = H, (un)substituted (cyclo)alkyl, etc.; A = bond, CH2CONR6 (R6 = R1); ring containing Y is mono- or bicyclic and including 4-10 members, with Y = O, S, etc.], and isomers and salts thereof, as drugs essentially used as IKK inhibitors. Compound preparation is included.				
IT	1036705-73-3P		1036705-74-4P		
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)				
	(2,4-Dianilinopyrimidine derivs., preparation thereof as drugs, pharmaceutical compns., and use as IKK inhibitors)				
RN	1036705-73-3	CAPLUS			
CN	Benzoic acid, 4-[[4-(phenylamino)-2-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)				





RN 1036705-74-4 CAPLUS

CN Benzoic acid, 4-[[4-(phenylamino)-2-pyrimidinyl]amino]- (CA INDEX NAME)




L7 ANSWER 18 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:1009042 CAPLUS  
 DN 149:293683  
 TI Combinations of therapeutic agents comprising  
 N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-  
 2E-2-propenamide for treating cancer  
 IN Atadja, Peter Wisdom; Shao, Wenlin; Bhalla, Kapil N.  
 PA Novartis A.-G., Switz.  
 SO PCT Int. Appl., 73pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008100985	A2	20080821	WO 2008-US53798	20080213
	WO 2008100985	A3	20081030		
	W:				
	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,				
	CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,				
	FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,				
	KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,				
	ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,				
	PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,				
	TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,				
	IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,				
	TR, BF, BJ, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
	TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,				
	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	AU 2008216327	A1	20080821	AU 2008-216327	20080213
	CA 2677651	A1	20080821	CA 2008-2677651	20080213
PRAI	US 2007-890005P	P	20070215		
	WO 2008-US53798	W	20080213		

AB The invention relates to a combination comprising the  
 N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-  
 2E-2-propenamide; and one or more pharmaceutically active agents;  
 pharmaceutical compns. comprising said combination; methods of treatment  
 comprising said combination; processes for making said combination; and a  
 com. package comprising said combination. Thus, combination of LBH589 and  
 velcade exhibited synergistic efficiency in treating pancreatic tumor,  
 tested with MIA PaCa-2 cells.

IT 761437-28-9  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (combinations of therapeutic agents comprising  
 N-hydroxy-3-[4-[[[2-(2-Me-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-  
 2-propenamide for treating cancer)  
 RN 761437-28-9 CAPLUS  
 CN Benzamide, 2-[[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-  
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/568,367



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L7 ANSWER 19 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:916378 CAPLUS  
 DN 149:224273  
 TI Anthranilamide inhibitors of aurora kinase and their preparation,  
 pharmaceutical compositions and use in the treatment of cancer  
 IN Axten, Jeffrey Michael; Bryan, Deborah L.; Drewry, David Harold; Faitg,  
 Thomas H.; Gallagher, Timothy Francis; Johnson, Neil W.; Kaspavec, Jiri;  
 Ralph, Jeffrey M.; Silva, Domingos J.  
 PA Smithkline Beecham Corporation, USA  
 SO PCT Int. Appl., 98pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008092049	A1	20080731	WO 2008-US51985	20080125
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM AU 2008207809 A1 20080731 AU 2008-207809 20080125 CA 2676257 A1 20080731 CA 2008-2676257 20080125 US 20080182852 A1 20080731 US 2008-19730 20080125 PRAI US 2007-886676P P 20070126 WO 2008-US51985 W 20080125				

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 149:224273

AB The invention relates to a compound represented by formula I or a  
 pharmaceutically acceptable salt thereof. Compds. of the invention are  
 useful in the treatment of diseases associated with Aurora kinase activity  
 such as cancer. Compds. of formula I wherein each R1 is H,  
 (CH2)0-3-N(R5)2, O(CH2)2-3-N(R5)2, CON(R5)2, CO2H, etc.; R2 is H, halo,  
 C1-3 alkyl, C1-3 alkoxy, CN, NO2, and CF3; each R3 is H, heterocycloalkyl,  
 cycloalkyl, Ph, etc.; R4 is halo, C1-3 alkyl and C1-3 alkoxy; each R5 is  
 independently C1-6 alkyl and COCH3; R5R5N taken together to form a  
 (un)substituted 5- to 6-membered heterocyclic ring; and their  
 pharmaceutically acceptable salts thereof, are claimed. Example compound II  
 was prepared by amination of 2-[(2,5-dichloro-4-pyrimidinyl)amino]benzamide  
 with 3-(1-pyrrolidinylmethyl)aniline. All the invention compds. were  
 evaluated for their aurora kinase inhibitory activity.


IT 1042434-40-1P 1042434-63-8P 1042434-64-9P  
 1042434-66-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of anthranilamide as aurora  
 kinase inhibitors useful in the treatment of cancer)


RN 1042434-40-1 CAPLUS

CN Benamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylthio)ethyl]- (CA INDEX NAME)




RN 1042434-63-8 CAPLUS

CN Benzoic acid, 4-[[5-fluoro-4-[[2-[[[1-methylethyl]amino]carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)




RN 1042434-64-9 CAPLUS

CN Benamide, 2-[[5-fluoro-2-[[4-(hydroxymethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1042434-66-1 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[(4-formylphenyl)amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



IT	1042432-41-6P	1042432-42-7P	1042432-43-8P
	1042432-45-0P	1042432-46-1P	1042432-48-3P
	1042432-50-7P	1042432-51-8P	1042432-53-0P
	1042432-55-2P	1042432-56-3P	1042432-61-0P
	1042432-62-1P	1042432-63-2P	1042432-66-5P
	1042432-68-7P	1042432-70-1P	1042432-71-2P
	1042432-72-3P	1042432-73-4P	1042432-74-5P
	1042432-77-8P	1042432-78-9P	1042432-80-3P
	1042432-82-5P	1042432-83-6P	1042432-84-7P
	1042432-86-9P	1042432-88-1P	1042432-89-2P
	1042432-91-6P	1042432-92-7P	1042432-93-8P


1042433-12-4P	1042433-13-5P	1042433-15-7P
1042433-17-9P	1042433-18-0P	1042433-19-1P
1042433-20-4P	1042433-22-6P	1042433-96-4P
1042433-97-5P	1042434-01-4P	1042434-02-5P
1042434-04-7P	1042434-14-9P	1042434-16-1P
1042434-17-2P	1042434-18-3P	1042434-19-4P
1042434-23-0P	1042434-24-1P	1042434-25-2P
1042434-26-3P	1042434-27-4P	1042434-28-5P
1042434-29-6P	1042434-30-9P	1042434-36-5P
1042434-37-6P	1042434-41-2P	1042434-42-3P
1042434-43-4P	1042434-44-5P	1042434-46-7P
1042434-47-8P	1042434-49-0P	1042434-51-4P
1042434-53-6P	1042434-55-8P	1042434-57-0P
1042434-59-2P	1042434-67-2P	1042434-68-3P
1042434-69-4P	1042434-70-7P	1042434-73-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of anthranilamide as aurora kinase inhibitors useful in the treatment of cancer)


RN 1042432-41-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-42-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-43-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-45-0 CAPLUS

CN Benzamide, 2-[[2-[[3-[2-(4-acetyl-1-piperazinyl)ethyl]phenyl]amino]-5-chloro-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-46-1 CAPLUS

CN Benzamide, 2-[[2-[[3-[(4-acetyl-1-piperazinyl)methyl]phenyl]amino]-5-chloro-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1042432-48-3 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1042432-50-7 CAPLUS




CN Benzamide, 2-[[5-chloro-2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-51-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-piperazinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1042432-53-0 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(1-piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-55-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


10/568,367




RN 1042432-56-3 CAPLUS  
 CN Benamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 1042432-61-0 CAPLUS  
 CN Benzoic acid, 4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042432-62-1 CAPLUS  
 CN Benamide, 2-[[5-chloro-2-[[4-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-63-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-66-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-68-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-70-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-methoxy-3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-71-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-72-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042432-73-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 1042432-74-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 1042432-77-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042432-78-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042432-80-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042432-82-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1042432-83-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 1042432-84-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 1042432-86-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 1042432-88-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 1042432-89-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-phenyl- (CA INDEX NAME)




RN 1042432-91-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylamino)ethyl]- (CA INDEX NAME)



RN 1042432-92-7 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 1042432-93-8 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[3-[2-(4-morpholinyl)ethyl]phenyl]- (CA INDEX NAME)






RN 1042433-12-4 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-13-5 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1042433-15-7 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-17-9 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-18-0 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1042433-19-1 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042433-20-4 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1042433-22-6 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[4-[(methylsulfonyl)methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 1042433-96-4 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)

10/568,367




●x HCl

RN 1042433-97-5 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[3-methyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042434-01-4 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-, hydrochloride (1:?) (CA INDEX NAME)




●x HCl

RN 1042434-02-5 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[4-[2-(4-methyl-1-

10/568,367


piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-,  
hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042434-04-7 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[3-methyl-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)-,  
hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 1042434-14-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 1042434-16-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1R)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-17-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-2-hydroxy-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-18-3 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(3-methylbutyl)- (CA INDEX NAME)

10/568,367



RN 1042434-19-4 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)



RN 1042434-23-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-24-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-25-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-1-(hydroxymethyl)-3-methylbutyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-26-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1R)-1-(hydroxymethyl)-3-methylbutyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1042434-27-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1S)-1-(hydroxymethyl)-2-methylpropyl]- (CA INDEX NAME)




Absolute stereochemistry.



RN 1042434-28-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1R)-1-(hydroxymethyl)-2-methylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1042434-29-6 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[(1R)-1-(hydroxymethyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1042434-30-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1,3-dioxolan-2-ylmethyl)- (CA INDEX NAME)




RN 1042434-36-5 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)



RN 1042434-37-6 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)



RN 1042434-41-2 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-

pyrimidinyl]amino]-N-[2-(methylsulfinyl)ethyl]- (CA INDEX NAME)




RN 1042434-42-3 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 1042434-43-4 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 1042434-44-5 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[4-(1H-1,2,4-triazol-1-ylmethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)



RN 1042434-46-7 CAPLUS  
 CN Benzamide, 2-[[2-[[4-[[[2-(ethylamino)ethyl]sulfonyl]methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042434-47-8 CAPLUS  
 CN Benzamide, 2-[[2-[[4-[[[2-(ethylamino)ethyl]sulfonyl]methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-46-7  
 CMF C25 H31 F N6 O3 S


10/568,367



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 1042434-49-0 CAPLUS


CN Benzamide, 2-[[2-[[4-[[[2-(diethylamino)ethyl]sulfonyl]methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-48-9

CMF C27 H35 F N6 O3 S


10/568,367



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 1042434-51-4 CAPLUS


CN Benzamide, 2-[[2-[[4-[[[2-(dimethylamino)ethyl]sulfonyl]methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-50-3

CMF C25 H31 F N6 O3 S


10/568,367



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1042434-53-6 CAPLUS

CN Benzamide, 2-[[2-[[4-[[2-aminoethyl)sulfonyl)methyl]phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-52-5


CMF C23 H27 F N6 O3 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 1042434-55-8 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[[2-(4-methyl-1-piperazinyl)ethyl]sulfonyl]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1042434-54-7


CMF C28 H36 F N7 O3 S





CM 2


CRN 76-05-1  
 CMF C2 H F3 O2



RN 1042434-57-0 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[4-[[[2-(4-morpholinyl)ethyl]sulfonyl]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)


CM 1

CRN 1042434-56-9  
 CMF C27 H33 F N6 O4 S



CM 2

CRN 76-05-1  
 CMF C2 H F3 O2




RN 1042434-59-2 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[4-[[[2-(methylethyl)ethyl]sulfonyl]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1


10/568,367

CRN 1042434-58-1  
CMF C24 H29 F N6 O3 S




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 1042434-67-2 CAPLUS  
CN Benzamide, 2-[[5-fluoro-2-[[4-[[[2-(methylsulfonyl)ethyl]amino]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042434-68-3 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[2-(2-hydroxyethyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042434-69-4 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[[2-(2-hydroxyethyl)sulfonyl]ethyl]amino]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042434-70-7 CAPLUS

CN Benzamide, 2-[[5-fluoro-2-[[4-[[2-(2-methoxyethyl)amino]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1042434-73-0 CAPLUS


CN Benzamide, 2-[[5-fluoro-2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)



IT 1042435-07-3P 1042435-09-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of anthranilamide as aurora kinase inhibitors  
 useful in the treatment of cancer)  
 RN 1042435-07-3 CAPLUS  
 CN Benzamide, 2-[[5-fluoro-2-[[4-[[2-  
 hydroxyethyl)sulfonyl]methyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-  
 methylethyl)- (CA INDEX NAME)




RN 1042435-09-5 CAPLUS  
 CN Benzamide, 2-[[2-[[4-[(ethenylsulfonyl)methyl]phenyl]amino]-5-fluoro-4-  
 pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 20 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:855179 CAPLUS  
 DN 150:15783  
 TI Dual Tyrosine Kinase Inhibitor for Focal Adhesion Kinase and Insulin-like Growth Factor-I Receptor Exhibits Anticancer Effect in Esophageal Adenocarcinoma In vitro and In vivo  
 AU Watanabe, Nobuyuki; Takaoka, Munenori; Sakurama, Kazufumi; Tomono, Yasuko; Hatakeyama, Shinji; Ohmori, Osamu; Motoki, Takayuki; Shirakawa, Yasuhiro; Yamatsuji, Tomoki; Haisa, Minoru; Matsuoka, Junji; Beer, David G.; Nagatsuka, Hitoshi; Tanaka, Noriaki; Naomoto, Yoshio  
 CS Department of Gastroenterological Surgery, Transplant, and Surgical Oncology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama Citizens Hospital, Okayama, Japan  
 SO Clinical Cancer Research (2008), 14(14), 4631-4639  
 CODEN: CCREF4; ISSN: 1078-0432  
 PB American Association for Cancer Research  
 DT Journal  
 LA English  
 AB Focal adhesion kinase (FAK) regulates integrin and growth factor-mediated signaling pathways to enhance cell migration, proliferation, and survival, and its up-regulation correlates malignant grade and poor outcome in several types of cancer. In this study, we aimed to raise a potential therapeutic strategy using a FAK inhibitor for Barrett's esophageal adenocarcinoma. The expression status of FAK in clin. Barrett's esophageal adenocarcinoma tissues was determined by immunohistochem. Cultured esophageal adenocarcinoma cells were treated with TAE226, a specific FAK inhibitor with an addnl. effect of inhibiting insulin-like growth factor-I receptor (IGF-IR), to assess its anticancer effect in vitro. Western blot was carried out to explore a participating signaling pathway for TAE226-induced cell death. Furthermore, TAE226 was orally administered to s.c. xenograft animals to investigate its anticancer effect in vivo. Strong expression of FAK was found in 94.0% of Barrett's esophageal adenocarcinoma compared with 17.9% of Barrett's epithelia, suggesting that FAK might play a critical role in the progression of Barrett's esophageal adenocarcinoma. When esophageal adenocarcinoma cells were treated with TAE226, cell proliferation and migration were greatly inhibited with an apparent structural change of actin fiber and a loss of cell adhesion. The activities of FAK, IGF-IR, and AKT were suppressed by TAE226 and subsequent dephosphorylation of BAD at Ser136 occurred, resulting in caspase-mediated apoptosis. In vivo tumor volume was significantly reduced by oral administration of TAE226. These results suggest that TAE226, a dual tyrosine kinase inhibitor for FAK and IGF-IR, could become a new remedy for Barrett's esophageal adenocarcinoma.  
 IT 761437-28-9  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor TAE226 exhibited anticancer effect in human Barrett's esophageal adenocarcinoma cell and mouse bearing tumor)  
 RN 761437-28-9 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/568,367




OSC.G	4	THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT	44	THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 21 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:833126 CAPLUS  
 DN 149:119694  
 TI 2,4-Dianilinopyrimidine derivatives, their preparation, pharmaceutical compositions, and their therapeutic use, especially IKK inhibitors  
 IN Wagnon, Jean; Nguetack, Jean Flaublert; Tonnerre, Bernard; Bosch, Michael; Bouaboula, Monsif; Casellas, Pierre  
 PA Sanofi Aventis, Fr.  
 SO Fr. Demande, 84pp.  
 CODEN: FRXXBL  
 DT Patent  
 LA French  
 FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2911137	A1	20080711	FR 2007-63	20070105
	FR 2911137	B1	20090220		
	CA 2672955	A1	20080821	CA 2008-2672955	20080102
	WO 2008099072	A2	20080821	WO 2008-FR1	20080102
	WO 2008099072	A3	20081113		
	W:				
	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 2104673	A2	20090930	EP 2008-750460	20080102
	R:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				
PRAI	FR 2007-63	A	20070105		
	WO 2008-FR1	W	20080102		
OS	MARPAT 149:119694				
AB	The invention discloses compds. I [one of R2-R4 = halo or CF3 and remaining R2-R4 = H, halo, etc.; R1 = H, (un)substituted (cyclo)alkyl, etc.; R5 = H, halo; A = bond, CH2CONR6 (R6 = R1); Y-containing ring = mono- or bicyclic ring (Y = O, S, etc.)], and salts and isomers thereof, for medicaments, especially as IKK inhibitors. Compound preparation is included.				
IT	1036705-73-3DP, derivs. 1036705-74-4DP, derivs. RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (dianilinopyrimidine derivs., preparation, pharmaceutical compns., and therapeutic use, especially IKK inhibitors)				
RN	1036705-73-3 CAPLUS				
CN	Benzoic acid, 4-[[4-(phenylamino)-2-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)				

10/568,367




RN 1036705-74-4 CAPLUS

CN Benzoic acid, 4-[[4-(phenylamino)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 22 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:821047 CAPLUS  
 DN 149:282622  
 TI FAK and IGF-1R interact to provide survival signals in human pancreatic adenocarcinoma cells  
 AU Liu, Weiguo; Bloom, David A.; Cance, William G.; Kurenova, Elena V.; Golubovskaya, Vita M.; Hochwald, Steven N.  
 CS Division of Surgical Oncology, University of Florida College of Medicine, Gainesville, FL, 32610, USA  
 SO Carcinogenesis (2008), 29(6), 1096-1107  
 CODEN: CRNGDP, ISSN: 0143-3334  
 PB Oxford University Press  
 DT Journal  
 LA English  
 AB Pancreatic cancer is a lethal disease accounting for the fourth leading cause of cancer death in USA. Focal adhesion kinase (FAK) and the insulin-like growth factor-I receptor (IGF-1R) are tyrosine kinases that activate common pathways, leading to increased proliferation and cell survival. Sparse information is available regarding their contribution to the malignant behavior of pancreatic cancer. We analyzed the relationship between FAK and IGF-1R in human pancreatic cancer cells, determined which downstream signaling pathways are altered following kinase inhibition or downregulation and studied whether dual kinase inhibition represents a potential novel treatment strategy in this deadly disease. Using immunopptn. and confocal microscopy, we show for the first time that FAK and IGF-1R phys. interact in pancreatic cancer cells and that inhibition of tyrosine phosphorylation of either kinase disrupts their interaction. Decreasing phosphorylation of either FAK or IGF-1R alone resulted in little inhibition of cell viability or increased apoptosis. However, dual inhibition of FAK, using either a dominant-neg. construct (FAK-CD) or small interfering RNA, and IGF-1R, using a specific small mol. tyrosine kinase inhibitor (AEW-541) or stable expression of a truncated, mutated IGF-1R, led to a synergistic decrease in cell proliferation and phosphorylation of extracellular signal-regulated kinase (ERK) and increase in cell detachment and apoptosis compared with inhibition of either pathway alone. Dual kinase inhibition with FAK-CD and AEW-541 resulted in a marked increase in apoptosis when FAK was displaced from the focal adhesions. Inhibition of both tyrosine kinase activities via a novel single small mol. inhibitor (TAE 226), at low doses specific for FAK and IGF-1R, resulted in significant inhibition of cell viability, decrease in phosphorylation of ERK and Akt and increase in apoptosis accompanied by cleavage of Poly (ADP-ribose) polymerase (PARP) and activation of caspase-3 in pancreatic cancer cells. Thus, simultaneous inhibition of both tyrosine kinases represents a potential novel therapeutic approach in human pancreatic adenocarcinoma.  
 IT 761437-28-9  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (FAK and IGF-1R interact to provide survival signals in human pancreatic adenocarcinoma cells)  
 RN 761437-28-9 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)  
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 23 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:804513 CAPLUS  
 DN 149:128852  
 TI Preparation of pyrimidines as Aurora kinase inhibitors  
 IN Krueger, Elaine B.; Rawson, Thomas E.; Burdick, Daniel J.; Liang, Jun;  
 Zhu, Bing-Yan  
 PA Genentech, Inc., USA  
 SO PCT Int. Appl., 68pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008079719	A1	20080703	WO 2007-US87454	20071213
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2007337088	A1	20080703	AU 2007-337088	20071213
	CA 2670645	A1	20080703	CA 2007-2670645	20071213
	EP 2099771	A1	20090916	EP 2007-855142	20071213
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRAI	US 2006-870784P	P	20061219		
	WO 2007-US87454	W	20071213		
OS	MARPAT 149:128852				
AB	Title compds. I [Q = -NR4-, -NR4C(O)-, -C(O)NR4-, etc.; X = H, hydroxyl, halo, etc.; Y = O, S or NR4; Z = H, alkyl, carbocycle, etc.; R1 = hydroxyl, halo, amino, etc.; R2 = hydroxyl, halo, amino, etc.; R4 = H or alkyl; m = 0-4; n = 0-3], useful for inhibiting the proliferation of a tumor cell, were prepared For example, treatment of tert-Bu 2-(2,5-dichloropyrimidin-4-ylamino)phenylcarbamate, e.g., prepared from 5-chlorouracil in 2 steps, with HCl followed by acylation with cyclopropanecarbonyl chloride and reaction with 4-morpholinoaniline afforded compound II [R = morpholin-4-yl]. Compds. of this invention that were tested in the ELISA assays were found to inhibit Aurora A and/or B kinase activity with an IC50 of less than 0.5 $\mu$ M, e.g., the IC50 of compound II [R = CN] was 0.0013 $\mu$ M for Aurora A.				
IT	1035561-76-2P	1035561-79-5P	1035561-83-1P		
	1035561-84-2P	1035561-85-3P			
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of pyrimidines as Aurora kinase inhibitors)				
RN	1035561-76-2	CAPLUS			
CN	Benzamide, 2-[[5-chloro-2-[[4-[(cyclopropylamino)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)				




RN 1035561-79-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(2-hydroxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-83-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1035561-84-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)



RN 1035561-85-3 CAPLUS

CN Benamide, 2-[[5-chloro-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




IT 1035562-32-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrimidines as Aurora kinase inhibitors)

RN 1035562-32-3 CAPLUS

CN Benzoic acid, 4-[[5-chloro-4-[[2-[(cyclopropylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 24 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:796944 CAPLUS  
 DN 149:104749  
 TI Preparation of pyrimidine-2,4-diamines for inhibition of the JAK pathway  
 IN Argade, Ankush; Sran, Arvinder; Carroll, David; Clough, Jeffrey Wayne;  
 Tso, Kin; Bhamidipati, Somasekhar; Thota, Sambaiah; Singh, Rajinder;  
 Taylor, Vanessa; Li, Hui; Masuda, Esteban  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 258pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008079907	A1	20080703	WO 2007-US88241	20071219
	W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20070203161	A1	20070830	US 2007-678429	20070223
PRAI	US 2006-871098P	P	20061220		
	US 2007-678429	A	20070223		
	US 2006-776636P	P	20060224		
	US 2006-450901	A2	20060608		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention encompasses pyrimidine-2,4-diamines I; wherein X = alkyl, alkoxy, amino, carboxy, carboxy ester, cyano, halo, nitro, alkenyl, alkynyl; Y is H, alkyl, amino, halo; ring A = aryl, heteroaryl, cycloalkyl, cyclo-alkenyl and heterocyclic, R = H, alkyl, alkenyl, alkynyl, cycloalkyl; ring A is not indolyl or benzimidazolyl; p = 0-3; q = 1-3; R2 = alkyl, alkoxy, amino, aryl, aryl-oxy, cycloalkyl, cycloalkyl heteroaryl, heteroaryl, heterocycle, heterocyclyl-oxy, carboxyl, carboxyl ester, OH, acylamino, amino-sulfonyl, alkynyl, alkylthio, amino-carbonyl, acyl, oxo, halo; R3 = alkyl, cycloalkyl, halo, heterocyclic, amino-sulfonyl; R4 and R5 are independently = H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, acyl; R4 and R5 together with the N atom to which they are attached, form a heterocycle; and metal or ammonium counterion; and the compns. and methods using these compds. in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful. Thus, N4-(3-acetyl-amino-4-hydroxyphenyl)-N2-(3-amino-sulfonyl-phenyl)-5-fluoro-2,4-pyrimidine-diamine was prepared by condensation of 4-amino-benzenesulfonamide with 2-chloro-5-fluoro-N4-[4-(3-fluoro-propyl)phenyl]-4-pyrimidin-amine. Results for an assay for Ramos B-cell line stimulated with IL-4, primary human T-cell proliferation assay stimulated with IL-2, assay for A549 epithelial line stimulated with IFN $\gamma$  and U937 IFN $\gamma$  ICAM1 FACS assay (all of which involve the JAK/Stat pathway) are tabulated for hundreds of examples of I. A method



of treating or preventing allograft transplant rejection in a transplant recipient, comprising administering to the transplant recipient an amount of a compound effective to treat or prevent the allograft transplant rejection wherein the compound is selected from the title compds, is claimed. A method of inhibiting a signal transduction cascade in which JAK3 kinase plays a role, comprising contacting a cell expressing a receptor involved in said signaling cascade with title compds, is claimed.


IT 916744-12-2P 916744-17-7P 947677-67-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine-2,4-diamine sulfonamides for inhibition of JAK pathway)


RN 916744-12-2 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916744-17-7 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)



RN 947677-67-0 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



10/568,367

RE.CNT 26      THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 25 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:734100 CAPLUS  
 DN 149:79629  
 TI Preparation of N,N'-diarylpyrimidinediamine for use as protein kinase inhibitors  
 IN Michellys, Pierre-Yves; Pei, Wei; Marsilje, Thomas H.; Lu, Wenshuo; Chen, Bei; Uno, Tetsuo; Jin, Yunho; Jiang, Tao  
 PA IRM LLC, Bermuda  
 SO PCT Int. Appl., 199pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008073687	A2	20080619	WO 2007-US85304	20071120
	WO 2008073687	A3	20080731		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	AU 2007333394	A1	20080619	AU 2007-333394	20071120
	CA 2671744	A1	20080619	CA 2007-2671744	20071120
	US 20080176881	A1	20080724	US 2007-943436	20071120
	KR 2009087127	A	20090814	KR 2009-714175	20071120
	EP 2091918	A2	20090826	EP 2007-864693	20071120
	R:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRAI	US 2006-869299P	P	20061208		
	US 2007-966449P	P	20070828		
	WO 2007-US85304	W	20071120		
OS	MARPAT 149:79629				
AB	Title compds. I [R1 and R2 independently = halo, OR12, (un)substituted alkyl, alkynyl, etc.; or one of R1 or R2 = H; or R1 and R2 together form (un)substituted monocyclic or fused carbocyclic ring, aryl, heteroaryl, etc.; R3 = CN, SO2R12, (CR5)2CO2R12, etc.; R4 = H, NO2, halo, (un)substituted alkyl, alkenyl, etc.; R5 = H or alkyl; R6 = substituted aryl or heteroaryl; R12 = H, alkyl, aryl, etc.], and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase inhibitors. Thus, e.g., II was prepared by amidation of 4-aminopiperidine-1-carboxylic acid tert-Bu ester with 2-chloro-4-isopropoxy-5-nitrobenzoyl chloride (preparation given), followed by coupling with vinylboronic acid di-Bu ester, cyclization, reduction, substitution with (2,5-dichloropyrimidin-4-yl)-[2-(propane-2-sulfonyl)phenyl]amine (preparation given), and deprotection. I were evaluated in BaF3-NPM-ALK cell assays and, in general, demonstrated IC50 values from 1 nM to 10 $\mu$ M.				
IT	1032900-37-0P	1032900-40-5P	1032900-41-6P		


1032900-42-7P	1032900-49-4P	1032900-68-7P
1032900-82-5P	1032900-86-9P	1032900-87-0P
1032901-11-3P	1032901-13-5P	1032901-14-6P
1032901-15-7P	1032901-16-8P	1032901-18-0P
1032901-22-6P	1032901-28-2P	1032901-32-8P
1032901-33-9P	1032901-34-0P	1032901-36-2P
1032901-38-4P	1032901-40-8P	1032901-42-0P
1032901-44-2P	1032901-45-3P	1032901-46-4P
1032901-47-5P	1032901-53-3P	1032901-54-4P
1032901-55-5P	1032901-56-6P	1032901-58-8P
1032901-59-9P	1032901-61-3P	1032901-62-4P
1032901-63-5P	1032901-64-6P	1032903-23-3P
1032903-40-4P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N,N'-diarylpyrimidinediamine for use as protein kinase inhibitors)


RN 1032900-37-0 CAPLUS

CN Benamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)



RN 1032900-40-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[cis-4-(dimethylamino)cyclohexyl]-5-methyl-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




Relative stereochemistry.

RN 1032900-41-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[trans-4-(dimethylamino)cyclohexyl]-5-methyl-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

Relative stereochemistry.




RN 1032900-42-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 1032900-49-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopropyl- (CA INDEX NAME)




RN 1032900-68-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-methyl-2-(1-methylethoxy)-5-(4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 1032900-82-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-methyl-2-(1-methylethoxy)-5-(3-methyl-5-isoxazolyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032900-86-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-(5-isoxazolyl)-4-methyl-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032900-87-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-methyl-2-(1-methylethoxy)-5-(2-methyl-1H-imidazol-5-yl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-11-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidiny)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-13-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidiny)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 1032901-14-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 1032901-15-7 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1032901-16-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 1032901-18-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-fluoro-5-methyl-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1032901-22-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(5-methoxy-2-methyl[1,1'-biphenyl]-4-yl)amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-28-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4'-(dimethylamino)-5-methoxy-2,3'-dimethyl[1,1'-biphenyl]-4-yl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-32-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methoxy-2-methyl-4'-(4-morpholinyl)[1,1'-biphenyl]-4-yl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-33-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methoxy-2-methyl-4'-(methanolsulfonyl)[1,1'-biphenyl]-4-yl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-34-0 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-2'-methyl- (CA INDEX NAME)




RN 1032901-36-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4'-acetyl-5-methoxy-2-methyl[1,1'-biphenyl]-4-yl)amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-38-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-N,2'-dimethyl- (CA INDEX NAME)




RN 1032901-40-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-2'-methyl- (CA INDEX NAME)




RN 1032901-42-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-methyl-4-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-44-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methyl-2-(1-methylethoxy)-4-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-45-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methyl-2-[(1-methyl-4-piperidinyl)oxy]-4-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032901-46-4 CAPLUS

CN Benzamide, 5-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl-4-(1-methylethoxy)-2-(4-pyridinyl)- (CA INDEX NAME)




RN 1032901-47-5 CAPLUS

CN Benzamide, 5-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2-(2-fluoro-4-pyridinyl)-N-methyl-4-(1-methylethoxy)- (CA INDEX NAME)




RN 1032901-53-3 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-2'-cyano-N-methyl-5'-(1-methylethoxy)- (CA INDEX NAME)




RN 1032901-54-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[4-[[2-(aminosulfonyl)phenyl]amino]-5-chloro-2-pyrimidinyl]amino]-N,2'-dimethyl-5'-(1-methylethoxy)- (CA INDEX NAME)




RN 1032901-55-5 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-cyclopropyl-5'-methoxy-2'-methyl- (CA INDEX NAME)




RN 1032901-56-6 CAPLUS

CN Acetamide, N-[[4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-2'-methyl[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)




RN 1032901-58-8 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(cyclopropylmethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-N,2'-dimethyl- (CA INDEX NAME)




RN 1032901-59-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[5-chloro-4-[[2-[(cyclobutylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-N,2'-dimethyl- (CA INDEX NAME)




RN 1032901-61-3 CAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 4'-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-5'-methoxy-2'-methyl- (CA INDEX NAME)




RN 1032901-62-4 CAPLUS

CN [1,1'-Biphenyl]-4-carboxamide, 4'-[[4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-5-fluoro-2-pyrimidinyl]amino]-5'-methoxy-N,2'-dimethyl- (CA INDEX NAME)



RN 1032901-63-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methoxy-2-methyl-4'-(4-morpholylsulfonyl)[1,1'-biphenyl]-4-yl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 1032901-64-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-methoxy-2-methyl-4'-(4-methyl-1-piperazinyl)[1,1'-biphenyl]-4-yl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)






RN 1032903-23-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 1032903-40-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-(1-methyl-4-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L7 ANSWER 26 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:690439 CAPLUS  
 DN 149:215075  
 TI 2,5-Diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3)  
 AU Lum, Christopher; Kahl, Jeff; Kessler, Linda; Kucharski, Jeff; Lundstrom, Jan; Miller, Stephen; Nakanishi, Hiroshi; Pei, Yazhong; Pryor, Kent; Roberts, Edward; Sebo, Lubomir; Sullivan, Robert; Urban, Jan; Wang, Zhijun  
 CS Kemia, Inc., San Diego, CA, 92121, USA  
 SO Bioorganic & Medicinal Chemistry Letters (2008), 18(12), 3578-3581  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Ltd.  
 DT Journal  
 LA English  
 AB The discovery of two classes of pyrimidine-based inhibitors of GSK-3 is described. Optimization of these series led to inhibitors with IC50 < 10 nM and >100-fold selectivity over Aurora A kinase. A proposed binding mode of 21b is presented. One compound (33) of the pyrimidine series showed promising pharmacokinetic parameters.  
 IT 358789-05-6 1043428-81-4  
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (2,5-diaminopyrimidines and 3,5-disubstituted azapurines as inhibitors of glycogen synthase kinase-3 (GSK-3))  
 RN 358789-05-6 CAPLUS  
 CN Benzoic acid, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1043428-81-4 CAPLUS  
 CN Benzoic acid, 4-[[5-fluoro-4-(phenylamino)-2-pyrimidinyl]amino]- (CA INDEX NAME)




OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 27 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:605237 CAPLUS  
 DN 149:44292  
 TI Development and Experimental Validation of a Docking Strategy for the  
 Generation of Kinase-Targeted Libraries  
 AU Gozalbes, Rafael; Simon, Laurence; Froloff, Nicolas; Sartori, Eric;  
 Monteils, Claude; Baudelle, Romuald  
 CS Cerep, Courtaboeuf, 91951, Fr.  
 SO Journal of Medicinal Chemistry (2008), 51(11), 3124-3132  
 CODEN: JMCMAR; ISSN: 0022-2623  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 149:44292  
 AB A high-throughput docking strategy for the filtering of in silico compds.  
 and the generation of kinase-targeted libraries is described. Systematic  
 docking and scoring in three kinase crystal 3D structures of 123  
 structurally diverse kinase ligands led to the determination of six thresholds  
 for each kinase. These thresholds were used as filters for the virtual  
 screening of two collections of compds.: a collection of more than 2500  
 drugs and drug-like compds. (neg. control) and a kinase-targeted library  
 of 1440 compds. This strategy was then exptl. validated by testing 60  
 compds. from the kinase-targeted library on 41 kinases from five different  
 families. The 60 compds. were split into those passing all the thresholds  
 and the others (30 compds. in each group). The overall hit enrichment was  
 6.70-fold higher in the first group, validating our approach for the  
 generation of kinase-targeted libraries and the identification of  
 scaffolds with high kinase inhibitory potential.  
 IT 1032182-71-0 1032183-86-0  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (development and validation of docking strategy for generation of  
 kinase-targeted libraries)  
 RN 1032182-71-0 CAPLUS  
 CN Benzamide, N-[2-[4-(dimethylamino)phenyl]ethyl]-4-[[2-[(3-  
 methylphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1032183-86-0 CAPLUS  
 CN Benzamide, N-methyl-3-[[2-[(3-methylphenyl)amino]-4-pyrimidinyl]amino]-N-  
 [2-(2-pyridinyl)ethyl]- (CA INDEX NAME)



10/568,367

OSC.G	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT	48	THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 28 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:502588 CAPLUS  
 DN 148:472065  
 TI Preparation of 2,4-pyrimidinediamine derivatives as JAK kinase inhibitors  
 IN Li, Hui; Argade, Ankush; Thota, Sambaiah; Carroll, David; Sran, Arvinder;  
 Cooper, Robin; Singh, Rajinder; Tso, Kin; Bhamidipati, Somasekhar  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 142pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008049123	A2	20080424	WO 2007-US82020	20071019
	WO 2008049123	A3	20080619		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW		
	RW:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA		
	CA 2673125	A1	20080424	CA 2007-2673125	20071019
	US 20080194603	A1	20080814	US 2007-875772	20071019
	EP 2089369	A2	20090819	EP 2007-854253	20071019
	R:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR		
PRAI	US 2006-862162P	P	20061019		
	WO 2007-US82020	W	20071019		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 148:472065

AB The title 2,4-pyrimidinediamine derivs. I [wherein A = (hetero)aryl; p = 0-5; q = 0-3; X = H, OH, (un)substituted alkyl, alkoxy, NH<sub>2</sub>, etc.; Y = H, (un)substituted aminosulfonylalkyl, etc.; Z1-Z3 = independently CH or N; R1 = H, (un)substituted (cyclo)alkyl, alkenyl, or alkynyl; R2 = independently (un)substituted alkyl, alkoxy, alkynyl, amino, etc.; R3 = independently (un)substituted alkyl, alkoxy, alkynyl, etc.; R4 = (un)substituted aminosulfonyl, aminosulfonylalkyl, etc.] or pharmaceutically acceptable salts thereof were prepared as JAK kinase inhibitors for the treatment of autoimmune disease, transplant rejection, type IV hypersensitivity, etc. For example, II was prepared in a multi-step synthesis. The compds. showed inhibitory activity with EC<sub>50</sub> of 40-100 nM against human U937 monocytic cell lines.

IT 1019855-56-1P 1019855-57-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 2,4-pyrimidinediamine derivs. as JAK kinase inhibitors)

RN 1019855-56-1 CAPLUS


CN Benzenemethanesulfonamide, 3-[[5-fluoro-4-[[3-

[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1019855-57-2 CAPLUS

CN Benzenemethanesulfonamide, 3-[[4-[[3-[(dimethylamino)sulfonyl]phenyl]amino]-5-fluoro-2-pyrimidinyl]amino]- (CA INDEX NAME)



L7 ANSWER 29 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:474245 CAPLUS  
 DN 148:447347  
 TI An oncogene arising from a fusion of the EML4 and ALK genes of human and  
 its use in the diagnosis and treatment of cancers  
 IN Mano, Hiroyuki; Kuromitsu, Sadao; Shindo, Nobuaki; Soga, Takatoshi;  
 Furutani, Takashi  
 PA Astellas Pharma Inc., Japan; Curegene K.K.  
 SO Can. Pat. Appl., 156pp.  
 CODEN: CPXXEB  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CA 2598893	A1	20080411	CA 2007-2598893	20070824
	US 20080090776	A1	20080417	US 2007-845498	20070827
	EP 1914240	A1	20080423	EP 2007-254044	20071011
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2008295444	A	20081211	JP 2007-265917	20071011
	JP 4303303	B2	20090729		
	US 20090099193	A1	20090416	US 2008-100595	20080410
	US 7605131	B2	20091020		
	JP 2009100783	A	20090514	JP 2009-35918	20090218
PRAI	JP 2006-277718	A	20061011		
	JP 2007-120670	A	20070501		
	CA 2007-2598893	A	20070824		
	EP 2007-254044	A	20071011		
	JP 2007-265917	A	20071011		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A chimeric gene arising from a fusion of the EML4 and ALK genes as a  
 result of an inversion on human chromosome 2 is identified in a number of  
 cancers. Detection of the oncogene, or its gene product, may be useful in  
 the diagnosis of cancers, and the gene product may be a target for drug  
 therapy. The fusion gene mRNA was identified in a lung adenocarcinoma  
 patient and was found in tissue from non-small cell lung cancer patients.  
 The fusion protein is active as a kinase, retaining the kinase activity of  
 the ALK anaplastic lymphoma kinase gene product. Inhibitors of the kinase  
 activity were effective at inhibiting growth of cells expressing the  
 oncogene. SiRNAs directed against the mRNA of the chimeric gene were also  
 effective at inhibiting cell proliferation.


IT 761436-81-1

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (as kinase inhibitor of EML4-ALK fusion protein; oncogene arising from  
 fusion of EML4 and ALK genes of human and its use in diagnosis and  
 treatment of cancers)

RN 761436-81-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-methyl-1-  
 piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/568,367





L7 ANSWER 30 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:161408 CAPLUS  
 DN 149:143328  
 TI TAE226 Inhibits Human Neuroblastoma Cell Survival  
 AU Beierle, Elizabeth A.; Trujillo, Angelica; Nagaram, Abhilasha;  
 Golubovskaya, Vita M.; Cance, William G.; Kurenova, Elena V.  
 CS Department of Surgery, College of Medicine, University of Florida,  
 Gainesville, FL, USA  
 SO Cancer Investigation (2008), 26(2), 145-151  
 CODEN: CINVD7; ISSN: 0735-7907  
 PB Informa Healthcare  
 DT Journal  
 LA English  
 AB Purpose. Neuroblastoma is one of the most devastating pediatric solid tumors and is unresponsive to many interventions. TAE226 is a novel small mol. FAK inhibitor. We investigated the effects of TAE226 on neuroblastoma cells in vitro. Materials and Methods. Human neuroblastoma cell lines were treated with varying concns. of TAE226. Following treatment, cell viability, cell cycle, and apoptosis were evaluated. Results. Treatment of human neuroblastoma cell lines with TAE226 resulted in a concentration dependent decrease in FAK phosphorylation, decrease in cellular viability, cell cycle arrest, and an increase in apoptosis. Conclusions. Targeting FAK provides potential therapeutic options for the treatment of neuroblastoma and deserves further investigation.  
 IT 761437-28-9  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (TAE226 decreased focal adhesion kinase Y397 phosphorylation, viability, resulted cell cycle arrest and increased apoptosis in human neuroblastoma cell)  
 RN 761437-28-9 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 31 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:43949 CAPLUS  
 DN 148:135983  
 TI Methods of using IGF1R and abl kinase modulators for the treatment of  
 cancer, and use with other therapies  
 IN Zhang, Wentao  
 PA Exelixis, Inc., USA  
 SO PCT Int. Appl., 187pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008005538	A2	20080110	WO 2007-US15585	20070703
	WO 2008005538	A3	20080724		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW		
	RW:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA		
	AU 2007269540	A1	20080110	AU 2007-269540	20070703
	CA 2656290	A1	20080110	CA 2007-2656290	20070703
	EP 2043651	A2	20090408	EP 2007-796723	20070703
	R:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS		
	US 20090232828	A1	20090917	US 2009-306606	20090415
PRAI	US 2006-818568P	P	20060705		
	WO 2007-US15585	W	20070703		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS CASREACT 148:135983; MARPAT 148:135983  
 AB The invention provides methods for treating cancer with a compound which inhibits kinases, more specifically IGF1R and Abl, in combination with treatments(s) selected from surgery, radiation, monoclonal antibody, bone marrow or peripheral blood stem cell transplantation, and one or more chemotherapeutic agent(s).  
 IT 898280-28-9  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (IGF1R and abl kinase modulators for treatment of cancer, and use with other therapies)  
 RN 898280-28-9 CAPLUS  
 CN Benzenepropanamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(diethylamino)ethyl]- (CA INDEX NAME)

10/568,367



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L7 ANSWER 32 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2007:1306239 CAPLUS  
 DN 148:623  
 TI Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma  
 AU Halder, Jyotsnabaran; Lin, Yvonne G.; Merritt, William M.; Spannuth, Whitney A.; Nick, Alpa M.; Honda, Toshiyuki; Kamat, Aparna A.; Han, Liz Y.; Kim, Tae Jin; Lu, Chunhua; Tari, Ana M.; Bornmann, William; Fernandez, Ariel; Lopez-Berestein, Gabriel; Sood, Anil K.  
 CS Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA  
 SO Cancer Research (2007), 67(22), 10976-10983  
 CODEN: CNREA8; ISSN: 0008-5472  
 PB American Association for Cancer Research  
 DT Journal  
 LA English  
 AB Focal adhesion kinase (FAK) overexpression is frequently found in ovarian and other cancers and is predictive of poor clin. outcome. In the current study, we characterized the biol. and therapeutic effects of a novel FAK inhibitor, TAE226. Taxane-sensitive (SKOV3i.p.1 and HeyA8) and taxane-resistant (HeyA8-MDR) cell lines were used for in vitro and in vivo therapy expts. using TAE226 alone and in combination with docetaxel. Assessment of cytotoxicity, cell proliferation [proliferating cell nuclear antigen (PCNA)], angiogenesis (CD31), and apoptosis (terminal nucleotidyl transferase-mediated nick end labeling) were done by immunohistochem. and immunofluorescence. In vitro, TAE226 inhibited the phosphorylation of FAK at both Y397 and Y861 sites, inhibited cell growth in a time- and dose-dependent manner, and enhanced docetaxel-mediated growth inhibition by 10- and 20-fold in the taxane-sensitive and taxane-resistant cell lines, resp. In vivo, FAK inhibition by TAE226 significantly reduced tumor burden in the HeyA8, SKOV3i.p.1, and HeyA8-MDR models (46-64%) compared with vehicle-treated controls. However, the greatest efficacy was observed with concomitant administration of TAE226 and docetaxel in all three models (85-97% reduction, all P values <0.01). In addition, TAE226 alone and in combination with chemotherapy significantly prolonged survival in tumor-bearing mice. Even in larger tumors, combination therapy with TAE226 and docetaxel resulted in tumor regression. The therapeutic efficacy was related to reduced pericyte coverage, induction of apoptosis of tumor-associated endothelial cells, and reduced microvessel d. and tumor cell proliferation. The novel FAK inhibitor, TAE226, offers an attractive therapeutic approach in ovarian carcinoma.  
 IT 761437-28-9  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antitumor efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma)  
 RN 761437-28-9 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



OSC.G	16	THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)
RE.CNT	49	THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 33 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2007:969605 CAPLUS  
 DN 147:323004  
 TI Preparation of pyrimidine-2,4-diamines for inhibition of the JAK pathway  
 IN Argade, Ankush; Sran, Arvinder; Carroll, David; Clough, Jeffrey; Tso, Kin;  
 Bhamidipati, Somasekhar; Thota, Sambaiah; Singh, Rajinder; Taylor,  
 Vanessa; Li, Hui; Masuda, Esteban  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO U.S. Pat. Appl. Publ., 106 pp., Cont.-in-part of U.S. Ser. No. 450,901.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070203161	A1	20070830	US 2007-678429	20070223
	US 20060293311	A1	20061228	US 2006-450901	20060608
	US 7491732	B2	20090217		
	WO 2008079907	A1	20080703	WO 2007-US88241	20071219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,				
	CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,				
	GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,				
	KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,				
	MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,				
	PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,				
	TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,				
	GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,				
	BY, KG, KZ, MD, RU, TJ, TM				
	US 20080221089	A1	20080911	US 2008-30069	20080212
	US 20080306099	A1	20081211	US 2008-30031	20080212
	US 20090041786	A1	20090212	US 2008-193627	20080818
PRAI	US 2006-776636P	P	20060224		
	US 2006-450901	A2	20060608		
	US 2006-871098P	P	20061220		
	US 2005-689032P	P	20050608		
	US 2005-706638P	P	20050808		
	US 2007-678429	A	20070223		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 147:323004

AB The invention encompasses pyrimidine-2,4-diamines I; wherein X = alkyl, alkoxy, amino, carboxy, carboxy ester, cyano, halo, nitro, alkenyl, alkynyl; Y is H, alkyl, amino, halo; ring A = aryl, heteroaryl, cycloalkyl, cyclo-alkenyl and heterocyclic, R = H, alkyl, alkenyl, alkynyl, cycloalkyl; ring A is not indolyl or benzimidazolyl; p = 0-3; q = 1-3; R2 = alkyl, alkoxy, amino, aryl, aryl-oxy, cycloalkyl, cycloalkyl heteroaryl, heteroaryl, heterocycle, heterocyclyl-oxy, carboxyl, carboxyl ester, OH, acylamino, amino-sulfonyl, alkynyl, alkylthio, amino-carbonyl, acyl, oxo, halo; R3 = alkyl, cycloalkyl, halo, heterocyclic, amino-sulfonyl; R4 and R5 are independently = H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, acyl; R4 and R5 together with the N atom to which they are attached, form a heterocycle; and metal or ammonium counterion; and the compns. and methods using these compds. in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful. Thus,

N4-(3-acetyl-amino-4-hydroxyphenyl)-N2-(3-amino-sulfonyl-phenyl)-5-fluoro-2,4-pyrimidine-diamine was prepared by condensation of 4-amino-benzenesulfonamide with 2-chloro-5-fluoro-N4-[4-(3-fluoro-propyl)phenyl]-4-pyrimidin-amine. Results for an assay for Ramos B-cell line stimulated with IL-4, primary human T-cell proliferation assay stimulated with IL-2, assay for A549 epithelial line stimulated with IFN $\gamma$  and U937 IFN $\gamma$  ICAM1 FACS assay (all of which involve the JAK/Stat pathway) are tabulated for hundreds of examples of I. A method of treating or preventing allograft transplant rejection in a transplant recipient, comprising administering to the transplant recipient an amount of a compound effective to treat or prevent the allograft transplant rejection wherein the compound is selected from the title compds, is claimed. A method of inhibiting a signal transduction cascade in which JAK3 kinase plays a role, comprising contacting a cell expressing a receptor involved in said signaling cascade with title compds, is claimed.


IT 916744-12-2P 916744-17-7P 947677-67-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine-2,4-diamine sulfonamides for inhibition of JAK pathway)


RN 916744-12-2 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)



RN 916744-17-7 CAPLUS


CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)



RN 947677-67-0 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


10/568,367




OSC.G      2      THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)



L7 ANSWER 34 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2007:746527 CAPLUS  
 DN 147:202997  
 TI N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: Indazoles as phenol isosteres with improved pharmacokinetics  
 AU Bamborough, Paul; Angell, Richard M.; Bhamra, Inder; Brown, David; Bull, James; Christopher, John A.; Cooper, Anthony W. J.; Fazal, Lynsey H.; Giordano, Ilaria; Hind, Lucy; Patel, Vipulkumar K.; Ranshaw, Lisa E.; Sims, Martin J.; Skone, Philip A.; Smith, Kathryn J.; Vickerstaff, Emma; Washington, Melanie  
 CS Medicines Research Centre, GlaxoSmithKline R&D, Hertfordshire, SG1 2NY, UK  
 SO Bioorganic & Medicinal Chemistry Letters (2007), 17(15), 4363-4368  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 147:202997  
 AB 2,4-Dianilino pyrimidines are well-known inhibitors of tyrosine kinases including lymphocyte specific kinase (Lck). Structure-activity relationships at the 4-position are discussed and rationalized. Examples bearing a 2-methyl-5-hydroxyaniline substituent at the 4-position were especially potent but showed poor oral pharmacokinetics. Replacement of this substituent by 4-amino(5-methyl-1H-indazole) yielded compds. with comparable enzyme potency and improved pharmacokinetic properties.  
 IT 944795-12-4P 944795-18-0P 944795-19-1P  
 944795-20-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (pyrimidinylindazolamine inhibitors of Lck as phenol isosteres with improved pharmacokinetics)  
 RN 944795-12-4 CAPLUS  
 CN Benzamide, 3-[[4-[(2-methylphenyl)amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 944795-18-0 CAPLUS  
 CN Benzamide, 3-[[2-[[3-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-4-methyl- (CA INDEX NAME)



RN 944795-19-1 CAPLUS


CN Benzamide, 3-[[2-[[3-(aminocarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N,4-trimethyl- (CA INDEX NAME)



RN 944795-20-4 CAPLUS

CN Benzamide, 3-[[4-[[2-methyl-5-[(methylsulfonyl)amino]phenyl]amino]-2-pyrimidinyl]amino]-N,N,4-trimethyl- (CA INDEX NAME)

10/568,367



OSC.G	11	THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
RE.CNT	19	THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 35 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2007:667606 CAPLUS

DN 147:63669

TI A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth

AU Shi, Qing; Hjelmeland, Anita B.; Keir, Stephen T.; Song, Linhua; Wickman, Sarah; Jackson, Dowdy; Ohmori, Osamu; Bigner, Darell D.; Friedman, Henry S.; Rich, Jeremy N.

CS Department of Surgery, Duke University Medical Center, Durham, NC, USA

SO Molecular Carcinogenesis (2007), 46(6), 488-496

CODEN: MOCAE8; ISSN: 0899-1987

PB Wiley-Liss, Inc.

DT Journal

LA English

AB Glioblastomas are highly lethal cancers that resist current therapies. Novel therapies under development target mol. mechanisms that promote glioblastoma growth. In glioblastoma patient specimens, the non-receptor tyrosine kinase focal adhesion kinase (FAK) is overexpressed. Upon growth factor receptor stimulation or integrin engagement, FAK is activated by phosphorylation on critical tyrosine residues. Activated FAK initiates a signal transduction cascade which promotes glioma growth and invasion by increasing cellular adhesion, migration, invasion, and proliferation. We find that human glioma cell lines express different levels of total FAK protein and activating phosphorylation of tyrosine residues Tyr397, Tyr861, and Tyr925. As all glioma cell lines examined expressed phosphorylated FAK, we examined the efficacy of a novel low-mol. weight inhibitor of FAK, TAE226, against human glioma cell lines. TAE226 inhibited the phosphorylation of FAK as well as the downstream effectors AKT, extracellular signal-related kinase, and S6 ribosomal protein in multiple glioma cell lines. TAE226 induced a concentration-dependent decrease

in


cellular proliferation with an associated G2 cell cycle arrest in every cell line and an increase in apoptosis in a cell-line-specific manner. TAE226 also decreased glioma cell adhesion, migration, and invasion through an artificial extracellular matrix. Together, these data demonstrate the potential benefit of TAE226 for glioma therapy.

IT 761437-28-9

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(low-mol. weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth)

RN 761437-28-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




10/568,367

OSC.G	24	THERE ARE 24 CAPLUS RECORDS THAT CITE THIS RECORD (24 CITINGS)
RE.CNT	19	THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 36 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2007:566890 CAPLUS  
 DN 147:180515  
 TI Virtual Screening Studies to Design Potent CDK2-Cyclin A Inhibitors  
 AU Vadivelan, S.; Sinha, Barij Nayan; Irudayam, Sheeba Jem; Jagarlapudi, Sarma A. R. P.  
 CS GVK Biosciences Pvt. Ltd., Hyderabad, 500037, India  
 SO Journal of Chemical Information and Modeling (2007), 47(4), 1526-1535  
 CODEN: JCISD8; ISSN: 1549-9596  
 PB American Chemical Society  
 DT Journal  
 LA English  
 AB The cell division cycle is controlled by cyclin-dependent kinases (CDK), which consist of a catalytic subunit (CDK1-CDK8) and a regulatory subunit (cyclin A-H). Pharmacophore anal. indicates that the best inhibitor model consists of (1) two hydrogen bond acceptors, (2) one hydrogen bond donor, and (3) one hydrophobic feature. The HypoRefine pharmacophore model gave an enrichment factor of 1.31 and goodness of fit score of 0.76. Docking studies were carried out to explore the structural requirements for the CDK2-cyclin A inhibitors and to construct highly predictive models for the design of new inhibitors. Docking studies demonstrate the important role of hydrogen bond and hydrophobic interactions in determining the inhibitor-receptor binding affinity. The validated pharmacophore model is further used for retrieving the most active hits/lead from a virtual library of mols. Subsequently, docking studies were performed on the hits, and novel series of potent leads were suggested based on the interaction energy between CDK2-cyclin A and the putative inhibitors.  
 IT 260044-97-1 280578-83-8 280578-93-0  
 RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)  
 (virtual screening studies to design CDK2-cyclin A inhibitors)  
 RN 260044-97-1 CAPLUS  
 CN 2-Propanol, 1-(dimethylamino)-3-[4-[[4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)




RN 280578-83-8 CAPLUS  
 CN 2-Propanol, 1-[[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)]- (CA INDEX NAME)



10/568,367

RN 280578-93-0 CAPLUS


CN 2-Propanol, 1-[4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)- (CA INDEX NAME)



OSC.G 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)  
RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 37 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2007:412514 CAPLUS  
 DN 147:28253  
 TI Inhibition of both focal adhesion kinase and insulin-like growth factor-I  
 receptor kinase suppresses glioma proliferation in vitro and in vivo  
 AU Liu, Ta-Jen; LaFortune, Tiffany; Honda, Toshiyuki; Ohmori, Osamu;  
 Hatakeyama, Shinji; Meyer, Thomas; Jackson, Dowdy; de Groot, John; Yung,  
 W. K. Alfred  
 CS Brain Tumor Center, Department of Neuro-Oncology, The University of Texas  
 M. D. Anderson Cancer Center, USA  
 SO Molecular Cancer Therapeutics (2007), 6(4), 1357-1367  
 CODEN: MCTOCF; ISSN: 1535-7163  
 PB American Association for Cancer Research  
 DT Journal  
 LA English  
 AB Multiple genetic aberrations in human gliomas contribute to their highly  
 infiltrative and rapid growth characteristics. Focal adhesion kinase  
 (FAK) regulates tumor migration and invasion. Insulin-like growth  
 factor-I receptor (IGF-IR), whose expression correlates with tumor grade,  
 is involved in proliferation and survival. We hypothesized that  
 inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter  
 called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR,  
 would suppress the growth and invasion of glioma cells. In culture,  
 TAE226 inhibited extracellular matrix-induced autophosphorylation of FAK  
 (Tyr397). TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR  
 and activity of its downstream target genes such as MAPK and Akt. TAE226  
 retarded tumor cell growth as assessed by a cell viability assay and  
 attenuated G2-M cell cycle progression associated with a decrease in cyclin  
 B1 and phosphorylated cdc2 (Tyr15) protein expression. TAE226 treatment  
 inhibited tumor cell invasion by at least 50% compared with the control in  
 an in vitro Matrigel invasion assay. Interestingly, TAE226 treatment of  
 tumor cells containing wild-type p53 mainly exhibited G2-M arrest, whereas  
 tumor cells bearing mutant p53 underwent apoptosis. Induction of  
 apoptosis by TAE226 was substantiated by detection of caspase-3/7  
 activation and poly(ADP-ribose) polymerase cleavage and by an Annexin V  
 apoptosis assay. More importantly, TAE226 treatment significantly  
 increased the survival rate of animals in an intracranial glioma xenograft  
 model. Collectively, these data show that blocking the signaling pathways  
 of FAK and IGF-IR with TAE226 has the potential to be an efficacious  
 treatment for human gliomas.  
 IT 761437-28-9, NVP-TAE 226  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (inhibition of FAK and IGF-I receptor kinase-related mutated  
 p53-regulated multiple pathways suppressed glioma proliferation by  
 TAE226)  
 RN 761437-28-9 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-  
 pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)





OSC.G	27	THERE ARE 27 CAPLUS RECORDS THAT CITE THIS RECORD (27 CITINGS)
RE.CNT	45	THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 38 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2007:61837 CAPLUS

DN 146:156236

TI Cellular cholesterol absorption modifiers, and their therapeutic use

IN Gardiner, Elisabeth M.; Duron, Sergio G.; Massari, Mark E.; Severance, Daniel L.; Semple, Joseph E.

PA Kalypsys, Inc., USA

SO PCT Int. Appl., 300pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007008541	A2	20070118	WO 2006-US26242	20060705
	WO 2007008541	A3	20070726		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2005-697659P	P	20050708		
	US 2005-697686P	P	20050708		
	US 2005-697814P	P	20050708		
	US 2005-727646P	P	20051017		
	US 2006-782303P	P	20060313		
OS	MARPAT 146:156236				
AB	The invention discloses compds. and methods useful as inhibitors of cholesterol absorption for the treatment or prevention of vascular disease and atherosclerosis.				
IT	920528-52-5 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cholesterol absorption modifiers and therapeutic use)				
RN	920528-52-5 CAPLUS				
CN	2,4-Pyrimidinediamine, N2-(4-methoxyphenyl)-N4-(2-methylphenyl)- (CA INDEX NAME)				

10/568,367



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L7 ANSWER 39 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:1338193 CAPLUS  
 DN 146:77052  
 TI Use of immobilized ligands and mass spectrometry for characterization of  
 enzymes and enzyme-compound complexes  
 IN Drewes, Gerard; Kuester, Bernhard; Kruse, Ulrich; Hopf, Carsten; Eberhard,  
 Dirk; Bantscheff, Marcus; Reader, Valerie  
 PA Cellzome AG, Germany  
 SO PCT Int. Appl., 129pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006134056	A1	20061221	WO 2006-EP62984	20060607
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1734367	A1	20061220	EP 2005-12722	20050614
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	AU 2006259153	A1	20061221	AU 2006-259153	20060607
	CA 2611365	A1	20061221	CA 2006-2611365	20060607
	EP 1891446	A1	20080227	EP 2006-763568	20060607
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008543296	T	20081204	JP 2008-516285	20060607
	IN 2007CN05761	A	20080613	IN 2007-CN5761	20071214
	US 20090238808	A1	20090924	US 2007-2222	20071214
	CN 101223447	A	20080716	CN 2006-80025846	20080115
PRAI	EP 2005-12722	A	20050614		
	US 2005-711399P	P	20050825		
	US 2006-782170P	P	20060314		
	WO 2006-EP62984	W	20060607		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The present invention relates to methods for the characterization of enzymes or of enzyme-compound complexes, wherein the enzyme is obtained from a protein preparation with the help of at least one broad spectrum ligand immobilized on a solid support and wherein the enzyme is characterized by mass spectrometry. These methods are useful for the screening of non-immobilized compound libraries, selectivity profiling of lead compds. and mechanism of action studies in living cells. Thus, "kinobeads", prepared by immobilization of broad-specificity protein kinase ligands on Sepharose beads, were used to isolate protein kinases from lysates of EGF-treated HeLa cells. Immobilized kinases were identified by use of mass spectrometric anal. of peptides. A total of 626 proteins were

identified by this method; of these, 100 were kinases. Using a conventional immunopptn. approach, 503 proteins were identified, of which only 12 were kinases. In another embodiment, kinases of a mouse brain lysate were immobilized on kinobeads and eluted with kinase ligands in order to assess the selectivity of the ligands. In a variation of this method, which allows one to determine a quant. protein affinity profile, cell lysates were first incubated with a kinase ligand, then passed over a kinobead column.

IT 916603-07-1DP, immobilized  
 RL: ARG (Analytical reagent use); SPN (Synthetic preparation); ANST (Analytical study); PREP (Preparation); USES (Uses)  
 (use of immobilized ligands and mass spectrometry for characterization of enzymes and enzyme-compound complexes)  
 RN 916603-07-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[4-(aminomethyl)phenyl]-5-fluoro-N4-phenyl- (CA INDEX NAME)



IT 916603-12-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (use of immobilized ligands and mass spectrometry for characterization of enzymes and enzyme-compound complexes)  
 RN 916603-12-8 CAPLUS  
 CN Carbamic acid, N-[[4-[[5-fluoro-4-(phenylamino)-2-pyrimidinyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
 RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 40 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:1331455 CAPLUS  
 DN 146:57580  
 TI Identification of novel enzyme-interacting compounds using immobilized  
 broad-spectrum ligands  
 IN Drewes, Gerard; Kuester, Bernhard; Kruse, Ulrich; Hopf, Carsten; Eberhard,  
 Dirk; Hantscheff, Marcus; Reader, Valerie  
 PA Cellzome AG, Germany  
 SO Eur. Pat. Appl., 63pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 3


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1734367	A1	20061220	EP 2005-12722	20050614
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	AU 2006259153	A1	20061221	AU 2006-259153	20060607
	CA 2611365	A1	20061221	CA 2006-2611365	20060607
	WO 2006134056	A1	20061221	WO 2006-EP62984	20060607
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1891446	A1	20080227	EP 2006-763568	20060607
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008543296	T	20081204	JP 2008-516285	20060607
	IN 2007CN05761	A	20080613	IN 2007-CN5761	20071214
	US 20090238808	A1	20090924	US 2007-2222	20071214
	CN 101223447	A	20080716	CN 2006-80025846	20080115
PRAI	EP 2005-12722	A	20050614		
	US 2005-711399P	P	20050825		
	US 2006-782170P	P	20060314		
	WO 2006-EP62984	W	20060607		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The present invention relates to methods for the characterization of enzymes or of enzyme-compound complexes, wherein the enzyme is obtained from a protein preparation with the help of at least one broad-spectrum ligand immobilized on a solid support and wherein the enzyme is characterized by mass spectrometry. Broad-spectrum enzyme ligands immobilized on a solid support enable the effective isolation of interacting enzymes out of a protein preparation, preferably a cell lysate. After this isolation, effective methods can be applied either for the characterization of the enzyme bound to the broad-spectrum ligand or for the identification of compound-enzyme interactions. Thus, 4 kinase ligands are immobilized on NHS-activated Sepharose 4 Fast Flow: bisindolylmaleimide VIII, purvalanol B,

7-(4-aminomethyl-phenylamino)-3-(2,6-dichlorophenyl)-1-methyl-1H-[1,6]naphthyridin-2-one, and (2-(4'-aminomethyl-phenylamine)-5-fluoropyrimidin-4-yl)-phenylamine. When mixed with HeLa cell lysates followed by mass spectrometric anal. of tryptic digests of the eluted enzymes, the "kinobeads" identify significantly more kinases compared to the immunopptn. method using anti-phosphotyrosine antibody beads. These methods are useful for the screening of non-immobilized compound libraries, selectivity profiling of lead compds., and mechanism of action studies in living cells.

IT 916603-07-1D, immobilized on NHS-activated Sepharose  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (kinase enzymes identified by; identification of novel enzyme-interacting compds. using immobilized broad-spectrum ligands)  
 RN 916603-07-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[4-(aminomethyl)phenyl]-5-fluoro-N4-phenyl- (CA INDEX NAME)



IT 916603-12-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (synthesis of kinase ligand; identification of novel enzyme-interacting compds. using immobilized broad-spectrum ligands)  
 RN 916603-12-8 CAPLUS  
 CN Carbamic acid, N-[[4-[[5-fluoro-4-(phenylamino)-2-pyrimidinyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 41 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:1312027 CAPLUS  
 DN 146:62737  
 TI Preparation of pyrimidine-2,4-diamines for inhibition of the JAK pathway  
 IN Li, Hui; Thota, Sambaiah; Carroll, David; Argade, Ankush; Tso, Kin; Sran, Arvinder; Clough, Jeffrey; Keim, Holger; Bhamidipati, Somasekhar; Taylor, Vanessa; Cooper, Robin; Singh, Rajinder; Wong, Brian  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 488pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006133426	A2	20061214	WO 2006-US22590	20060608
	WO 2006133426	A3	20071108		
	W:	AE, AG, AL, AM, AN, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HA, HE, HI, HO, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PG, PH, PL, PT, PU, PY, RE, RO, RU, SC, SD, SE, SG, SK, SL, SM, SN, SO, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	AU 2006254840	A1	20061214	AU 2006-254840	20060608
	CA 2608367	A1	20061214	CA 2006-2608367	20060608
	EP 1904457	A2	20080402	EP 2006-784727	20060608
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
	BR 200610876	A2	20081202	BR 2006-10876	20060608
	JP 2008543778	T	20081204	JP 2008-515989	20060608
	MX 2007015464	A	20080304	MX 2007-15464	20071206
	IN 2007KN04776	A	20080718	IN 2007-KN4776	20071210
	CN 101282945	A	20081008	CN 2006-80020533	20071210
	NO 2008000075	A	20080303	NO 2008-75	20080104
	KR 2008017454	A	20080226	KR 2008-700447	20080107
	US 20080306099	A1	20081211	US 2008-30031	20080212
	US 20090041786	A1	20090212	US 2008-193627	20080818
PRAI	US 2005-689032P	P	20050608		
	US 2005-706638P	P	20050808		
	US 2006-776636P	P	20060224		
	US 2006-450901	A1	20060608		
	WO 2006-US22590	W	20060608		

OS MARPAT 146:62737

AB The invention encompasses pyrimidine-2,4-diamines (shown as I and other Markush structures shown in the claims; variables defined below; e.g. N-(3-aminosulfonylphenyl)-5-fluoro-N'-[4-[(5-methylisoxazol-3-yl)methoxy]phenyl]-2,4-pyrimidinediamine (shown as II)) and the compns. and methods using these compds. in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful. For I: X = (un)substituted alkyl,




(un)substituted alkoxy, (un)substituted amino, carboxy, carboxy ester, cyano, halo, nitro, (un)substituted alkenyl, (un)substituted alkynyl; R = H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl; ring A = aryl, heteroaryl, cycloalkyl, cycloalkenyl and heterocyclic, wherein ring A is not indolyl or benzimidazolyl; Y = a bond, -NR<sup>7</sup>-, -C(O)NR<sup>7</sup>-, -NR<sup>7</sup>C(O)-, -NR<sup>7</sup>C(O)O-, -OC(O)NR<sup>7</sup>-, -NR<sup>7</sup>C(O)NR<sup>7</sup>-, O and S, where R<sup>7</sup> = H, (un)substituted alkyl; alk is a bond or a straight or branched chain alkylene group, wherein when alk and Y each are a bond then R<sup>1</sup> is attached to ring A by a single covalent bond; R<sup>1</sup> = cyano, acylamino, aminoacyl, (un)substituted aryl, carboxy, carboxy ester, carboxy ester oxy, (un)substituted heteroaryl, (un)substituted heterocyclic, acyl, aminoacyloxy, and aminocarbonylamino; or R<sup>1</sup>-alk-Y is R<sup>10</sup>-C(O)-S-alk-C(O)-, wherein alk is as defined herein and R<sup>10</sup> is (un)substituted alkyl; or R<sup>1</sup>-alk-Y- is R<sup>11</sup>R<sup>12</sup>NS(O)<sub>2</sub>-, wherein R<sup>11</sup> and R<sup>12</sup> independently are (un)substituted alkyl; p = 0-3 when ring A is a single ring or p is 0-5 when ring A comprises multiple rings. Each R<sub>2</sub> = (un)substituted alkyl, (un)substituted alkoxy, (un)substituted amino, (un)substituted aryl, (un)substituted aryloxy, cyano, (un)substituted cycloalkyl, (un)substituted cycloalkoxy, et al. or two R<sub>2</sub> can form an oxo; Z<sub>1</sub>, Z<sub>2</sub>, and Z<sub>3</sub> each independently is C or N with provisos; q = 0-3; each R<sub>3</sub> = H, (un)substituted alkyl, (un)substituted alkoxy, (un)substituted cycloalkyl, halo, (un)substituted heterocyclic; R<sub>4</sub> and R<sub>5</sub> = H, (un)substituted alkyl, acyl and metal or ammonium counterion; addnl. details including provisos are given in the claims. Results for an assay for Ramos B-cell line stimulated with IL-4, primary human T-cell proliferation assay stimulated with IL-2, assay for A549 epithelial line stimulated with IFN $\gamma$  and U937 IFN $\gamma$  ICAM1 FACS assay (all of which involve the JAK/Stat pathway) are tabulated for hundreds of examples of I. Although the methods of preparation are not claimed, preps. and/or characterization data for many examples of I are included. For example, II was prepared by N-alkylation of 3-aminobenzenesulfonamide by 2-chloro-5-fluoro-N-[4-[(5-methylisoxazol-3-yl)methoxy]phenyl]-4-pyrimidinamine, which was prepared from 5-methyl-3-[(4-aminophenoxy)methyl]isoxazole (preparation given) and 2,4-dichloro-5-fluoropyrimidine.

IT 916742-30-8P, N-(3-Aminosulfonyl-5-methylphenyl)-5-fluoro-N'-[4-[[[1-methylpyrazol-3-yl)amino]carbonyl]phenyl]-2,4-pyrimidinediamine  
 916742-31-9P, N-(3-Aminosulfonyl-5-methylphenyl)-5-fluoro-N'-[4-[[[1-ethylpyrazol-5-yl)amino]carbonyl]phenyl]-2,4-pyrimidinediamine  
 916742-32-0P, N-(3-Aminosulfonyl-5-methylphenyl)-5-fluoro-N'-[4-[[[1-methylpyrazol-5-yl)amino]carbonyl]phenyl]-2,4-pyrimidinediamine  
 916742-33-1P, N-(3-Aminosulfonyl-5-methylphenyl)-5-fluoro-N'-[4-[[[1H-pyrazol-3-yl)amino]carbonyl]phenyl]-2,4-pyrimidinediamine  
 916744-12-2P, N-(3-Aminosulfonyl-4-methylphenyl)-5-fluoro-N'-[4-(prop-2-ynylaminosulfonyl)phenyl]-2,4-pyrimidinediamine  
 916744-17-7P, N-(3-Aminosulfonyl-4-methylphenyl)-5-fluoro-N'-[3-(prop-2-ynylaminosulfonyl)phenyl]-2,4-pyrimidinediamine  
 916745-20-5P, N-(3-Aminosulfonyl-4-methylphenyl)-5-fluoro-N'-[3-(N-methylaminosulfonyl)phenyl]-2,4-pyrimidinediamine 916745-22-7P  
 , N-(3-Aminosulfonyl-4-methylphenyl)-5-fluoro-N'-[3-(N,N-dimethylaminosulfonyl)phenyl]-2,4-pyrimidinediamine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine-2,4-diamine sulfonamides for inhibition of JAK pathway)


RN 916742-30-8 CAPLUS

CN Benzamide, 4-[[2-[[3-(aminosulfonyl)-5-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 916742-31-9 CAPLUS

CN Benzamide, 4-[[2-[[3-(aminosulfonyl)-5-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-ethyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 916742-32-0 CAPLUS

CN Benzamide, 4-[[2-[[3-(aminosulfonyl)-5-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-(1-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)




RN 916742-33-1 CAPLUS

CN Benzamide, 4-[[2-[[3-(aminosulfonyl)-5-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-1H-pyrazol-3-yl- (CA INDEX NAME)



RN 916744-12-2 CAPLUS


CN Benzenesulfonamide, 4-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)



RN 916744-17-7 CAPLUS


CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-

fluoro-4-pyrimidinyl]amino]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 916745-20-5 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 916745-22-7 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-(aminosulfonyl)-4-methylphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L7 ANSWER 42 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:1256680 CAPLUS  
 DN 146:20278  
 TI 2,4-Pyrimidinediamine compound JAK kinase inhibitors, and their  
 therapeutic use  
 IN Wong, Brian  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO U.S. Pat. Appl. Publ., 26pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060270694	A1	20061130	US 2006-416652	20060502
	CA 2604551	A1	20070308	CA 2006-2604551	20060502
	WO 2007027238	A2	20070308	WO 2006-US17008	20060502
	WO 2007027238	A3	20070913		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,				
	KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,				
	MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,				
	SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,				
	VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				
	CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,				
	GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1883302	A2	20080206	EP 2006-824733	20060502
	R:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,				
	BA, HR, MK, YU				
	JP 2008540436	T	20081120	JP 2008-510173	20060502
PRAI	US 2005-678241P	P	20050503		
	WO 2006-US17008	W	20060502		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The invention provides 2,4-pyrimidinediamine compds. that selectively inhibit JAK kinase as compared to Syk kinase, as well as various methods of using the JAK-selective compds. for treating e.g. an immune-related disease.

IT 844435-03-6 845820-93-1  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (pyrimidinediamine compound JAK kinase inhibitors, and therapeutic use)

RN 844435-03-6 CAPLUS


CN Benzamide, 4,4'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis- (CA INDEX NAME)

10/568,367



RN 845820-93-1 CAPLUS

CN Glycine, N-[4-[[4-[[4-(aminocarbonyl)phenyl]amino]-5-fluoro-2-pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L7 ANSWER 43 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:681435 CAPLUS  
 DN 145:137879  
 TI Pyrimidine derivative kinase modulators and therapeutic use  
 IN Chen, Jeff; Dalrymple, Lisa Esther; Epshteyn, Sergey; Forsyth, Timothy  
 Patrick; Huynh, Tai Phat; Ibrahim, Mohamed Abdulkader; Leahy, James W.;  
 Lewis, Gary Lee; Mann, Grace; Mann, Lary W.; Noguchi, Robin Tammie;  
 Ridgway, Brian Hugh; Sangalang, Joan Cruz; Schnepf, Kevin Luke; Shi, Xian;  
 Takeuchi, Craig Stacy; Williams, Matthew Alan; Nuss, John; Cheung, Atwood  
 K.  
 PA Exelixis, Inc., USA  
 SO PCT Int. Appl., 194 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074057	A2	20060713	WO 2005-US47402	20051228
WO 2006074057	A3	20061026		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005322855	A1	20060713	AU 2005-322855	20051228
CA 2590110	A1	20060713	CA 2005-2590110	20051228
EP 1841760	A2	20071010	EP 2005-855893	20051228
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008526759	T	20080724	JP 2007-549634	20051228
US 20080249079	A1	20081009	US 2008-722719	20080321
PRAI US 2004-640439P	P	20041230		
US 2005-704863P	P	20050801		
WO 2005-US47402	W	20051228		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 145:137879; MARPAT 145:137879

AB The invention provides pyrimidine derivs. and methods for inhibition of kinases, more specifically IGF1R kinases. The invention also provides compds. and methods for inhibition of wildtype Abl. The invention provides compds. for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compds. of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compns. which contain these compds., and methods of using them to treat kinase-dependent diseases and conditions. Preparation of pyrimidine derivs. is included.


IT 898280-28-9

10/568,367

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(pyrimidine derivative kinase modulators and therapeutic use)

RN 898280-28-9 CAPLUS

CN Benzenepropanamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(diethylamino)ethyl]- (CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)



L7 ANSWER 44 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:513675 CAPLUS  
 DN 145:34151  
 TI Combinations of JAK kinase inhibitors  
 IN Cooke, Nigel Graham; Manley, Paul W.  
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
 SO PCT Int. Appl., 61 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006056399	A2	20060601	WO 2005-EP12480	20051122
	WO 2006056399	A3	20060831		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	AU 2005309019	A1	20060601	AU 2005-309019	20051122
	CA 2586605	A1	20060601	CA 2005-2586605	20051122
	CN 101106983	A	20080116	CN 2005-80046883	20051122
	EP 1885352	A2	20080213	EP 2005-814596	20051122
	R:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR		
	JP 2008520612	T	20080619	JP 2007-541823	20051122
	BR 2005017887	A	20081021	BR 2005-17887	20051122
	IN 2007DN03463	A	20070831	IN 2007-DN3463	20070509
	US 20090156602	A1	20090618	US 2007-719838	20070521
	MX 2007006204	A	20070620	MX 2007-6204	20070523
	KR 2007085433	A	20070827	KR 2007-711743	20070523
PRAI	US 2004-630713P	P	20041124		
	WO 2005-EP12480	W	20051122		


AB The invention provides a pharmaceutical combination comprising (a) at least one agent selected from Bcr-Abl, Flt-3, FAK and RAF kinase inhibitors; and (b) at least one JAK kinase inhibitor, and a method for treating or preventing a proliferative disease using such a combination. A preferred embodiment of the invention is the combination of a RAF inhibitor, e.g., (4-tert-butylphenyl)-(4-pyridin-4-yl-methyl-isoquinolin-1-yl)amine or [4,7']bi-isoquinolinyl-1-yl-4-(tert-butylphenyl)amine, and a JAK kinase inhibitor, such as PNU 156804 or WHI-P 131 for the treatment of myelomas, especially multiple myeloma.

IT 761437-28-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (combinations of JAK kinase inhibitors with other protein kinase inhibitors for treatment or prevention of proliferative disease)

RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



OSC.G	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT	9	THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 45 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:193590 CAPLUS  
 DN 144:274291  
 TI Preparation of bis(arylamino)pyrimidine derivatives as antitumor agents  
 IN Imbach, Patricia; Kawahara, Eiji; Konishi, Kazuhide; Matsuura, Naoko;  
 Miyake, Takahiro; Ohmori, Osamu; Roesel, Johannes; Teno, Naoki; Umemura,  
 Ichiro  
 PA Novartis AG, Switz.; Novartis Pharma GmbH  
 SO PCT Int. Appl., 118 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021454	A2	20060302	WO 2005-EP9251	20050826
	WO 2006021454	A3	20060504		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	AU 2005276582	A1	20060302	AU 2005-276582	20050826
	AU 2005276582	B2	20090716		
	CA 2577251	A1	20060302	CA 2005-2577251	20050826
	EP 1784392	A2	20070516	EP 2005-776772	20050826
	R:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR		
	CN 101048386	A	20071003	CN 2005-80036888	20050826
	JP 2008510763	T	20080410	JP 2007-528754	20050826
	BR 2005014681	A	20080617	BR 2005-14681	20050826
	ZA 2007001406	A	20080827	ZA 2007-1406	20070215
	IN 2007DN01410	A	20070824	IN 2007-DN1410	20070221
	MX 2007002254	A	20070420	MX 2007-2254	20070223
	KR 2007054223	A	20070528	KR 2007-706800	20070326
	NO 2007001593	A	20070522	NO 2007-1593	20070327
	US 20090131436	A1	20090521	US 2009-574019	20090112
PRAI	GB 2004-19161	A	20040827		
	WO 2005-EP9251	W	20050826		

OS CASREACT 144:274291; MARPAT 144:274291

AB Title compds. I [R1 = H, (substituted) 5- or 6-membered heterocyclyl; R2 = H; R3 = (substituted) sulfamoyl, carbamoyl, 5- or 6-membered heterocyclyl; R2R3 together with N to which they are attached form heterocyclyl; R5 = halo; R7 = H, alkoxy, carbamoyl, (substituted) 5- or 6-membered heterocyclyl; R8 = H, halo, alkoxy, carbamoyl, (substituted) 5- or 6-membered heterocyclyl; R7R8 together form a 6-membered heterocyclyl; R9 = H, (substituted) 5- or 6-membered heterocyclyl; R10 = H, alkoxy], or salts thereof, were prepared. For example, title compound II was prepared from 2-(2,5-dichloropyrimidin-4-ylamino)-N-isobutylbenzenesulfonamide and 4-amino-3-methoxy-N-methylbenzamide. I inhibited ALK (anaplastic lymphoma

kinase) with IC50 = 0.01-1  $\mu$ M.


IT	845813-84-5P	845814-57-5P	878158-44-2P
	878158-45-3P	878158-46-4P	878158-47-5P
	878158-48-6P	878158-49-7P	878158-50-0P
	878158-51-1P	878158-52-2P	878158-53-3P
	878158-54-4P	878158-55-5P	878158-56-6P
	878158-57-7P	878158-58-8P	878158-59-9P
	878158-60-2P	878158-61-3P	878158-62-4P
	878158-63-5P	878158-64-6P	878158-65-7P
	878158-66-8P	878158-67-9P	878158-68-0P
	878158-69-1P	878158-70-4P	878158-71-5P
	878158-72-6P	878158-74-8P	878158-75-9P
	878158-76-0P	878158-77-1P	878158-78-2P
	878158-79-3P	878158-80-6P	878158-81-7P
	878158-82-8P	878158-83-9P	878158-84-0P
	878158-85-1P	878158-86-2P	878158-87-3P
	878158-88-4P	878158-89-5P	878158-90-8P
	878158-91-9P	878158-92-0P	878158-93-1P
	878158-94-2P	878158-95-3P	878158-96-4P
	878158-98-6P	878159-00-3P	878159-01-4P
	878159-03-6P	878159-04-7P	878159-05-8P
	878159-06-9P	878159-07-0P	878159-09-2P
	878159-10-5P	878159-11-6P	878159-12-7P
	878159-61-6P	878159-62-7P	878159-63-8P
	878159-64-9P	878159-65-0P	878159-66-1P
	878159-67-2P	878159-68-3P	878159-69-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bis(arylamino)pyrimidine derivs. as kinase inhibitors and antitumor agents)


RN 845813-84-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-57-5 CAPLUS

CN Benzenesulfonamide, 2-[[[5-bromo-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 878158-44-2 CAPLUS

CN Benzamide, 4-[[5-chloro-4-[[2-[[2-methylpropyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxy-N-methyl- (CA INDEX NAME)




RN 878158-45-3 CAPLUS

CN Benzamide, 3-[[5-chloro-4-[[2-[[2-methylpropyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-4-methoxy-N-methyl- (CA INDEX NAME)




RN 878158-46-4 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[2-methylpropyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-methyl- (CA INDEX NAME)




RN 878158-47-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-48-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-49-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(2R)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878158-50-0 CAPLUS


CN Benzenesulfonamide, 2-[[[5-chloro-2-[[2-methoxy-4-[(2S)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 878158-51-1 CAPLUS

CN Benzenesulfonamide, 2-[[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-52-2 CAPLUS


CN Benzenesulfonamide, 2-[[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-53-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 878158-54-4 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-55-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)






RN 878158-56-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[2-methylpropyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 878158-57-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-(4-hydroxy-1-piperidinyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-58-8 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[5-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878158-59-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 878158-60-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1,2,2,6,6-pentamethyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 878158-61-3 CAPLUS

CN Benzamide, 3-[[5-chloro-4-[[2-[[[(2-methylpropyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-4-methoxy- (CA INDEX NAME)



RN 878158-62-4 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-methyl- (CA INDEX NAME)



RN 878158-63-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-methyl-, (3S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878158-64-6 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-methyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 878158-65-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 878158-66-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 878158-67-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-(4-hydroxy-1-piperidiny)l]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-68-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[[1-(1-methylethyl)-4-piperidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 878158-69-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-fluoro-2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 878158-70-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[(2S)-1-methyl-2-pyrrolidinyl]methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 878158-71-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[[2-(2-methyl-2-pyrrolidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 878158-72-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,4-dimethoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-74-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,4-dimethoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-75-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[[2,4-dimethoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-76-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-77-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-78-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,5-dimethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 878158-79-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 878158-80-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-[2-(4-hydroxy-1-piperidinyloxy)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 878158-81-7 CAPLUS




CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl-  
(CA INDEX NAME)




RN 878158-82-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 878158-83-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,4-dimethoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-84-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-85-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-(4-hydroxy-1-piperidinyloxy)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-86-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[(1-methyl-4-piperidinyloxy)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-87-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[[1-(1-methylethyl)-4-piperidinyloxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-88-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-89-5 CAPLUS

CN Benzenesulfonamide, 2-[[[5-bromo-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-90-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-91-9 CAPLUS

CN Benzenesulfonamide, 2-[[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-92-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-93-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-94-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 878158-95-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 878158-96-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 878158-98-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-hydroxypropyl)- (CA INDEX NAME)




RN 878159-00-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(3-hydroxypropyl)- (CA INDEX NAME)




RN 878159-01-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)




RN 878159-03-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-ethoxyethyl)- (CA INDEX NAME)




RN 878159-04-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 878159-05-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-N-propyl- (CA INDEX NAME)




RN 878159-06-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-N-(2-methylpropyl)- (CA INDEX NAME)




RN 878159-07-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 878159-09-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)



RN 878159-10-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-N-propyl- (CA INDEX NAME)






RN 878159-11-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-N-(2-methylpropyl)- (CA INDEX NAME)



RN 878159-12-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 878159-61-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(ethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 878159-62-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 878159-63-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878159-64-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3R)-3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878159-65-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 878159-66-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 878159-67-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 878159-68-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 878159-69-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(cyclopropylmethoxy)-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

||  
O

OSC.G	5	THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT	6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 46 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:260035 CAPLUS  
 DN 142:336377  
 TI Preparation of 2,4-di(phenylamino)pyrimidines useful in the treatment of  
 proliferative disorders  
 IN Imbach, Patricia; Roesel, Johannes  
 PA Novartis AG, Switz.; Novartis Pharma GmbH  
 SO PCT Int. Appl., 39 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005026130	A1	20050324	WO 2004-EP10466	20040917
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004272288	A1	20050324	AU 2004-272288	20040917
	AU 2004272288	B2	20081113		
	CA 2538413	A1	20050324	CA 2004-2538413	20040917
	EP 1663992	A1	20060607	EP 2004-765358	20040917
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1852900	A	20061025	CN 2004-80026942	20040917
	BR 2004014544	A	20061107	BR 2004-14544	20040917
	JP 2007505858	T	20070315	<del>JP 2006-526595</del>	20040917
	US 20070105839	A1	20070510	US 2006-571733	20060314
	IN 2006CN00922	A	20070615	IN 2006-CN922	20060316
	MX 2006003054	A	20060531	MX 2006-3054	20060317
PRAI	US 2003-504374P	P	20030918		
	WO 2004-EP10466	W	20040917		

OS CASREACT 142:336377; MARPAT 142:336377

AB The title compds. I [X = CR0, N; R0, R1-R4 = H, OH, alkyl, etc.; or R3 and R4 form together with the nitrogen and carbon atoms to which they are attached a 5-10 membered heterocyclic ring and comprising addnl. 1-3 heteroatoms selected from N, O and S; or R1-R3 = halo, haloalkyl, alkoxy, etc.; or R1 and R2 form aryl or 5-10 membered heteroaryl; R5, R6 = H, halo, CN, alkyl, etc.; R7-R9 = H, OH, alkyl, etc.], useful for preventing or treating proliferative disorders such as a tumor disease, by inhibiting ALK activity, were prepared E.g., a 2-step synthesis of 2-[2-(1H-indazol-6-ylamino)-pyrimidin-4-ylamino]benzenesulfonamide, starting from 2-aminobenzenesulfonamide and 2,4-dichloropyrimidine, was given. The compds. I were tested for inhibition of ALK tyrosine kinase in various cellular assays (data were given for representative compds. I).

IT	604800-89-7P	604800-97-7P	604801-01-6P
	604801-02-7P	604801-05-0P	604801-07-2P
	604801-11-8P	604801-13-0P	604801-14-1P
	604801-18-5P	604801-19-6P	604801-25-4P


604801-27-6P	604801-33-4P	604801-34-5P
604801-57-2P	604801-60-7P	604801-63-0P
604801-74-3P	604802-26-8P	604802-60-0P
848468-24-6P	848468-32-6P	848468-33-7P
848468-34-8P	848468-35-9P	848468-37-1P
848468-38-2P	848468-39-3P	848468-41-7P
848468-42-8P	848468-43-9P	848468-46-2P
848468-48-4P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-di(phenylamino)pyrimidines useful in the treatment of proliferative disorders)


RN 604800-89-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604800-97-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[(hexahydro-1-methyl-1H-azepin-4-yl)oxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-01-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-[3-(1H-imidazol-1-yl)propoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-02-7 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-

piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-05-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-(2-hydroxyethoxy)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-07-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-1,2,4-triazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-11-8 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 604801-13-0 CAPLUS




CN Benzenesulfonamide, 2-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-14-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-18-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-19-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-(3,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-25-4 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-[3-(1H-imidazol-1-yl)propoxy]phenyl]amino]-4-

pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-27-6 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-33-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-34-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 604801-57-2 CAPLUS

CN Benzenesulfonamide, 3-[[5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-60-7 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-63-0 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-74-3 CAPLUS

CN Benzenesulfonamide, N-butyl-3-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-26-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604802-60-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-24-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(hexahydro-1-methyl-1H-azepin-4-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-32-6 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-33-7 CAPLUS

CN Benzamide, N-hydroxy-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-34-8 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848468-35-9 CAPLUS


CN Benzenesulfonamide, N,N-dimethyl-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848468-37-1 CAPLUS


CN Benzenesulfonamide, N-propyl-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-

pyrimidinyl]amino]- (CA INDEX NAME)



RN 848468-38-2 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848468-39-3 CAPLUS

CN Benzenesulfonamide, N-[2-(2-hydroxyethoxy)ethyl]-4-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OMe

— OMe


RN 848468-41-7 CAPLUS

CN Benzenesulfonamide, N-2-thiazolyl-4-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 848468-42-8 CAPLUS


CN Benzenesulfonamide, N-2-propen-1-yl-3-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 848468-43-9 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-2-propen-1-yl- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 848468-46-2 CAPLUS


CN Benzenesulfonamide, N-butyl-3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

10/568,367



RN 848468-48-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[3-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



OSC.G 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 47 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:158647 CAPLUS  
 DN 142:261547

TI Preparation of 2,4-pyrimidinediamines useful in the treatment of  
 neoplastic diseases, inflammatory and immune system disorders  
 IN Garcia-echeverria, Carlos; Kanazawa, Takanori; Kawahara, Eiji; Masuya,  
 Keiichi; Matsuura, Naoko; Miyake, Takahiro; Ohmori, Osamu; Umemura,  
 Ichiro; Steensma, Ruo; Chopiuk, Greg; Jiang, Jiqing; Wan, Yongqin; Ding,  
 Qiang; Zhang, Qiong; Gray, Nathanael Schiander; Karanewsky, Donald  
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.; IRM LLC  
 SO PCT Int. Appl., 285 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

Applicant's

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016894	A1	20050224	WO 2004-EP9099	20040813
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004264382	A1	20050224	AU 2004-264382	20040813
CA 2533320	A1	20060224	CA 2004-2533320	20040813
EP 1660458	A1	20060531	EP 2004-764093	20040813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1832929	A	20060913	CN 2004-80022725	20040813
BR 2004013616	A	20061017	BR 2004-13616	20040813
JP 2007502260	T	20070208	JP 2006-522998	20040813
SG 145749	A1	20080929	SG 2008-6063	20040813
KR 2006039938	A	20060509	KR 2006-703056	20060214
KR 904570	B1	20090625		
MX 2006001759	A	20060512	MX 2006-1759	20060214
IN 2006CN00553	A	20070706	IN 2006-CN553	20060214
NO 2006001214	A	20060515	NO 2006-1214	20060315
US 20080132504	A1	20080605	US 2006-568367	20060818
AU 2008229685	A1	20081030	AU 2008-229685	20080929
PRAI GB 2003-19227	A	20030815		
GB 2003-22370	A	20030924		
AU 2004-264382	A3	20040813		
WO 2004-EP9099	W	20040813		
OS CASREACT 142:261547; MARPAT 142:261547				
AB The title compds. I [R = aryl, heteroaryl, cycloalkyl and heterocycloalkyl; R0-R3 = H, alkyl, cycloalkyl, etc.; R4 = H, alkyl; R5, R6 = H, alkyl, alkoxyalkyl, etc.], useful for the manufacture of a medicament for the treatment or prevention of a disease which responds to inhibition of FAK and/or ALK and/or ZAP-70 and/or IGF-IR, were prepared and formulated. E.g., a 2-step synthesis of II, starting from 2,4-dichloro-5-nitropyrimidine and 2-amino-N-methylbenzenesulfonamide, was				

given. The compds. I have IC50 values in the range of 10 nM to 2  $\mu$ M in cell-free ZAP-70 kinase assay.


IT 1044080-82-1

RL: PRPH (Prophetic)

(Preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)

RN 1044080-82-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(3-methoxy-5-phenoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




IT 761436-62-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)

RN 761436-62-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



IT	761436-43-5P	761436-45-7P	761436-46-8P
	761436-47-9P	761436-48-0P	761436-49-1P
	761436-50-4P	761436-52-6P	761436-53-7P
	761436-57-1P	761436-58-2P	761436-59-3P
	761436-60-6P	761436-61-7P	761436-63-9P
	761436-64-0P	761436-65-1P	761436-66-2P
	761436-67-3P	761436-68-4P	761436-69-5P
	761436-70-8P	761436-71-9P	761436-72-0P
	761436-74-2P	761436-75-3P	761436-76-4P
	761436-77-5P	761436-81-1P	761436-82-2P
	761436-83-3P	761436-84-4P	761436-85-5P
	761436-86-6P	761436-88-8P	761436-89-9P
	761436-90-2P	761436-91-3P	761436-93-5P
	761436-94-6P	761436-95-7P	761436-96-8P
	761436-97-9P	761436-98-0P	761436-99-1P
	761437-00-7P	761437-01-8P	761437-02-9P

761437-03-0P	761437-04-1P	761437-05-2P
761437-06-3P	761437-07-4P	761437-08-5P
761437-09-6P	761437-10-9P	761437-11-0P
761437-12-1P	761437-13-2P	761437-14-3P
761437-15-4P	761437-16-5P	761437-17-6P
761437-18-7P	761437-20-1P	761437-21-2P
761437-22-3P	761437-23-4P	761437-24-5P
761437-25-6P	761437-26-7P	761437-28-9P
761437-29-0P	761437-30-3P	761437-31-4P
761437-32-5P	761437-33-6P	761437-34-7P
761437-35-8P	761437-36-9P	761437-37-0P
761437-39-2P	761437-40-5P	761437-41-6P
761437-42-7P	761437-43-8P	761437-44-9P
761437-45-0P	761437-46-1P	761437-47-2P
761437-48-3P	761437-49-4P	761437-50-7P
761437-51-8P	761437-52-9P	761437-53-0P
761437-54-1P	761437-55-2P	761437-59-6P
761437-60-9P	761437-61-0P	761437-62-1P
761437-63-2P	761437-64-3P	761437-65-4P
761437-66-5P	761437-67-6P	761437-68-7P
761437-69-8P	761437-84-7P	761437-85-8P
761437-99-4P	761438-01-1P	761438-02-2P
761438-03-3P	761438-04-4P	761438-05-5P
761438-06-6P	761438-07-7P	761438-08-8P
761438-09-9P	761438-10-2P	761438-11-3P
761438-12-4P	761438-13-5P	761438-14-6P
761438-15-7P	761438-16-8P	761438-17-9P
761438-18-0P	761438-19-1P	761438-20-4P
761438-21-5P	761438-22-6P	761438-23-7P
761438-24-8P	761438-26-0P	761438-27-1P
761438-28-2P	761438-29-3P	761438-30-6P
761438-31-7P	761438-32-8P	761438-33-9P
761438-34-0P	761438-35-1P	761438-36-2P
761438-37-3P	761438-38-4P	761438-39-5P
761438-40-8P	761438-43-1P	761438-44-2P
761438-45-3P	761438-46-4P	761438-47-5P
761438-48-6P	761438-49-7P	761438-50-0P
761438-51-1P	761438-52-2P	761438-53-3P
761438-54-4P	761438-55-5P	761438-56-6P
761438-57-7P	761438-58-8P	761438-59-9P
761438-60-2P	761438-61-3P	761438-62-4P
761438-63-5P	761438-64-6P	761438-65-7P
761438-66-8P	761438-67-9P	761438-68-0P
761438-69-1P	761438-70-4P	761438-71-5P
761438-72-6P	761438-73-7P	761438-74-8P
761438-75-9P	761438-76-0P	761438-77-1P
761438-78-2P	761438-79-3P	761438-80-6P
761438-81-7P	761438-82-8P	761438-83-9P
761438-84-0P	761438-85-1P	761438-86-2P
761438-87-3P	761438-88-4P	761439-98-9P
845811-03-2P	845811-04-3P	845811-05-4P
845811-06-5P	845811-07-6P	845811-08-7P
845811-09-8P	845811-10-1P	845811-11-2P
845811-12-3P	845811-13-4P	845811-14-5P
845811-18-9P	845811-19-0P	845811-20-3P
845811-21-4P	845811-22-5P	845811-23-6P
845811-24-7P	845811-25-8P	845811-26-9P


845811-27-0P      845811-29-2P      845811-31-6P  
 845811-32-7P      845811-33-8P      845811-34-9P  
 845811-48-5P      845811-49-6P      845811-50-9P  
 845811-51-0P      845811-52-1P      845811-53-2P  
 845811-55-4P      845811-56-5P      845811-57-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)


RN 761436-43-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-45-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,4-dimethylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-46-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-methoxy-2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-47-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-fluoro-4-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-48-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxy-4-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-49-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-50-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-52-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-53-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-butylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-57-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,3-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-58-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-59-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,3,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-60-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4,5-dimethoxy-2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-61-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(1-methylethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-63-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-64-0 CAPLUS




CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-65-1 CAPLUS

CN Benzamide, 3-[[5-bromo-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-cyclohexyl-4-methyl- (CA INDEX NAME)




RN 761436-66-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(1-piperazinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-67-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4'-methoxy-4-methyl[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-68-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-69-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2'-methoxy-4-methyl[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-70-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(3'-methoxy-4-methyl[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-71-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-ethoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




CN Benzenesulfonamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-77-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-81-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-82-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(4-cyano-1-piperidinyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-83-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-thiomorpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-84-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[bis(2-methoxyethyl)amino]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-85-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-bromo-4-[[2-((methylamino)sulfonyl]phenyl]amino)-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761436-86-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(1,1-dioxido-4-thiomorpholinyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-88-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-89-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-90-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(1H-imidazol-1-yl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-91-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-93-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[(2-hydroxyethyl)propylamino]-2-methylphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-94-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-chloro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-95-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[3-(dimethylamino)-2-methylphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-96-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-97-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-diethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761436-98-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4,4'-dimethoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-99-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-00-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-01-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-methoxy-2-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-02-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(2-hydroxyethoxy)-5-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-03-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-ethoxy-5-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-04-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-methoxy-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-05-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-methoxy-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-06-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-(dimethylamino)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-07-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-08-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(3-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-09-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(2-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-10-9 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[5-bromo-4-[[2-

[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-  
(CA INDEX NAME)




RN 761437-11-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-12-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-13-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-4-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-14-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-15-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-16-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[(1-acetyl-4-piperidinyl)oxy]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-17-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[5-[(1-acetyl-4-piperidinyl)oxy]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-18-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-20-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-21-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-22-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-23-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-24-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-25-6 CAPLUS




CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(2-methyl-1H-imidazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-26-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-29-0 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-30-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761437-31-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-32-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-33-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-34-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-35-8 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-36-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-hydroxy-1-piperidiny1)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-37-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[4-(2-ethoxyethoxy)-1-piperidiny1]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-39-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(2-methoxyethoxy)-1-piperidiny1]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-40-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-41-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-42-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)



RN 761437-43-8 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-44-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-45-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-46-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-47-2 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 761437-48-3 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-49-4 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-

piperidiny]methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA  
INDEX NAME)




RN 761437-50-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-51-8 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-52-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)





RN 761437-53-0 CAPLUS


CN Benzamide, 2-[[2-[[5-[[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-54-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 761437-55-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-59-6 CAPLUS

CN Benzamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-60-9 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-61-0 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-62-1 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-63-2 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-64-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-65-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-66-5 CAPLUS


CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-67-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidiny]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 761437-68-7 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-69-8 CAPLUS  
 CN Benzamide, 2-[[2-[[5-[1,4'-bipiperidin-1'-yl]-2-methoxyphenyl]amino]-5-

chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-84-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 761437-85-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761437-99-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-fluoro-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 761438-01-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methyamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-02-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(ethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-03-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-04-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-05-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 761438-06-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 761438-07-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)






RN 761438-08-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-09-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-10-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-2,2-dimethylpropyl]amino]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-11-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-fluoro-2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-12-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-fluoro-2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-13-5 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[[[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]- (CA INDEX NAME)



RN 761438-14-6 CAPLUS


CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[[1-(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)




RN 761438-15-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 761438-16-8 CAPLUS


CN Benzenesulfonamide, 2-[[[5-chloro-2-[[2-methoxy-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 761438-17-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-2-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)




RN 761438-18-0 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-N,N-diethyl- (CA INDEX NAME)




RN 761438-19-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761438-20-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)




RN 761438-21-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-fluoro-2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-22-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3-hydroxy-2,2-dimethylpropyl)amino]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-23-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(2-hydroxy-1,1-dimethylethyl)amino]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-24-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-26-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-27-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-28-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-fluoro-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 761438-29-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 761438-30-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)






RN 761438-31-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 761438-32-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)amino]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-33-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-34-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-35-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-36-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(difluoromethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-37-3 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]- (CA INDEX NAME)




RN 761438-38-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-39-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-40-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-43-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-44-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-dimethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-45-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-dimethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-46-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-47-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-((methylamino)sulfonyl]phenyl)amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761438-48-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-49-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-50-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-51-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-(4-hydroxy-1-piperidiny1)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-52-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[3-(dimethylamino)-1-pyrrolidiny1]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-53-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-54-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-55-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-56-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-57-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761438-58-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[(1-methyl-4-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-59-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-60-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-61-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-62-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-63-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-64-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-65-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[3-(methyamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-66-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-67-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4,5-dimethoxy-2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-68-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 761438-69-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 761438-70-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 761438-71-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 761438-72-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 761438-73-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 761438-74-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 761438-75-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-76-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-77-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-78-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(ethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-79-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-80-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-81-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-82-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)



RN 761438-83-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-84-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)







RN 761438-85-1 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 761438-86-2 CAPLUS  
 CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[(cyclobutylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]- (CA INDEX NAME)




RN 761438-87-3 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 761438-88-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 761439-98-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845811-03-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845811-04-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)-  
(CA INDEX NAME)




RN 845811-05-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)-  
(CA INDEX NAME)



RN 845811-06-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845811-07-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-

piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-08-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[5-chloro-4-[[2-  
[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]-  
(CA INDEX NAME)




RN 845811-09-8 CAPLUS

CN	Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)	(CA INDEX NAME)
----	--	-----------------




RN 845811-10-1 CAPLUS

CN	Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (NAME)	(CA INDEX)
----	--	------------




RN 845811-11-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-12-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845811-13-4 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845811-14-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[1-(1-methylethyl)-3-

pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-18-9 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845811-19-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845811-20-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845811-21-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 845811-22-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-23-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845811-24-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)



RN 845811-25-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)



RN 845811-26-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)






RN 845811-27-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 845811-29-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845811-31-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-3-pyrrolidinyloxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 845811-32-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)



RN 845811-33-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 845811-34-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845811-48-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845811-49-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 845811-50-9 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 845811-51-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845811-52-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-53-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-[1,4'-bipiperidin]-1'-yl)-2-ethoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845811-55-4 CAPLUS


CN Benzamide, 2-[[2-[[4-[[1,4'-bipiperidin]-1'-yl]-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845811-56-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845811-57-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT	845811-58-7P	845811-59-8P	845811-60-1P
	845811-61-2P	845811-63-4P	845811-64-5P
	845811-65-6P	845811-66-7P	845811-67-8P
	845811-68-9P	845811-70-3P	845811-73-6P
	845811-74-7P	845811-75-8P	845811-76-9P
	845811-77-0P	845811-79-2P	845811-80-5P
	845811-82-7P	845811-83-8P	845811-85-0P
	845811-86-1P	845811-87-2P	845811-89-4P
	845811-90-7P	845811-91-8P	845811-92-9P
	845811-93-0P	845811-94-1P	845811-95-2P
	845811-96-3P	845811-97-4P	845811-99-6P
	845812-01-3P	845812-09-1P	845812-11-5P
	845812-15-9P	845812-17-1P	845812-19-3P
	845812-25-1P	845812-27-3P	845812-29-5P
	845812-31-9P	845812-32-0P	845812-33-1P
	845812-34-2P	845812-35-3P	845812-37-5P
	845812-39-7P	845812-40-0P	845812-42-2P
	845812-43-3P	845812-44-4P	845812-45-5P
	845812-46-6P	845812-47-7P	845812-48-8P
	845812-50-2P	845812-52-4P	845812-53-5P
	845812-54-6P	845812-55-7P	845812-57-9P
	845812-58-0P	845812-59-1P	845812-60-4P
	845812-62-6P	845812-63-7P	845812-64-8P
	845812-65-9P	845812-67-1P	845812-68-2P
	845812-69-3P	845812-71-7P	845812-72-8P
	845812-74-0P	845812-75-1P	845812-76-2P
	845812-78-4P	845812-79-5P	845812-80-8P
	845812-81-9P	845812-82-0P	845812-83-1P
	845812-84-2P	845812-87-5P	845812-88-6P
	845812-89-7P	845812-91-1P	845812-92-2P
	845812-93-3P	845812-94-4P	845812-95-5P
	845812-98-8P	845812-99-9P	845813-00-5P
	845813-02-7P	845813-03-8P	845813-04-9P
	845813-06-1P	845813-07-2P	845813-09-4P
	845813-10-7P	845813-11-8P	845813-12-9P
	845813-13-0P	845813-14-1P	845813-15-2P
	845813-16-3P	845813-17-4P	845813-18-5P
	845813-19-6P	845813-20-9P	845813-21-0P
	845813-22-1P	845813-23-2P	845813-26-5P
	845813-27-6P	845813-28-7P	845813-30-1P
	845813-31-2P	845813-32-3P	845813-33-4P
	845813-34-5P	845813-35-6P	845813-36-7P
	845813-37-8P	845813-38-9P	845813-39-0P

845813-41-4P	845813-42-5P	845813-43-6P
845813-44-7P	845813-45-8P	845813-46-9P
845813-47-0P	845813-48-1P	845813-49-2P
845813-50-5P	845813-51-6P	845813-52-7P
845813-53-8P	845813-54-9P	845813-55-0P
845813-56-1P	845813-57-2P	845813-58-3P
845813-59-4P	845813-60-7P	845813-61-8P
845813-62-9P	845813-63-0P	845813-64-1P
845813-65-2P	845813-68-5P	845813-70-9P
845813-72-1P	845813-74-3P	845813-77-6P
845813-78-7P	845813-80-1P	845813-81-2P
845813-82-3P	845813-83-4P	845813-84-5P
845813-85-6P	845813-86-7P	845813-87-8P
845813-88-9P	845813-89-0P	845813-90-3P
845813-91-4P	845813-92-5P	845813-93-6P
845813-94-7P	845813-95-8P	845813-96-9P
845813-97-0P	845813-98-1P	845813-99-2P
845814-00-8P	845814-01-9P	845814-02-0P
845814-03-1P	845814-04-2P	845814-05-3P
845814-06-4P	845814-07-5P	845814-08-6P
845814-09-7P	845814-10-0P	845814-11-1P
845814-13-3P	845814-15-5P	845814-18-8P
845814-19-9P	845814-20-2P	845814-21-3P
845814-24-6P	845814-27-9P	845814-28-0P
845814-29-1P	845814-32-6P	845814-33-7P
845814-34-8P	845814-35-9P	845814-36-0P
845814-37-1P	845814-38-2P	845814-40-6P
845814-41-7P	845814-42-8P	845814-43-9P
845814-44-0P	845814-45-1P	845814-46-2P
845814-47-3P	845814-48-4P	845814-49-5P
845814-50-8P	845814-51-9P	845814-52-0P
845814-53-1P	845814-54-2P	845814-55-3P
845814-56-4P	845814-57-5P	845814-59-7P
845814-60-0P	845814-61-1P	845814-62-2P
845814-63-3P	845814-64-4P	845814-65-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)

RN 845811-58-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845811-59-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845811-60-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845811-61-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.






RN 845811-63-4 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-3-(ethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845811-64-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)




RN 845811-65-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[[(cyclopropylmethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)




RN 845811-66-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(cyclobutylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)




RN 845811-67-8 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[1-methylethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)




RN 845811-68-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-bromo-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-3-ethoxyphenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 845811-70-3 CAPLUS


CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(ethylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]- (CA INDEX NAME)



RN 845811-73-6 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845811-74-7 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-methyl-4-piperidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845811-75-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845811-76-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845811-77-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845811-79-2 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-80-5 CAPLUS

CN Benzamide, 5-[1,4'-bipiperidin]-1'-yl-2-[[5-chloro-4-[[2-[(ethylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-82-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)phenyl]- (CA INDEX NAME)




RN 845811-83-8 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(ethylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1,1-dimethylethoxy)phenyl]- (CA INDEX NAME)




RN 845811-85-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1,1-dimethylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845811-86-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-(1,1-dimethylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845811-87-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845811-89-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845811-90-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-91-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845811-92-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(4-morpholinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845811-93-0 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(4-methyl-1-piperazinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 845811-94-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[[2-(dimethylamino)ethyl]amino]-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-95-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(2-methoxyethoxy)-4-(4-(dimethylamino)ethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-96-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(2-methoxyethoxy)-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-97-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[[2-(dimethylamino)ethyl]amino]-2-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845811-99-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-(4-morpholinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845812-01-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-(4-morpholinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-09-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethyl-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-11-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethyl-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-15-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethyl-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 845812-17-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethyl-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845812-19-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(4-morpholinyl)-2-propylphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-25-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845812-27-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 845812-29-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 845812-31-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845812-32-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-33-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845812-34-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-(2-methylpropoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-35-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(2-methylpropoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.

10/568,367



RN 845812-37-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-(2-methylpropoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845812-39-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-40-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-42-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845812-43-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845812-44-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.






RN 845812-45-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-46-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-(1-propoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-47-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845812-48-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845812-50-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyl)oxy]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 845812-52-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[[ (3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-53-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[[ (3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-54-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-55-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-57-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-58-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-59-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845812-60-4 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 845812-62-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845812-63-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845812-64-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 845812-65-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 845812-67-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845812-68-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[(4-methyl-1-

piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 845812-69-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 845812-71-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

10/568,367




RN 845812-72-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 845812-74-0 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)






RN 845812-75-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 845812-76-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[2-(4-methyl-1-piperazinyl)ethyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 845812-78-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845812-79-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 845812-80-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 845812-81-9 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl-2-(1-methylethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)





RN 845812-82-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-  
[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1-  
methylethoxy)phenyl]- (CA INDEX NAME)




RN 845812-83-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-  
[(cyclopropylmethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-  
(1-methylethoxy)phenyl]- (CA INDEX NAME)




RN 845812-84-2 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-  
[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1-  
methylethoxy)phenyl]- (CA INDEX NAME)




RN 845812-87-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-88-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845812-89-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 845812-91-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl-  
(CA INDEX NAME)




RN 845812-92-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl-  
(CA INDEX NAME)




RN 845812-93-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl-  
(CA INDEX NAME)




RN 845812-94-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845812-95-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (cyclopropylmethyl)- (CA INDEX NAME)



RN 845812-98-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

NAME)




RN 845812-99-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 845813-00-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 845813-02-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-

dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-03-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-04-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-06-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




NAME)

PAGE 1-A




PAGE 2-A




RN 845813-07-2 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 845813-09-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[[ (3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-10-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[ (3R)-1-methyl-3-

pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-11-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-12-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-13-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-14-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-15-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845813-16-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845813-17-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-18-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-19-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845813-20-9 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845813-21-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-22-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-23-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-26-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-27-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-28-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-30-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(cyclopropylmethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 845813-31-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[[ (3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-32-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845813-33-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(cyclopropylmethoxy)-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-34-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-35-6 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-ethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-36-7 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-37-8 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-ethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-38-9 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[ (3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-39-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-([1,4'-bipiperidin]-1'-ylcarbonyl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-41-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-42-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-43-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-44-7 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-ethoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-45-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-46-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-47-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-48-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-49-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-50-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845813-51-6 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[2-ethoxy-4-(4-ethyl-1-piperazinyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-52-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845813-53-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-54-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.






RN 845813-55-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[2-(dimethylamino)ethyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-56-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-57-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-ethoxyphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-58-3 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[2-ethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-59-4 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)




RN 845813-60-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 845813-61-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-[2-(diethylamino)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-62-9 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-([1,4'-bipiperidin]-1'-ylcarbonyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-63-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-64-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-65-2 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-([1,4'-bipiperidin]-1'-ylcarbonyl)-2-ethoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-68-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(cyclopropylmethoxy)-4-[4-(4-morpholinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

10/568,367



RN 845813-70-9 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl-2-(cyclopropylmethoxy)phenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl-(CA INDEX NAME)



RN 845813-72-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(4-methyl-1-

piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-74-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 845813-77-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[ (3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 845813-78-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(1-methylpyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-80-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845813-81-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(1-(dimethylamino)pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-82-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-[2-(ethylmethylanilino)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-83-4 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 845813-84-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845813-85-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[2-(ethylmethylanino)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 845813-86-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[2-(diethylamino)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-87-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-88-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-[2-(hexahydro-1H-azepin-1-yl)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-89-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[2-(hexahydro-1H-azepin-1-yl)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-90-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 845813-91-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[2-(diethylamino)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 845813-92-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845813-93-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845813-94-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[2-(diethylamino)ethoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845813-95-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-96-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845813-97-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845813-98-1 CAPLUS

CN Acetamide, N-[1-[4-[5-bromo-4-[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)



RN 845813-99-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845814-00-8 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845814-01-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[2-(dimethylamino)ethyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-02-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-03-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-2-ethoxyphenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-04-2 CAPLUS

CN Acetamide, N-[1-[3-ethoxy-4-[[5-fluoro-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]phenyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)




RN 845814-05-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)-2,2-dimethylpropyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-06-4 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[[2-[(2-methylpropyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-ethoxyphenyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)




RN 845814-07-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-fluoro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845814-08-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-09-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)


Absolute stereochemistry.





RN 845814-10-0 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)



RN 845814-11-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-13-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-15-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-18-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-19-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-20-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-21-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845814-24-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 845814-27-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-28-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-(1,1-dimethylethyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-29-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-32-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-33-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-fluoro-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-34-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845814-35-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[[3-(dimethylamino)propyl]amino]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)



RN 845814-36-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 845814-37-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 845814-38-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-40-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 845814-41-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 845814-42-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)




RN 845814-43-9 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845814-44-0 CAPLUS


CN Benzamide, 2-[[5-bromo-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845814-45-1 CAPLUS


CN Benzamide, 2-[[5-bromo-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)






RN 845814-46-2 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-47-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-48-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-49-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-diethoxy-4-(tetrahydro-2H-1,2-oxazin-2-yl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-50-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-51-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-52-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-53-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-54-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845814-55-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845814-56-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845814-57-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845814-59-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-60-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-61-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-62-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845814-63-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845814-64-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845814-65-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




IT	845814-66-6P	845814-67-7P	845814-68-8P
	845814-69-9P	845814-70-2P	845814-71-3P
	845814-72-4P	845814-75-7P	845814-76-8P
	845814-77-9P	845814-78-0P	845814-79-1P
	845814-81-5P	845814-85-9P	845814-86-0P
	845814-87-1P	845814-88-2P	845814-89-3P
	845814-92-8P	845814-93-9P	845814-94-0P
	845814-95-1P	845814-96-2P	845814-97-3P
	845814-98-4P	845815-00-1P	845815-03-4P
	845815-04-5P	845815-06-7P	845815-07-8P
	845815-09-0P	845815-10-3P	845815-12-5P
	845815-14-7P	845815-15-8P	845815-30-7P
	845815-31-8P	845815-33-0P	845815-34-1P
	845815-35-2P	845815-64-7P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)


RN 845814-66-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845814-67-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845814-68-8 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[(2-methoxy-5-methylphenyl)amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 845814-69-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)






RN 845814-70-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-diethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-71-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-72-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 845814-75-7 CAPLUS

CN Benzenesulfonamide, 3-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845814-76-8 CAPLUS

CN Benzenesulfonamide, 3-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 845814-77-9 CAPLUS


CN Benzenesulfonamide, 3-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-propyl- (CA INDEX NAME)



RN 845814-78-0 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)

NAME)




RN 845814-79-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 845814-81-5 CAPLUS

CN Methanesulfonamide, N-[2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 845814-85-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-3-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 845814-86-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-3-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)-  
(CA INDEX NAME)



RN 845814-87-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-3-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)-  
(CA INDEX NAME)




RN 845814-88-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)

10/568,367


Absolute stereochemistry.



RN 845814-89-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(cyclopropylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 845814-92-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-3-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 845814-93-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-3-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 845814-94-0 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-ethoxy-3-[(1-ethyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)



RN 845814-95-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-96-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-2-ethoxyphenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845814-97-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3S)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-(CA INDEX NAME)


Absolute stereochemistry.



RN 845814-98-4 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-(CA INDEX NAME)

Absolute stereochemistry.




RN 845815-00-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(dimethylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-(1-methylethoxy)phenyl]-(CA INDEX NAME)




RN 845815-03-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(trifluoromethyl)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845815-04-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(trifluoromethyl)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845815-06-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




10/568,367



RN 845815-07-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]-2-(trifluoromethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845815-09-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-cyano-4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 845815-10-3 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-cyano-4-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 845815-12-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-(2,2,2-trifluoroethoxy)phenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845815-14-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[4-(dimethylamino)-1-piperidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 845815-15-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 845815-30-7 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[4-[4-(dimethylamino)-1-piperidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 845815-31-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 845815-33-0 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[4-(dimethylamino)-1-piperidinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 845815-34-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(1-methylethoxy)-4-[4-(2-oxo-1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 845815-35-2 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[4-[2-(dimethylamino)ethyl]-1-piperazinyl]-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



RN 845815-64-7 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA

INDEX NAME)



OSC.G	12	THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
RE.CNT	19	THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 48 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:158646 CAPLUS  
 DN 142:254587  
 TI Methods for treating or preventing autoimmune diseases with  
 2,4-pyrimidinediamine compounds  
 IN Rajinder, Singh; Ankush, Argade; Li, Hui; Bhamidipati, Somasekhar;  
 Carroll, David; Sylvain, Catherine; Clough, Jeffrey; Keim, Holger  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 276 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016893	A2	20050224	WO 2004-US24716	20040730
	WO 2005016893	A3	20050609		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
	AU 2004265288	A1	20050224	AU 2004-265288	20040730
	CA 2533377	A1	20050224	CA 2004-2533377	20040730
	US 20050209224	A1	20050922	US 2004-903870	20040730
	US 7122542	B2	20061017		
	US 20050234049	A1	20051020	US 2004-903263	20040730
	EP 1656372	A2	20060517	EP 2004-786150	20040730
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004013018	A	20061003	BR 2004-13018	20040730
	CN 1849318	A	20061018	CN 2004-80022235	20040730
	JP 2007500722	T	20070118	JP 2006-522105	20040730
	SG 145698	A1	20080929	SG 2008-5659	20040730
	RU 2356901	C2	20090527	RU 2006-106180	20040730
	KR 2006056353	A	20060524	KR 2006-701947	20060127
	MX 2006001099	A	20060920	MX 2006-1099	20060127
	IN 2006KN00449	A	20070622	IN 2006-KN449	20060227
	NO 2006000992	A	20060228	NO 2006-992	20060228
	US 20070167439	A1	20070719	US 2006-539147	20061005
	US 7452879	B2	20081118		
	US 20080312438	A1	20081218	US 2006-539142	20061005
	US 7582648	B2	20090901		
	US 20070225495	A1	20070927	US 2006-539520	20061006
	US 7560466	B2	20090714		
PRAI	US 2003-491641P	P	20030730		
	US 2003-531598P	P	20031219		
	US 2004-572246P	P	20040518		
	US 2004-903263	A1	20040730		
	US 2004-903870	A1	20040730		
	WO 2004-US24716	W	20040730		

OS MARPAT 142:254587

AB The invention provides methods for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compds., as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compds. include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosus and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.


IT 844435-02-5P 844435-03-6P 844435-10-5P  
845820-86-2P 845820-90-8P 845820-91-9P  
845820-93-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrimidinediamine compds. for treatment or prevention of autoimmune diseases)


RN 844435-02-5 CAPLUS

CN Benzamide, 4-[[2-[(3-chloro-4-methoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 844435-03-6 CAPLUS


CN Benzamide, 4,4'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis- (CA INDEX NAME)



RN 844435-10-5 CAPLUS


CN Benzamide, 4-[[5-fluoro-4-(phenylamino)-2-pyrimidinyl]amino]- (CA INDEX NAME)






RN 845820-86-2 CAPLUS

CN Glycine, N-[4-[[5-fluoro-2-[[3-(hydroxymethyl)phenyl]amino]-4-pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)




RN 845820-90-8 CAPLUS

CN Glycine, N,N'-[(5-fluoro-2,4-pyrimidinediyl)bis(imino-4,1-phenylenecarbonyl)]bis-, dimethyl ester (9CI) (CA INDEX NAME)




RN 845820-91-9 CAPLUS

CN Glycine, N-[4-[[2-[[4-(aminocarbonyl)phenyl]amino]-5-fluoro-4-pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)



RN 845820-93-1 CAPLUS

CN Glycine, N-[4-[[4-[[4-(aminocarbonyl)phenyl]amino]-5-fluoro-2-pyrimidinyl]amino]benzoyl]-, methyl ester (CA INDEX NAME)



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)  
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 49 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:136565 CAPLUS  
 DN 142:212327  
 TI 2,4-pyrimidinediamine compounds and uses as antiproliferative agents  
 IN Argade, Ankush; Singh, Rajinder; Li, Hui; Carroll, David; Catalano, Susan  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 179 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005013996	A2	20050217	WO 2004-US25409	20040806
	WO 2005013996	A3	20050609		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 20050113398	A1	20050526	US 2004-913270	20040806
	EP 1663242	A2	20060607	EP 2004-780274	20040806
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	JP 2007501793	T	20070201	JP 2006-522744	20040806
	US 20070299060	A1	20071227	US 2006-567506	20061206
	US 20080009494	A1	20080110	US 2006-567276	20061206
	US 20080009484	A1	20080110	US 2006-567824	20061207
	US 20080021020	A1	20080124	US 2006-567817	20061207
	US 20080027045	A1	20080131	US 2006-567820	20061207
PRAI	US 2003-494008P	P	20030807		
	US 2004-572534P	P	20040518		
	US 2004-572507P	P	20040518		
	US 2004-580765P	P	20040618		
	US 2004-913270	A1	20040806		
	WO 2004-US25409	W	20040806		
	US 2004-628199P	P	20041115		
	US 2004-628496P	P	20041115		
	US 2005-650195P	P	20050203		
	US 2005-133419	A1	20050518		


# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 142:212327  
 AB The invention provides 2,4-pyrimidinediamine compds. having antiproliferative activity, compns. comprising the compds. and methods of using the compds. to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.  
 IT 844433-66-5P 844435-02-5P 844435-03-6P 844435-10-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyrimidinediamine compds. and uses as antiproliferative agents for treatment of cancer)


RN 844433-66-5 CAPLUS

CN Acetic acid, 2-[4-[[5-fluoro-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-  
(CA INDEX NAME)




RN 844435-02-5 CAPLUS

CN Benzamide, 4-[[2-[(3-chloro-4-methoxyphenyl)amino]-5-fluoro-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 844435-03-6 CAPLUS

CN Benzamide, 4,4'-[(5-fluoro-2,4-pyrimidinediyl)diimino]bis- (CA INDEX NAME)



RN 844435-10-5 CAPLUS

CN Benzamide, 4-[[5-fluoro-4-(phenylamino)-2-pyrimidinyl]amino]- (CA INDEX NAME)



OSC.G	9	THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
RE.CNT	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 50 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2004:780679 CAPLUS  
 DN 141:296041  
 TI Preparation of novel 2,4-di(phenylamino)pyrimidines useful in the  
 treatment of neoplastic diseases, inflammatory and immune system disorders  
 IN Garcia-Echeverria, Carlos; Kanazawa, Takanori; Kawahara, Eiji; Masuya,  
 Keiichi; Matsuura, Naoko; Miyake, Takahiro; Ohmori, Osamu; Umemura, Ichiro  
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.  
 SO PCT Int. Appl., 185 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004080980	A1	20040923	WO 2004-EP2616	20040312
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004220338	A1	20040923	AU 2004-220338	20040312
	AU 2004220338	B2	20081009		
	CA 2518932	A1	20040923	CA 2004-2518932	20040312
	EP 1606265	A1	20051221	EP 2004-719989	20040312
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008347	A	20060321	BR 2004-8347	20040312
	CN 1788001	A	20060614	CN 2004-80013041	20040312
	JP 2006520354	T	20060907	JP 2006-504673	20040312
	NZ 542219	A	20090131	NZ 2004-542219	20040312
	ZA 2005006751	A	20070228	ZA 2005-6751	20050823
	IN 2005CN02241	A	20070831	IN 2005-CN2241	20050913
	NO 2005004726	A	20051208	NO 2005-4726	20051013
	US 20060247241	A1	20061102	US 2006-549250	20060518
	IN 2009CN00759	A	20090605	IN 2009-CN759	20090209
PRAI	GB 2003-5929	A	20030314		
	GB 2003-19227	A	20030815		
	GB 2003-22370	A	20030924		
	WO 2004-EP2616	A	20040312		
	IN 2005-CN2241	A3	20050913		

OS MARPAT 141:296041

AB The title pyrimidine derivs. I [R0-R3 = H, alkyl, aryl, etc.; or R0 and R1, R1 and R2, and/or R2 and R3 form, together with the carbon atoms to which they are attached, 5-6 membered carbocyclic or heterocyclic ring comprising 0-3 heteroatoms selected from N, O and S; R4 = H, alkyl; R5, R6 = H, alkyl, alkoxyalkyl, halo, etc.; R7-R10 = alkyl, cycloalkyl, aryl, etc.; or R7 and R8, R8 and R9, and/or R9 and R10 form, together with the carbon atoms to which they are attached, 5-6 membered carbocyclic or heterocyclic ring comprising 0-3 heteroatoms selected from N, O and S; A = C, N], useful as FAK or/and IGF-1 receptor inhibitors in the treatment of


neoplastic diseases, inflammatory and immune system disorders, were prepared and formulated. E.g., a 2-step synthesis of II from 2,4-dichloro-5-nitropyrimidine, 2-amino-N-methylbenzenesulfonamide, and 2,5-dimethoxyaniline which showed IC50 of 140 nM in FAK assay, was given. The pharmaceutical composition comprising the compound I is claimed.

IT 761436-62-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of 2,4-di(phenylamino)pyrimidines as FAK or/and IGF-1 receptor inhibitors useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)

RN 761436-62-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



IT	761436-43-5P	761436-45-7P	761436-46-8P
	761436-47-9P	761436-48-0P	761436-49-1P
	761436-50-4P	761436-52-6P	761436-53-7P
	761436-57-1P	761436-58-2P	761436-59-3P
	761436-60-6P	761436-61-7P	761436-63-9P
	761436-64-0P	761436-65-1P	761436-66-2P
	761436-67-3P	761436-68-4P	761436-69-5P
	761436-70-8P	761436-71-9P	761436-72-0P
	761436-74-2P	761436-75-3P	761436-76-4P
	761436-77-5P	761436-81-1P	761436-82-2P
	761436-83-3P	761436-84-4P	761436-85-5P
	761436-86-6P	761436-88-8P	761436-89-9P
	761436-90-2P	761436-91-3P	761436-93-5P
	761436-94-6P	761436-95-7P	761436-96-8P
	761436-97-9P	761436-98-0P	761436-99-1P
	761437-00-7P	761437-01-8P	761437-02-9P
	761437-03-0P	761437-04-1P	761437-05-2P
	761437-06-3P	761437-07-4P	761437-08-5P
	761437-09-6P	761437-10-9P	761437-11-0P
	761437-12-1P	761437-13-2P	761437-14-3P
	761437-15-4P	761437-16-5P	761437-17-6P
	761437-18-7P	761437-20-1P	761437-21-2P
	761437-22-3P	761437-23-4P	761437-24-5P
	761437-25-6P	761437-26-7P	761437-28-9P
	761437-29-0P	761437-30-3P	761437-31-4P
	761437-32-5P	761437-33-6P	761437-34-7P
	761437-35-8P	761437-36-9P	761437-37-0P
	761437-39-2P	761437-40-5P	761437-41-6P
	761437-42-7P	761437-43-8P	761437-44-9P
	761437-45-0P	761437-46-1P	761437-47-2P


761437-48-3P	761437-49-4P	761437-50-7P
761437-51-8P	761437-52-9P	761437-53-0P
761437-54-1P	761437-55-2P	761437-59-6P
761437-60-9P	761437-61-0P	761437-62-1P
761437-63-2P	761437-64-3P	761437-65-4P
761437-66-5P	761437-67-6P	761437-68-7P
761437-69-8P	761437-84-7P	761437-85-8P
761437-99-4P	761438-01-1P	761438-02-2P
761438-03-3P	761438-04-4P	761438-05-5P
761438-06-6P	761438-07-7P	761438-08-8P
761438-09-9P	761438-10-2P	761438-11-3P
761438-12-4P	761438-13-5P	761438-14-6P
761438-15-7P	761438-16-8P	761438-17-9P
761438-18-0P	761438-19-1P	761438-20-4P
761438-21-5P	761438-22-6P	761438-23-7P
761438-24-8P	761438-26-0P	761438-27-1P
761438-28-2P	761438-29-3P	761438-30-6P
761438-31-7P	761438-32-8P	761438-33-9P
761438-34-0P	761438-35-1P	761438-36-2P
761438-37-3P	761438-38-4P	761438-39-5P
761438-40-8P	761438-43-1P	761438-44-2P
761438-45-3P	761438-46-4P	761438-47-5P
761438-48-6P	761438-49-7P	761438-50-0P
761438-51-1P	761438-52-2P	761438-53-3P
761438-54-4P	761438-55-5P	761438-56-6P
761438-57-7P	761438-58-8P	761438-59-9P
761438-60-2P	761438-61-3P	761438-62-4P
761438-63-5P	761438-64-6P	761438-65-7P
761438-66-8P	761438-67-9P	761438-68-0P
761438-69-1P	761438-70-4P	761438-71-5P
761438-72-6P	761438-73-7P	761438-74-8P
761438-75-9P	761438-76-0P	761438-77-1P
761438-78-2P	761438-79-3P	761438-80-6P
761438-81-7P	761438-82-8P	761438-83-9P
761438-84-0P	761438-85-1P	761438-86-2P
761438-87-3P	761438-88-4P	761439-98-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-di(phenylamino)pyrimidines as FAK or/and IGF-1 receptor inhibitors useful in the treatment of neoplastic diseases, inflammatory and immune system disorders)

RN 761436-43-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761436-45-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,4-dimethylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-46-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-methoxy-2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-47-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-fluoro-4-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-48-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxy-4-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-49-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-50-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-52-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-methoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-53-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2-butylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-57-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,3-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-58-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-59-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,3,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-60-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4,5-dimethoxy-2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-61-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(1-methylethyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-63-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-64-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(4-morpholinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-65-1 CAPLUS

CN Benzamide, 3-[[5-bromo-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-N-cyclohexyl-4-methyl- (CA INDEX NAME)




RN 761436-66-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(1-piperazinylcarbonyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-67-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4'-methoxy-4-methyl[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-68-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(1-piperidinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-69-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2'-methoxy-4-methyl[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-70-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(3'-methoxy-4-methyl[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-71-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-ethoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-72-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-ethoxy-4'-methoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-74-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-75-3 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761436-76-4 CAPLUS  
 CN Benzenesulfonamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-77-5 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-81-1 CAPLUS  
 CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761436-82-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(4-cyano-1-piperidiny)]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-83-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-thiomorpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-84-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[bis(2-methoxyethyl)amino]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-85-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-bromo-4-[[2-  
[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-  
(CA INDEX NAME)




RN 761436-86-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(1,1-dioxido-4-thiomorpholinyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-88-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-89-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-90-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-(1H-imidazol-1-yl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-91-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[(4-methyl-1-piperazinyl)carbonyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-93-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-[(2-hydroxyethyl)propylamino]-2-methylphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-94-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-chloro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-95-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[3-(dimethylamino)-2-methylphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-96-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-5-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-97-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(2,5-diethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-98-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4,4'-dimethoxy[1,1'-biphenyl]-3-yl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761436-99-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-00-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-01-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-methoxy-2-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-02-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-(2-hydroxyethoxy)-5-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-03-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-ethoxy-5-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-04-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-methoxy-2-(1-methylethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-05-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-methoxy-2-(1-propoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-06-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[5-(dimethylamino)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-07-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-08-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(3-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-09-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(2-pyridinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-10-9 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-bromo-4-[[2-




[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-  
(CA INDEX NAME)




RN 761437-11-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-12-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-13-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methyl-4-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-14-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-15-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[3-(4-morpholinyl)propoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-16-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[(1-acetyl-4-piperidinyl)oxy]-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-17-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[5-[(1-acetyl-4-piperidinyloxy)-2-methoxyphenyl]amino]-5-bromo-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-18-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-[(1-methyl-4-piperidinyloxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-20-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-piperidinyloxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-21-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-piperidinyloxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-22-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-23-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-24-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-25-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(2-methyl-1H-imidazol-1-yl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-26-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-28-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-29-0 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-30-3 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761437-31-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-32-5 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-33-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-34-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-35-8 CAPLUS

CN Benzamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-36-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-(4-hydroxy-1-piperidiny1)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-37-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[4-(2-ethoxyethoxy)-1-piperidiny1]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-39-2 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(2-methoxyethoxy)-1-piperidiny1]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-40-5 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761437-41-6 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-42-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)



RN 761437-43-8 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-44-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-45-0 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[4-[(9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-46-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 761437-47-2 CAPLUS


CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)carbonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 761437-48-3 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-49-4 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-(4-methyl-1-piperazinyl)piperidin-1-yl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

piperidiny]methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-50-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-51-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-52-9 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-5-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761437-53-0 CAPLUS


CN Benzamide, 2-[[2-[[5-[[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-54-1 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 761437-55-2 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-59-6 CAPLUS

CN Benzamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-60-9 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-61-0 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-62-1 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-63-2 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761437-64-3 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-65-4 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)



RN 761437-66-5 CAPLUS

CN Benzamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-67-6 CAPLUS


CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidiny]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




PAGE 1-A



PAGE 2-A




RN 761437-68-7 CAPLUS  
 CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-69-8 CAPLUS  
 CN Benzamide, 2-[[2-[[5-[1,4'-bipiperidin-1'-yl]-2-methoxyphenyl]amino]-5-(1-methyl-4-piperidin-1-yl)-4-pyrimidinyl]amino]-N-ethyl-

chloro-4-pyrimidinyl]amino]-N-ethyl- (CA INDEX NAME)




RN 761437-84-7 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 761437-85-8 CAPLUS

CN Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761437-99-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-fluoro-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(2,2,2-trifluoroethyl)- (CA INDEX NAME)




RN 761438-01-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methyamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-02-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(ethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-03-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-04-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-05-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-06-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-07-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-08-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-09-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-10-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-2,2-dimethylpropyl]amino]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-11-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-fluoro-2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-12-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-fluoro-2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-13-5 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[[[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]- (CA INDEX NAME)



RN 761438-14-6 CAPLUS


CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]-N-methyl- (CA INDEX NAME)




RN 761438-15-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(1-pyrrolidinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 761438-16-8 CAPLUS

CN Benzenesulfonamide, 2-[[[5-chloro-2-[[2-methoxy-4-[(2S)-2-(1-pyrrolidinylmethyl)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 761438-17-9 CAPLUS




CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-2-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)




RN 761438-18-0 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-N,N-diethyl- (CA INDEX NAME)




RN 761438-19-1 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[[[(1-methylethyl)amino]sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761438-20-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)-  
(CA INDEX NAME)




RN 761438-21-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[3-fluoro-2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-22-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(3-hydroxy-2,2-dimethylpropyl)amino]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-23-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(2-hydroxy-1,1-dimethylethyl)amino]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-24-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(dimethylamino)-2,2-dimethylpropoxy]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-26-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-27-1 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-28-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-fluoro-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-29-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 761438-30-6 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)



RN 761438-31-7 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(9aR)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 761438-32-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)amino]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethyl)- (CA INDEX NAME)




RN 761438-33-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-34-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-35-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-36-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-(difluoromethoxy)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-37-3 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]- (CA INDEX NAME)




RN 761438-38-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-39-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-40-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-[1,4'-bipiperidin]-1'-yl]-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-43-1 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-44-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-dimethoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)






RN 761438-45-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2,5-dimethoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-46-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-(4-methyl-1-piperazinyl)-2-propoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-47-5 CAPLUS

CN 3-Piperidinecarboxamide, 1-[4-[[5-chloro-4-[[2-[(methylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]- (CA INDEX NAME)




RN 761438-48-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-49-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-50-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-51-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-(4-hydroxy-1-piperidinyl)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-52-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[5-[3-(dimethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-53-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-54-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-55-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-56-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-57-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-58-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[(1-methyl-4-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-59-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-60-2 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[[1-(1-methylethyl)-3-pyrrolidinyl]oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 761438-61-3 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)

pyrrolidinyloxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-62-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[(1-ethyl-3-pyrrolidinyloxy)-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-63-5 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-64-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(5-[1,4'-bipiperidin]-1'-yl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-65-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-5-[3-(methyamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-66-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[5-(4-acetyl-1-piperazinyl)-2-methoxyphenyl]amino]-5-chloro-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-67-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4,5-dimethoxy-2-methylphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 761438-68-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)




RN 761438-69-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)



RN 761438-70-4 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)



RN 761438-71-5 CAPLUS


CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylpropyl)- (CA INDEX NAME)






RN 761438-72-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(5-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 761438-73-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[(4-fluoro-2-methoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 761438-74-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(2-methylpropyl)- (CA INDEX NAME)




RN 761438-75-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-76-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-methyl-1-piperazinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-77-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[3-(methylamino)-1-pyrrolidinyl]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-78-2 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[4-[3-(ethylamino)-1-pyrrolidinyl]-2-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-79-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-piperidinyl)methoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-80-6 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-81-7 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-82-8 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-83-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-ethylpropyl)- (CA INDEX NAME)




RN 761438-84-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 761438-85-1 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclobutyl- (CA INDEX NAME)




RN 761438-86-2 CAPLUS

CN Acetamide, N-[1-[4-[[5-chloro-4-[[2-[(cyclobutylamino)sulfonyl]phenyl]amino]-2-pyrimidinyl]amino]-3-methoxyphenyl]-3-pyrrolidinyl]- (CA INDEX NAME)




RN 761438-87-3 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)




RN 761438-88-4 CAPLUS

CN Benzenesulfonamide, 2-[[5-chloro-2-[[2-methoxy-4-[(1-methyl-4-piperidinyl)oxy]phenyl]amino]-4-pyrimidinyl]amino]-N-cyclopentyl- (CA INDEX NAME)



RN 761439-98-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)



OSC.G 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)  
 RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 51 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2004:718507 CAPLUS  
 DN 141:243557  
 TI Preparation of pyrimidine derivatives as Polo-like kinases inhibitors for  
 treatment of cancers  
 IN Davis-Ward, Ronda; Mook, Robert Anthony, Jr.; Neeb, Michael J.; Salovich,  
 James M.  
 PA SmithKline Beecham Corporation, USA  
 SO PCT Int. Appl., 115 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004074244	A2	20040902	WO 2004-US4197	20040211
	WO 2004074244	A3	20041111		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1597251	A2	20051123	EP 2004-710264	20040211
	EP 1597251	B1	20090610		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2006518386	T	20060810	JP 2006-503537	20040211
	AT 433447	T	20090615	AT 2004-710264	20040211
	ES 2325440	T3	20090904	ES 2004-710264	20040211
	US 20070010668	A1	20070111	US 2005-545352	20050811
	US 7514446	B2	20090407	US 2006-545352	20060131
PRAI	US 2003-448795P	P	20030220		
	WO 2004-US4197	W	20040211		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 141:243557

AB Title compds. represented by the formula I [wherein R1 = H, halo, alkyl, alkenyl, alkynyl; R2 = halo, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, etc.; R3 = independently H or alkyl; R4 = independently halo, (cyclo)alkyl, (cyclo)alkenyl, NO2, etc.; R5 = independently alkyl, alkenyl, amino, etc.; Y = carbonylalkyl, amino, sulfonyl, etc.; m = 0-3; n = 0-5; and pharmaceutically acceptable salts, solvates or physiol. functional derivs. thereof] were prepared as Polo-like kinases (PLK) inhibitors. For example, reaction of 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]benzamide with 3,4,5-trimethoxyaniline gave II•HCl in 35% yield. I were tested for inhibition of PLK1 and methylene blue growth. Thus, I and their pharmaceutical compns. are useful for the treatment of PLK-mediated conditions and a susceptible neoplasm, such as breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma, ovarian cancer, pancreatic cancer, squamous carcinoma, carcinoma of the head and neck, and esophageal carcinoma (no data).


IT 748798-16-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrimidine derivs. as Polo-like kinases inhibitors for treatment of cancers)

RN 748798-16-5 CAPLUS

CN Benzamide, 2-[[5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-(1,1-dimethylethyl)- (CA INDEX NAME)



Claims require that R10 is other than hydrogen ... ethyl, etc.  
not a 103 reference

OSC.G 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 52 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2004:142963 CAPLUS  
 DN 140:199334  
 TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor  
 modulators for treatment of autoimmune diseases  
 IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Clough, Jeffrey; Keim,  
 Holger; Sylvain, Catherine; Li, Hui; Bhamidipati, Somasekhar  
 PA Rigel Pharmaceuticals, USA  
 SO PCT Int. Appl., 811 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004014382	A1	20040219	WO 2003-US24087	20030729
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2492325	A1	20040219	CA 2003-2492325	20030729
	AU 2003265336	A1	20040225	AU 2003-265336	20030729
	AU 2003265336	B2	20080619		
	EP 1534286	A1	20050601	EP 2003-784871	20030729
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013059	A	20050705	BR 2003-13059	20030729
	JP 2006514989	T	20060518	JP 2005-506142	20030729
	NZ 537752	A	20061222	NZ 2003-537752	20030729
	ZA 2005000775	A	20080625	ZA 2005-775	20030729
	US 7517886	B2	20090414	US 2003-631029	20030729
	US 20070060603	A1	20070315		
	SE 2005000203	A	20050329	SE 2005-203	20050127
	NO 2005001069	A	20050228	NO 2005-1069	20050228
	IN 2005KN00302	A	20060421	IN 2005-KN302	20050228
	US 20060135543	A1	20060622	US 2005-299207	20051208
	US 7435814	B2	20081014		
	IN 2007KN02546	A	20070824	IN 2007-KN2546	20070709
	US 20080039622	A1	20080214	US 2007-782581	20070724
	US 7550460	B2	20090623		
	US 20090082567	A1	20090326	US 2008-199705	20080827
	US 20090156622	A1	20090618	US 2008-273357	20081118
	AU 2008252053	A1	20090108	AU 2008-252053	20081203
PRAI	US 2002-399673P	P	20020729		
	US 2003-443949P	P	20030131		
	US 2003-452339P	P	20030306		
	US 2003-631029	A	20030729		
	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-434277P	P	20021217		
	AU 2003-208931	A3	20030131		

US 2003-355543	A1	20030131
WO 2003-US24087	W	20030729
US 2004-858343	A3	20040601
IN 2005-KN302	A3	20050228
US 2005-149418	A1	20050608
US 2006-539041	A1	20061005
US 2006-539054	A3	20061005

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 140:199334; MARPAT 140:199334

AB The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compds., as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Title compds. I [wherein L1 and L2 = independently a bond or a linker; R2 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R4 = H or R2; R5 = R6 or (un)substituted alkyl, alkenyl, or alkynyl; R6 = independently H, an electroneg. group, protected alc. or thiol, haloalkyl(oxy), halo, CN, NC, OCN, SCN, NO, NO2, N3, or (un)substituted amino, sulfamoyl(oxy), acyl, carboxy, carbamoyl, (hetero)aryl(alkyl), etc.; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5  $\mu$ M and 4.4  $\mu$ M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. Specific examples of autoimmune diseases that can be treated or prevented with I and their pharmaceutical compns. include rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis (no data).


IT 575484-54-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of autoimmune diseases)

RN 575484-54-7 CAPLUS

CN Benzamide, 3-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



OSC.G	12	THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
RE.CNT	12	THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 53 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2003:757684 CAPLUS

DN 139:292258

TI Pyrimidine derivatives

IN Baenteli, Rolf; Zenke, Gerhard; Cooke, Nigel Graham; Duthaler, Rudolf;  
Thoma, Gebhard; Von Matt, Anette; Honda, Toshiyuki; Matsuura, Naoko;  
Nonomura, Kazuhiko; Ohmori, Osamu; Umemura, Ichiro; Hinterding, Klaus;  
Papageorgiou, Christos

PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003078404	A1	20030925	WO 2003-EP2710	20030314
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2479133	A1	20030925	CA 2003-2479133	20030314
	AU 2003227070	A1	20030929	AU 2003-227070	20030314
	AU 2003227070	B2	20070201		
	EP 1487805	A1	20041222	EP 2003-744366	20030314
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008461	A	20050118	BR 2003-8461	20030314
	JP 2005527529	T	20050915	JP 2003-576410	20030314
	CN 1697830	A	20051116	CN 2003-806101	20030314
	NZ 535109	A	20060526	NZ 2003-535109	20030314
	RU 2324684	C2	20080520	RU 2004-130488	20030314
	IN 2004CN02025	A	20060224	IN 2004-CN2025	20040910
	MX 2004009058	A	20050125	MX 2004-9058	20040915
	NO 2004004374	A	20041014	NO 2004-4374	20041014
	US 20060100227	A1	20060511	US 2005-507060	20050613
	ZA 2004006709	A	20060531	ZA 2004-6709	20060330
PRAI	GB 2002-6215	A	20020315		
	WO 2003-EP2710	W	20030314		

OS MARPAT 139:292258

AB The pyrimidine derivs. (I) are claimed, wherein X = =CR or =N, R, R1, R2, R3, R4 independently is H, OH, C1-8alkyl, C2-8alkenyl, C3-8cycloalkyl, C3-8cycloalkyl-C1-8alkyl, hydroxyC1-8alkyl, C1-8alkoxyC1-8alkyl, hydroxyC1-8alkoxyC1-8alkyl, arylC1-8alkyl which optionally may be substituted on the ring by OH, C1-8alkoxy, carboxy, C1-8alkoxycarbonyl or R3 and R4 form together with N and C atoms to which they are attached to a 5-10 membered heterocyclic ring containing 1, 2 or 3 heteroatoms of N, O or S; R1 and R2 form together with C atoms to which they are attached aryl of 5-10 membered heteroaryl moiety containing 1-2 heteroatoms of N, O, S; R and R6 independently is H, halo, CN, C1-8alkyl, haloC1-8alkyl, C2-8alkenyl, C2-8alkynyl, C3-8cycloalkyl, C3-8cycloalkylC1-8alkyl, C5-10arylC1-8alkyl,; R7, R8 and R9 is independently H, OH, C1-8alkyl, C2-8alkenyl, haloC1-8alkyl, C1-8alkoxy, C3-8cycloalkyl, C3-8cycloalkylC1-8,

arylC1-8alkyl. disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK. I are useful in disorders where ZAP-70 and/or Syk inhibition plays a role or caused by a malfunction of signal cascades connected with FAK.

Pharmaceutical compns. containing I are claimed.


IT 1066516-64-0 1066516-65-1 1066516-67-3  
 1066516-69-5 1066516-73-1 1066516-76-4  
 1066516-80-0 1066516-92-4 1066516-93-5  
 1066516-97-9 1066516-98-0 1066516-99-1

RL: PRPH (Prophetic)

(Pyrimidine derivatives)


RN 1066516-64-0 CAPLUS

CN Benzenesulfonamide, 2-[[5-iodo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1066516-65-1 CAPLUS

CN Benzamide, 4-[[4-[[2-(aminosulfonyl)phenyl]amino]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 1066516-67-3 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1066516-69-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1066516-73-1 CAPLUS

CN Benzenesulfonamide, N-methyl-2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1066516-76-4 CAPLUS

CN Benzenesulfonamide, 4-[[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1066516-80-0 CAPLUS

CN Benzenesulfonamide, 3-[[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1066516-92-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(4-hydroxy-3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1066516-93-5 CAPLUS

CN Benzenesulfonamide, 4-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1066516-97-9 CAPLUS

CN Benzenesulfonamide, 2-[[5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)




RN 1066516-98-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1066516-99-1 CAPLUS

CN Benzenesulfonamide, 4-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




IT	604800-89-7P	604800-97-7P	604800-98-8P
	604801-01-6P	604801-02-7P	604801-05-0P
	604801-07-2P	604801-11-8P	604801-13-0P
	604801-14-1P	604801-18-5P	604801-19-6P
	604801-25-4P	604801-27-6P	604801-33-4P
	604801-34-5P	604801-39-0P	604801-40-3P
	604801-41-4P	604801-42-5P	604801-46-9P
	604801-47-0P	604801-48-1P	604801-51-6P
	604801-53-8P	604801-54-9P	604801-57-2P
	604801-60-7P	604801-63-0P	604801-69-6P
	604801-70-9P	604801-74-3P	604801-75-4P
	604801-96-9P	604802-26-8P	604802-60-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation as protein kinase inhibitor)

RN 604800-89-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604800-97-7 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[(hexahydro-1-methyl-1H-azepin-4-




yl)oxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604800-98-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(hexahydro-1-methyl-1H-azepin-2-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-01-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[3-(1H-imidazol-1-yl)propoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-02-7 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-05-0 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-(2-hydroxyethoxy)-4-methoxyphenyl]amino]-4-

pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-07-2 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-1,2,4-triazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-11-8 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 604801-13-0 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-[2-(1-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-14-1 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-

pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-18-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-19-6 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-25-4 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(4-morpholinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-27-6 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-33-4 CAPLUS

Benzenesulfonamide, 2-[[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]amino]-  
(CA INDEX NAME)




RN 604801-34-5 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N,N-dimethyl- (CA INDEX NAME)




RN 604801-39-0 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-2-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-40-3 CAPLUS

CN Benamide, N-hydroxy-2-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-41-4 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxyethyl)-2-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-42-5 CAPLUS


CN Benzenesulfonamide, N,N-dimethyl-2-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-46-9 CAPLUS


CN Benzenesulfonamide, N-propyl-2-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-

pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-47-0 CAPLUS


CN Benzenesulfonamide, 2-[[2-[(2,4-dimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-48-1 CAPLUS

CN Benzenesulfonamide, N-[2-(2-hydroxyethoxy)ethyl]-4-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe


RN 604801-51-6 CAPLUS

CN Benzenesulfonamide, N-2-thiazolyl-4-[[2-[(2,3,4-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-53-8 CAPLUS

CN Benzenesulfonamide, N-(1-methylethenyl)-3-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-54-9 CAPLUS

CN Benzenesulfonamide, 3-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-57-2 CAPLUS

CN Benzenesulfonamide, 3-[[5-bromo-2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-60-7 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-63-0 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604801-69-6 CAPLUS


CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]-N-(1-methylethenyl)- (CA INDEX NAME)



RN 604801-70-9 CAPLUS


CN Benzenesulfonamide, 3-[[2-[[3-(2-hydroxyethoxy)-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)






RN 604801-74-3 CAPLUS

CN Benzenesulfonamide, N-butyl-3-[[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 604801-75-4 CAPLUS

CN Benzenesulfonamide, 3-[[2-[[3-[2-(1H-imidazol-1-yl)ethoxy]-4-methoxyphenyl]amino]-4-pyrimidinyl]amino]-N-methyl- (CA INDEX NAME)



RN 604801-96-9 CAPLUS


CN Benzenesulfonamide, 2-[[5-bromo-2-[[4-methoxy-3-[2-(1-methyl-4-piperidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)



RN 604802-26-8 CAPLUS


CN Benzenesulfonamide, 2-[[2-[[3-[2-(1-piperazinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

10/568,367




RN 604802-60-0 CAPLUS

CN Benzenesulfonamide, 2-[[2-[[4-methoxy-3-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




OSC.G 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (22 CITINGS)  
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 54 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2003:665537 CAPLUS  
 DN 139:301291  
 TI Imidazo[1,2-a]pyridines: A potent and selective class of cyclin-Dependent kinase inhibitors identified through structure-Based hybridization  
 AU Anderson, Malcolm; Beattie, John F.; Breault, Gloria A.; Breed, Jason; Byth, Kate F.; Culshaw, Janet D.; Ellston, Rebecca P. A.; Green, Stephen; Minshull, Claire A.; Norman, Richard A.; Pauptit, Richard A.; Stanway, Judith; Thomas, Andrew P.; Jewsbury, Philip J.  
 CS AstraZeneca, Cheshire, SK10 4TG, UK  
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(18), 3021-3026  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 OS CASREACT 139:301291  
 AB High-throughput screening identified the imidazo[1,2-a]pyridine and bisanilinopyrimidine series as inhibitors of the cyclin-dependent kinase CDK4. Comparison of their exptl.-determined binding modes and emerging structure-activity trends led to the development of potent and selective imidazo[1,2-a]pyridine inhibitors for CDK4 and in particular CDK2.  
 IT 260044-97-1  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (imidazopyridines and bisanilinopyrimidines as inhibitors of cyclin-dependent kinase CDK4)  
 RN 260044-97-1 CAPLUS  
 CN 2-Propanol, 1-(dimethylamino)-3-[4-[[4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)




OSC.G 53 THERE ARE 53 CAPLUS RECORDS THAT CITE THIS RECORD (54 CITINGS)  
 RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 55 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2003:665524 CAPLUS  
 DN 139:332352  
 TI Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2:  
 identification and optimization of substituted 2,4-bis anilino pyrimidines  
 AU Breault, Gloria A.; Ellston, Rebecca P. A.; Green, Stephen; James, S.  
 Russell; Jewsbury, Philip J.; Midgley, Catherine J.; Pauptit, Richard A.;  
 Minshull, Claire A.; Tucker, Julie A.; Pease, J. Elizabeth  
 CS AstraZeneca, Cheshire, SK10 4TG, UK  
 SO Bioorganic & Medicinal Chemistry Letters (2003), 13(18), 2961-2966  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science B.V.  
 DT Journal  
 LA English  
 OS CASREACT 139:332352  
 AB Through chemical modification and x-ray crystallog. we identified the 2,4-bis  
 anilino pyrimidines as potent inhibitors of CDK4. Herein, we describe the  
 optimization of this series.  
 IT 260044-97-1P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation and structure-activity relationship studies of bis anilino  
 pyrimidines as cyclin-dependent kinase 4 inhibitors for treatment for  
 cancer)  
 RN 260044-97-1 CAPLUS  
 CN 2-Propanol, 1-(dimethylamino)-3-[4-[[4-(phenylamino)-2-  
 pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)




IT 280578-83-8 280578-93-0 280579-01-3  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (preparation and structure-activity relationship studies of bis anilino  
 pyrimidines as cyclin-dependent kinase 4 inhibitors for treatment for  
 cancer)  
 RN 280578-83-8 CAPLUS  
 CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-  
 (dimethylamino)- (CA INDEX NAME)




RN 280578-93-0 CAPLUS

CN 2-Propanol, 1-[4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)- (CA INDEX NAME)



RN 280579-01-3 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[4-[[5-fluoro-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)



OSC.G 31 THERE ARE 31 CAPLUS RECORDS THAT CITE THIS RECORD (32 CITINGS)

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 56 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2003:610204 CAPLUS  
 DN 139:164801  
 TI Preparation of 2,4-pyrimidinediamines as IgE and/or IgG receptor  
 modulators for treatment of allergic diseases, inflammatory conditions,  
 and tissue destruction  
 IN Singh, Rajinder; Argade, Ankush; Payan, Donald G.; Molineaux, Susan;  
 Holland, Sacha J.; Clough, Jeffrey; Keim, Holger; Bhamidipati, Somasekhar;  
 Sylvain, Catherine; Li, Weigun; Rossi, Alexander B.  
 PA Rigel Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 648 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063794	A2	20030807	WO 2003-US3022	20030131
	WO 2003063794	A3	20031204		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2474277	A1	20030807	CA 2003-2474277	20030131
	EP 1471915	A2	20041103	EP 2003-707654	20030131
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005516046	T	20050602	JP 2003-563490	20030131
	CN 1625400	A	20050608	CN 2003-803180	20030131
	BR 2003007355	A	20060411	BR 2003-7355	20030131
	NZ 534361	A	20080430	NZ 2003-534361	20030131
	AU 2003208931	B2	20080904	AU 2003-208931	20030131
	RU 2343148	C2	20090110	RU 2004-126431	20030131
	ZA 2005000775	A	20080625	ZA 2005-775	20030729
	ZA 2004005979	A	20070425	ZA 2004-5979	20040727
	MX 2004007386	A	20060427	MX 2004-7386	20040730
	IN 2004KN01139	A	20060512	IN 2004-KN1139	20040809
	NO 2004003632	A	20041026	NO 2004-3632	20040831
	US 20060135543	A1	20060622	US 2005-299207	20051208
	US 7435814	B2	20081014		
	US 20080039622	A1	20080214	US 2007-782581	20070724
	US 7550460	B2	20090623		
	US 20090082567	A1	20090326	US 2008-199705	20080827
	US 20090156622	A1	20090618	US 2008-273357	20081118
	AU 2008252053	A1	20090108	AU 2008-252053	20081203
PRAI	US 2002-353267P	P	20020201		
	US 2002-353333P	P	20020201		
	US 2002-399673P	P	20020729		
	US 2002-434277P	P	20021217		
	AU 2003-208931	A3	20030131		
	US 2003-355543	A1	20030131		

WO 2003-US3022	W	20030131
US 2004-858343	A3	20040601
US 2005-149418	A1	20050608
US 2006-539041	A1	20061005
US 2006-539054	A3	20061005

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 139:164801

AB Title compds. I [wherein L1 and L2 = independently a bond or a linker; R2 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R4 = H or R2; R5 = R6 or (un)substituted alkyl, alkenyl, or alkynyl; R6 = independently H, an electroneg. group, protected alc. or thiol, haloalkyl(oxy), halo, CN, NC, OCN, SCN, NO, NO2, N3, or (un)substituted amino, sulfamoyl(oxy), acyl, carboxy, carbamoyl, (hetero)aryl(alkyl), etc.; with provisos and exclusions; and salts, hydrates, solvates, N-oxides, and prodrugs thereof] were prepared as inhibitors of the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators. For example, coupling of 2,4-dichloropyrimidine with 4-ethoxyaniline in EtOH provided N2,N4-bis(4-ethoxyphenyl)-2,4-pyrimidinediamine (II). The latter inhibited degranulation of bone marrow derived mast cells challenged with anti-IgE and ionomycin with IC50 values of 4.5  $\mu$ M and 4.4  $\mu$ M, resp. Thus, I and their pharmaceutical compns. are useful in the treatment and prevention of diseases characterized by, caused by, or associated with the release of chemical mediators via degranulation of mast, basophil, neutrophil, or eosinophil cells and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. The treatment and prevention of allergic diseases, low grade scarring, diseases associated with tissue destruction, diseases associated with tissue inflammation, inflammation, and scarring are targeted uses (no data).


IT 575484-54-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IgE and/or IgG receptor modulator; preparation of pyrimidinediamines as IgE and/or IgG receptor modulators for treatment of allergic diseases, inflammatory conditions, and tissue destruction)

RN 575484-54-7 CAPLUS

CN Benzamide, 3-[[5-fluoro-2-[[3-[2-(methylamino)-2-oxoethoxy]phenyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




10/568,367

OSC.G 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS RECORD (32 CITINGS)



L7 ANSWER 57 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2002:97583 CAPLUS  
 DN 137:93720  
 TI The 'Eenie-Meenie reaction'. Displacement reactions of  
 bisanilinopyrimidines  
 AU Pearson, Stuart E.; Wood, Robin  
 CS AstraZeneca, Macclesfield, Cheshire, SK10 4TG, UK  
 SO Tetrahedron Letters (2002), 43(7), 1303-1306  
 CODEN: TELEAY; ISSN: 0040-4039  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 137:93720  
 AB A novel acid-catalyzed nucleophilic displacement reaction of pyrimidines  
 is described, involving quinone-methide type chemical A wide range of  
 nucleophiles can be tolerated. A similar mechanism is also applied to the  
 synthesis of a tricyclic system (I).  
 IT 441753-61-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (nucleophilic substitution reaction of bisanilinopyrimidines)  
 RN 441753-61-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-(butoxymethyl)phenyl]-N4-phenyl- (CA  
 INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)  
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 58 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2001:661404 CAPLUS  
 DN 135:227011  
 TI Preparation of 2,4-di(hetero)arylamino(oxy)-5-substituted pyrimidines as  
 antineoplastic agents  
 IN Pease, Elizabeth Janet; Williams, Emma Jane; Bradbury, Robert Hugh;  
 Pearson, Stuart Eric  
 PA Astrazeneca Ab, Swed.; Astrazeneca Uk Ltd.  
 SO PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064656	A1	20010907	WO 2001-GB829	20010226
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2398887	A1	20010907	CA 2001-2398887	20010226
	CA 2398887	C	20081216		
	EP 1278735	A1	20030129	EP 2001-906021	20010226
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008879	A	20030429	BR 2001-8879	20010226
	JP 2003525279	T	20030826	JP 2001-563498	20010226
	NZ 520502	A	20040528	NZ 2001-520502	20010226
	AU 2001233979	B2	20041111	AU 2001-233979	20010226
	CN 1220684	C	20050928	CN 2001-805846	20010226
	IL 150920	A	20090803	IL 2001-150920	20010226
	ZA 2002006192	A	20031126	ZA 2002-6192	20020802
	US 20030181474	A1	20030925	US 2002-203025	20020805
	US 6838464	B2	20050104		
	MX 2002007581	A	20021213	MX 2002-7581	20020806
	NO 2002004126	A	20020829	NO 2002-4126	20020829
	NO 325443	B1	20080505		
	JP 2005041878	A	20050217	JP 2004-245381	20040825
	US 20050090515	A1	20050428	US 2004-995931	20041124
	US 7067522	B2	20060627		
	KR 2007106806	A	20071105	KR 2007-723656	20071015
	KR 855258	B1	20080829		
PRAI	GB 2000-4887	A	20000301		
	JP 2001-563498	A3	20010226		
	WO 2001-GB829	W	20010226		
	US 2002-203025	A1	20020805		
	KR 2002-711409	A3	20020830		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 135:227011

AB The title compds. [I; Q1, Q2 = (un)substituted aryl, carbon linked heteroaryl; one of Q1 and Q2 or both is substituted on a ring carbon by one substituent selected from N-(di)alkylamino, Ph, heterocyclyl, etc.; G

= O, NR<sub>2</sub>; R<sub>2</sub> = H, alkyl, alkenyl, etc.; R<sub>1</sub> = H, halo, OH, etc.] and their pharmaceutically acceptable salts, useful as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors, were prepared and formulated. Thus, reacting 4-anilino-5-bromo-2-chloropyrimidine with 4-aminobenzyl alc. in the presence of ethereal HCl in BuOH/MeOH followed by treatment of the intermediate with ethylene glycol afforded 19% II which showed IC<sub>50</sub> of 0.679  $\mu$ M when tested in vitro assay for the CDK4 inhibitory activity.


IT 358789-56-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 2,4-di(hetero)arylamino(oxy)-5-substituted pyrimidines as antineoplastic agents)

RN 358789-56-7 CAPLUS

CN Ethanol, 2-[[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenyl]methoxy]- (CA INDEX NAME)




IT	358789-27-2P	358789-28-3P	358789-29-4P
	358789-30-7P	358789-31-8P	358789-34-1P
	358789-35-2P	358789-37-4P	358789-38-5P
	358789-39-6P	358789-40-9P	358789-41-0P
	358789-42-1P	358789-43-2P	358789-45-4P
	358789-46-5P	358789-47-6P	358789-48-7P
	358789-49-8P	358789-50-1P	358789-51-2P
	358789-57-8P	358789-58-9P	358789-59-0P
	358789-60-3P	358789-61-4P	358789-67-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-di(hetero)arylamino(oxy)-5-substituted pyrimidines as antineoplastic agents)


RN 358789-27-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[2-(dimethylamino)ethoxy]phenyl]-N4-phenyl- (CA INDEX NAME)




RN 358789-28-3 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]ethyl]- (CA INDEX NAME)



RN 358789-29-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N4-phenyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 358789-30-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-N4-phenyl-, hydrochloride (1:3) (CA INDEX NAME)




● 3 HCl

RN 358789-31-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-N4-phenyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 358789-34-1 CAPLUS  
CN 2,4-Pyrimidinediamine, N4-phenyl-N2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-  
(CA INDEX NAME)




RN 358789-35-2 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 358789-37-4 CAPLUS

CN Acetic acid, 2-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)




RN 358789-38-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-(aminomethyl)phenyl]-5-bromo-N4-phenyl- (CA INDEX NAME)




RN 358789-39-6 CAPLUS

CN Benzoic acid, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-, 2-(diethylamino)ethyl ester (CA INDEX NAME)




RN 358789-40-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-(2-aminoethyl)phenyl]-5-bromo-N4-phenyl- (CA INDEX NAME)




RN 358789-41-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-[2-(diethylamino)ethoxy]phenyl]-N4-phenyl- (CA INDEX NAME)




RN 358789-42-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-[2-(4-morpholinyl)ethoxy]phenyl]-N4-phenyl- (CA INDEX NAME)




RN 358789-43-2 CAPLUS

CN Ethanone, 2-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-1-[4-(1-methylethyl)-1-piperazinyl]- (CA INDEX NAME)




RN 358789-45-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-phenyl-N2-[4-(4-piperidinyloxy)phenyl]- (CA INDEX NAME)



RN 358789-46-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[(1-methyl-4-piperidinyl)oxy]phenyl]-N4-phenyl- (CA INDEX NAME)



RN 358789-47-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[(1-methyl-2-piperidinyl)methoxy]phenyl]-N4-phenyl- (CA INDEX NAME)






RN 358789-48-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[(1-methyl-3-piperidinyl)oxy]phenyl]-N4-phenyl- (CA INDEX NAME)




RN 358789-49-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-[(1-methyl-3-piperidinyl)methoxy]phenyl]-N4-phenyl- (CA INDEX NAME)




RN 358789-50-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[2-(diethylamino)ethoxy]phenyl]-N4-phenyl- (CA INDEX NAME)




RN 358789-51-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-phenyl-N2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (CA INDEX NAME)




RN 358789-57-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[[2-(diethylamino)ethoxy]methyl]phenyl]-N4-phenyl- (CA INDEX NAME)



RN 358789-58-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[[2-(4-morpholinyl)ethoxy]methyl]phenyl]-N4-phenyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 358789-59-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-phenyl-N2-[4-[[2-(1-morpholinyl)ethoxy]methyl]phenyl]- (CA INDEX NAME)


10/568,367

pyrrolidinyl)ethoxy)methyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 2 HCl

RN 358789-60-3 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[[2-(4-methyl-1-piperazinyl)ethoxy)methyl]phenyl]-N4-phenyl-, hydrochloride (1:3) (CA INDEX NAME)


10/568,367



●3 HCl


RN 358789-61-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-phenyl-N2-[4-[2-(1-pyrrolidinyl)ethyl]phenyl]- (CA INDEX NAME)



RN 358789-67-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-phenyl-N2-[4-(4-piperidinylmethoxy)phenyl]- (CA INDEX NAME)



IT 358789-68-1P

358789-83-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2,4-di(hetero)arylamino(oxy)-5-substituted pyrimidines as

antineoplastic agents)


RN 358789-68-1 CAPLUS

CN Benzeneethanol, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 358789-83-0 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OSC.G 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (29 CITINGS)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 59 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2001:661403 CAPLUS  
 DN 135:227010  
 TI Preparation of 2,4-di(hetero)arylamino(oxy)-5-substituted pyrimidines as  
 antineoplastic agents  
 IN Pease, Elizabeth Janet; Breault, Gloria Anne; Williams, Emma Jane;  
 Bradbury, Robert Hugh; Morris, Jeffrey James  
 PA Astrazeneca Ab, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 74 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001064655	A1	20010907	WO 2001-GB824	20010226
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2398685	A1	20010907	CA 2001-2398685	20010226
	AU 2001033976	A	20010912	AU 2001-33976	20010226
	AU 771144	B2	20040311		
	BR 2001008834	A	20021210	BR 2001-8834	20010226
	EP 1268444	A1	20030102	EP 2001-906018	20010226
	EP 1268444	B1	20070117		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003525278	T	20030826	JP 2001-563497	20010226
	NZ 520414	A	20040625	NZ 2001-520414	20010226
	CN 1211373	C	20050720	CN 2001-805751	20010226
	ES 2278720	T3	20070816	ES 2001-906018	20010226
	IL 150921	A	20081103	IL 2001-150921	20010226
	MX 2002007302	A	20021129	MX 2002-7302	20020726
	ZA 2002006195	A	20031126	ZA 2002-6195	20020802
	US 20030149266	A1	20030807	US 2002-203154	20020806
	US 6649608	B2	20031118		
	NO 2002004153	A	20021029	NO 2002-4153	20020830
	NO 325100	B1	20080204		
	KR 771455	B1	20071031	KR 2002-711399	20020830
PRAI	GB 2000-4890	A	20000301		
	WO 2001-GB824	W	20010226		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 135:227010

AB The title compds. [I; Q1, Q2 = (un)substituted aryl or carbon linked heteroaryl; and one or both Q1 and Q2 are substituted on a ring carbon by (CH2)nY(CH2)mZ or II (Y = NHCO, CONH; Z = (un)substituted cycloalkyl, Ph, heterocyclyl, etc.; n = 0-1; m = 1-3; Q3 = (un)substituted nitrogen linked heterocycle); G = O, NR2; R2 = H, alkyl, alkenyl, etc.; R1 = H, halo, OH, etc.] and their pharmaceutically acceptable salts, useful as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors, were prepared and formulated. Thus, reacting 4-anilino-2,5-dichloropyrimidine with 4-aminobenzoic acid followed by

amidation of the resulting 4-anilino-2-(4-carboxyanilino)-5-chloropyrimidine with 1-(3-aminopropyl)imidazole afforded III [X = Cl; R = 3-(imidazol-1-yl)propylamino]. E.g., the title compound III [X = Br; R = 2-(piperidino)ethylamino] showed IC<sub>50</sub> of 0.235  $\mu$ M when tested in vitro assay for the CDK4 inhibitory activity.

IT	358787-83-4P	358787-84-5P	358787-85-6P
	358787-86-7P	358787-87-8P	358787-88-9P
	358787-89-0P	358787-90-3P	358787-91-4P
	358787-92-5P	358787-93-6P	358787-94-7P
	358787-95-8P	358787-96-9P	358787-97-0P
	358787-98-1P	358787-99-2P	358788-00-8P
	358788-01-9P	358788-02-0P	358788-23-5P
	358788-24-6P	358788-25-7P	358788-26-8P
	358788-27-9P	358788-28-0P	358788-29-1P
	358788-30-4P	358788-31-5P	358788-32-6P
	358788-33-7P	358788-34-8P	358788-35-9P
	358788-36-0P	358788-37-1P	358788-38-2P
	358788-39-3P	358788-40-6P	358788-81-5P
	358788-82-6P	358788-86-0P	


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-di(hetero)arylamino(oxy)-5-substituted pyrimidines as antineoplastic agents)

RN 358787-83-4 CAPLUS


CN Benzamide, 4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)

PAGE 1-A






RN 358787-84-5 CAPLUS  
 CN Benzamide, 4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 358787-85-6 CAPLUS  
 CN Benzamide, 4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 358787-86-7 CAPLUS  
 CN Benzamide, 4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)







RN 358787-87-8 CAPLUS

CN Benzamide, 4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 358787-88-9 CAPLUS

CN Benzamide, 4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(diethylamino)ethyl]- (CA INDEX NAME)




RN 358787-89-0 CAPLUS

CN Benzamide, 4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)




RN 358787-90-3 CAPLUS

CN Benzamide, 4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 358787-91-4 CAPLUS

CN Benzamide, 4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)ethyl]- (CA INDEX NAME)




RN 358787-92-5 CAPLUS

CN Benzamide, 4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(4-thiomorpholinyl)ethyl]- (CA INDEX NAME)




RN 358787-93-6 CAPLUS

CN Benzamide, 3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 358787-94-7 CAPLUS

CN Benzamide, 3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(8-oxa-3-azabicyclo[3.2.1]oct-3-yl)ethyl]- (CA INDEX NAME)




RN 358787-95-8 CAPLUS

CN Benzamide, 3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(4-thiomorpholinyl)ethyl]- (CA INDEX NAME)




RN 358787-96-9 CAPLUS

CN Benzamide, 3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)



RN 358787-97-0 CAPLUS


CN Benzamide, 3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)



RN 358787-98-1 CAPLUS


CN Benzamide, 3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(4-

morpholinyl)ethyl]- (CA INDEX NAME)




RN 358787-99-2 CAPLUS

CN Benzamide, 3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)




RN 358788-00-8 CAPLUS

CN Benzamide, 3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 358788-01-9 CAPLUS

CN Benzamide, 3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(diethylamino)ethyl]- (CA INDEX NAME)



RN 358788-02-0 CAPLUS


CN Benzamide, 3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX NAME)



RN 358788-23-5 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(1H-imidazol-1-yl)propyl]- (CA INDEX NAME)


PAGE 1-A






RN 358788-24-6 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (CA INDEX NAME)




RN 358788-25-7 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(1H-indol-3-yl)ethyl]- (CA INDEX NAME)




RN 358788-26-8 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(4-morpholinyl)propyl]- (CA INDEX NAME)



RN 358788-27-9 CAPLUS


CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 358788-28-0 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

PAGE 1-A









RN 358788-29-1 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(dibutylamino)propyl]- (CA INDEX NAME)




RN 358788-30-4 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-(3-butoxypropyl)- (CA INDEX NAME)




RN 358788-31-5 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[3-(methylthio)propyl]- (CA INDEX NAME)




RN 358788-32-6 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(dibutylamino)ethyl]- (CA INDEX NAME)



RN 358788-33-7 CAPLUS


CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(2-thienyl)ethyl]- (CA INDEX NAME)




RN 358788-34-8 CAPLUS

CN Methanone, [4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenyl][4-(1-pyrrolidinyl)-1-piperidinyl]- (CA INDEX NAME)


PAGE 1-A






RN 358788-35-9 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-(imidazo[1,2-a]pyridin-2-ylmethyl)- (CA INDEX NAME)




RN 358788-36-0 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 358788-37-1 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)ethyl]- (CA INDEX NAME)



RN 358788-38-2 CAPLUS


CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(methylthio)ethyl]- (CA INDEX NAME)




RN 358788-39-3 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 358788-40-6 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[(5-methyl-2-furanyl)methyl]- (CA INDEX NAME)




RN 358788-81-5 CAPLUS

CN Benzeneacetamide, N-[2-[[bis(1-methylethyl)amino]ethyl]-4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 358788-82-6 CAPLUS

CN Benzeneacetamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 358788-86-0 CAPLUS

CN Benzamide, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-N-[2-(diethylamino)ethyl]- (CA INDEX NAME)


IT 358789-02-3P 358789-03-4P 358789-05-6P  
358789-19-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2,4-di(hetero)aryl amino(oxy)-5-substituted pyrimidines as antineoplastic agents)


RN 358789-02-3 CAPLUS

CN Benzoic acid, 4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 358789-03-4 CAPLUS

CN Benzoic acid, 3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 358789-05-6 CAPLUS

CN Benzoic acid, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 358789-19-2 CAPLUS

CN Benzoic acid, 4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-, methyl ester (CA INDEX NAME)



OSC.G 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 60 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2000:457043 CAPLUS  
 DN 133:89537  
 TI Preparation of 2,4-pyrimidinediamine derivatives as anticancer agents  
 IN Bradbury, Robert Hugh; Breault, Gloria Anne; Jewsbury, Philip John; Pease, Janet Elizabeth  
 PA Astrazeneca UK Limited, UK  
 SO PCT Int. Appl., 137 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039101	A1	20000706	WO 1999-GB4325	19991220
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2352896	A1	20000706	CA 1999-2352896	19991220
	EP 1140860	A1	20011010	EP 1999-962375	19991220
	EP 1140860	B1	20040922		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 9916590	A	20011023	BR 1999-16590	19991220
	JP 2002533446	T	20021008	JP 2000-591012	19991220
	AU 763091	B2	20030710	AU 2000-18743	19991220
	NZ 512118	A	20030829	NZ 1999-512118	19991220
	AT 277020	T	20041015	AT 1999-962375	19991220
	ES 2228145	T3	20050401	ES 1999-962375	19991220
	CN 1285580	C	20061122	CN 1999-816278	19991220
	IL 143806	A	20090615	IL 1999-143806	19991220
	ZA 2001004413	A	20020829	ZA 2001-4413	20010529
	NO 2001003038	A	20010822	NO 2001-3038	20010619
	NO 319815	B1	20050919		
	MX 2001006575	A	20011203	MX 2001-6575	20010625
	US 6593326	B1	20030715	US 2001-868602	20010823
PRAI	GB 1998-28511	A	19981224		
	WO 1999-GB4325	W	19991220		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 133:89537

AB The present invention relates to the title compds. (I) [wherein R1 = H, (un)substituted alkyl, alkenyl, or alkynyl, benzyl, 2-phenylethyl, phthalimidoalkyl, or cycloalkylalkyl; Rx = halo, OH, NO2, NH2, CN, SH, CO2H, SO2NH2, NHCHO, ureido, etc.; Q1 and Q2 = independently (un)substituted aryl, 5- or 6-membered monocycle, or 9- or 10-membered bicyclic heterocycle], processes for their manufacture, and pharmaceutical compns. containing them. For example, addition of 4-[2-hydroxy-3-(N,N-dimethylamino)propoxy]aniline•HCl in MeOH to 5-bromo-2-chloro-4-(indan-5-ylamino)pyrimidine in BuOH (preps. given) and heating to 100°C for 18 h gave II (42%). I inhibited the effects of cyclin-dependent serine/threonine kinases (CDKs), showing selectivity for CDK2 (no data), CDK4 (IC50 ranging from 0.02 μM to 0.07 μM), and

CDK6 (no data). In a tyrosine kinase activity assay using Sf21 cells transfected with plaque-pure FAK recombinant virus, I also inhibited focal adhesion kinase 3 (FAK3) with IC50 ranging from 0.032  $\mu$ M to 0.07  $\mu$ M. Typical IC50 values for I when tested for inhibition of cell growth in an Sulforhodamine B (SRB) assay were in the range of 1 mM to 1 nM. Thus, I possess anti-cancer properties, including anti-cell-migration, antiproliferation and/or apoptotic properties. Such properties are expected to be of value in the treatment of disease states associated with aberrant cell cycles and cell proliferation such as cancers (solid tumors and leukemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, hemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases, and ocular diseases with retinal vessel proliferation.


IT 280578-83-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2,4-pyrimidinediamine anticancer agents by coupling halopyrimidines with anilines and optional derivatization)

RN 280578-83-8 CAPLUS

CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)- (CA INDEX NAME)



IT 280578-93-0P 280579-01-3P 280579-49-9P  
 280579-54-6P 280579-90-0P 280580-27-0P,  
 4-Anilino-5-chloro-2-{4-[2-hydroxy-3-(isopropylamino)propoxy]anilino}pyrimidine 280580-29-2P  
 280580-65-6P 280580-70-3P 280580-71-4P  
 280580-73-6P 280580-74-7P 280580-75-8P  
 280580-77-0P 280580-79-2P 280580-80-5P  
 280580-82-7P 280580-83-8P 280580-84-9P,  
 4-Anilino-5-bromo-2-{4-[2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy]anilino}pyrimidine 280580-85-0P,  
 4-Anilino-5-bromo-2-{3-[2-hydroxy-3-(4-methylpiperazin-1-yl)propoxy]anilino}pyrimidine 280580-86-1P,  
 4-Anilino-5-bromo-2-{4-[3-(4-methylpiperazin-1-yl)propoxy]anilino}pyrimidine 280580-87-2P,  
 4-Anilino-5-bromo-2-{3-[3-(4-methylpiperazin-1-yl)propoxy]anilino}pyrimidine 280580-88-3P  
 280580-89-4P 280580-91-8P 280580-94-1P  
 280580-96-3P, 4-Anilino-5-bromo-2-[4-(3-morpholinopropoxy)anilino]pyrimidine dihydrochloride  
 280580-98-5P 280581-26-2P,  
 4-Anilino-5-bromo-2-{4-[2-hydroxy-3-(N',N'-dimethylhydrazino)propoxy]anilino}pyrimidine 280581-27-3P  
 280581-28-4P 280581-29-5P 280581-30-8P




280581-31-9P      280581-32-0P      280581-33-1P,  
 4-Anilino-5-bromo-2-{4-[3-ethoxy-2-(hydroxy)propoxy]anilino}pyrimidine  
 280581-35-3P, 4-Anilino-5-bromo-2-(4-{N-[2-hydroxy-3-(N,N-  
 dimethylamino)propyl]-N-methylamino}anilino)pyrimidine  
 280581-36-4P, 4-Anilino-5-bromo-2-{4-[2-hydroxy-2-methyl-3-  
 (isopropylamino)propoxy]anilino}pyrimidine      280581-38-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 2,4-pyrimidinediamine anticancer agents by coupling halopyrimidines with anilines and optional derivatization)


RN 280578-93-0 CAPLUS

CN 2-Propanol, 1-[4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)- (CA INDEX NAME)




RN 280579-01-3 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[4-[[5-fluoro-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)




RN 280579-49-9 CAPLUS

CN Benzamide, 4-[[5-bromo-2-[[4-[3-(dimethylamino)-2-hydroxypropoxy]phenyl]amino]-4-pyrimidinyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 280579-54-6 CAPLUS  
 CN Benzenesulfonamide, 4-[[5-bromo-2-[[4-[3-(dimethylamino)-2-hydroxypropoxy]phenyl]amino]-4-pyrimidinyl]amino]-, hydrochloride (1:1)  
 (CA INDEX NAME)



● HCl


RN 280579-90-0 CAPLUS  
 CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 280580-27-0 CAPLUS

CN 2-Propanol, 1-[4-[[5-chloro-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-[(1-methylethyl)amino]- (CA INDEX NAME)




RN 280580-29-2 CAPLUS

CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-[(1-methylethyl)amino]- (CA INDEX NAME)




RN 280580-65-6 CAPLUS

CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-[(1-methylethyl)(phenylmethyl)amino]- (CA INDEX NAME)




RN 280580-70-3 CAPLUS

CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(cyclopentylamino)- (CA INDEX NAME)



RN 280580-71-4 CAPLUS


CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-[(2-methylpropyl)amino]- (CA INDEX NAME)




RN 280580-73-6 CAPLUS

CN 1-Pyrrolidineethanol,  $\alpha$ -[[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]methyl]- (CA INDEX NAME)


PAGE 1-A






RN 280580-74-7 CAPLUS

CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(methylamino)- (CA INDEX NAME)




RN 280580-75-8 CAPLUS

CN 2-Propanol, 1-amino-3-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)




RN 280580-77-0 CAPLUS

CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(ethylamino)- (CA INDEX NAME)




RN 280580-79-2 CAPLUS

CN 4-Morpholineethanol,  $\alpha$ -[[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]methyl]- (CA INDEX NAME)




RN 280580-80-5 CAPLUS

CN Ethanone, 1-[4-[3-[4-[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-2-hydroxypropyl]-1-piperaziny]- (CA INDEX NAME)




RN 280580-82-7 CAPLUS

CN 2-Propanol, 1-[3-[4-[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-[(1-methylethyl)amino]- (CA INDEX NAME)




RN 280580-83-8 CAPLUS

CN 2-Propanol, 1-[4-[3-[4-[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)




RN 280580-84-9 CAPLUS

CN 1-Piperazineethanol,  $\alpha$ -[[4-[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]methyl]-4-methyl- (CA INDEX NAME)




RN 280580-85-0 CAPLUS

CN 1-Piperazineethanol,  $\alpha$ -[[3-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]methyl]-4-methyl- (CA INDEX NAME)




RN 280580-86-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]-N4-phenyl- (CA INDEX NAME)




RN 280580-87-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[3-[3-(4-methyl-1-piperazinyl)propoxy]phenyl]-N4-phenyl- (CA INDEX NAME)




RN 280580-88-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[3-(diethylamino)propoxy]phenyl]-N4-phenyl- (CA INDEX NAME)




RN 280580-89-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[3-(dimethylamino)propoxy]phenyl]-N4-phenyl- (CA INDEX NAME)



RN 280580-91-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[3-[(1-methylethyl)amino]propoxy]phenyl]-N4-phenyl- (CA INDEX NAME)



RN 280580-94-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[3-(1H-imidazol-1-yl)propoxy]phenyl]-N4-phenyl- (CA INDEX NAME)





RN 280580-96-3 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[3-(4-morpholinyl)propoxy]phenyl]-N4-phenyl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 280580-98-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-[3-(dimethylamino)propyl]amino]phenyl]-N4-phenyl- (CA INDEX NAME)




RN 280581-26-2 CAPLUS

CN 2-Propanol, 1-[4-[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(2,2-dimethylhydrazinyl)- (CA INDEX NAME)




RN 280581-27-3 CAPLUS

CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-3-fluorophenoxy]-3-[(2-methylpropyl)amino]- (CA INDEX NAME)



RN 280581-28-4 CAPLUS


CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-3-fluorophenoxy]-3-(cyclopentylamino)- (CA INDEX NAME)




RN 280581-29-5 CAPLUS

CN 1-Pyrrolidineethanol,  $\alpha$ -[[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-3-fluorophenoxy]methyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 280581-30-8 CAPLUS  
 CN 1-Piperazineethanol,  $\alpha$ -[[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-3-fluorophenoxy]methyl]-4-methyl- (CA INDEX NAME)




RN 280581-31-9 CAPLUS  
 CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-3-fluorophenoxy]-3-(dimethylamino)- (CA INDEX NAME)




RN 280581-32-0 CAPLUS

CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]-3-fluorophenoxy]-3-(2,2-dimethylhydrazinyl)- (CA INDEX NAME)




RN 280581-33-1 CAPLUS

CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-ethoxy- (CA INDEX NAME)




RN 280581-35-3 CAPLUS

CN 2-Propanol, 1-[[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenyl]methylamino]-3-(dimethylamino)- (CA INDEX NAME)



RN 280581-36-4 CAPLUS


CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-2-methyl-3-[(1-methylethyl)amino]- (CA INDEX NAME)



RN 280581-38-6 CAPLUS

CN 2-Propanol, 1-[4-[[5-bromo-4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]-3-(dimethylamino)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



IT 280581-40-0P, 4-Anilino-5-bromo-2-[4-(2,3-epoxypropoxy)-2-fluoroanilino]pyrimidine 280581-41-1P,  
4-Anilino-5-bromo-2-[4-(2,3-epoxypropoxy)anilino]pyrimidine  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of 2,4-pyrimidinediamine anticancer agents by coupling  
halopyrimidines with anilines and optional derivatization)


RN 280581-40-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-fluoro-4-(2-oxiranylmethoxy)phenyl]-N4-phenyl- (CA INDEX NAME)



RN 280581-41-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[4-(2-oxiranylmethoxy)phenyl]-N4-phenyl- (CA INDEX NAME)



OSC.G	76	THERE ARE 76 CAPLUS RECORDS THAT CITE THIS RECORD (81 CITINGS)
RE.CNT	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 61 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2000:161263 CAPLUS  
 DN 132:194385  
 TI Preparation of bis(arylamino)pyrimidine derivatives as anticancer agents  
 IN Breault, Gloria Anne; Pease, Janet Elizabeth  
 PA Zeneca Limited, UK  
 SO PCT Int. Appl., 112 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000012485	A1	20000309	WO 1999-GB2790	19990824
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9954382	A	20000321	AU 1999-54382	19990824
	EP 1107957	A1	20010620	EP 1999-940401	19990824
	EP 1107957	B1	20061018		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
	JP 2002523497	T	20020730	JP 2000-567515	19990824
	AT 342892	T	20061115	AT 1999-940401	19990824
	ES 2274634	T3	20070516	ES 1999-940401	19990824
	HK 1035531	A1	20070330	HK 2001-106036	20010827
	US 20050090493	A1	20050428	US 2004-771118	20040204
	US 7176212	B2	20070213		
PRAI	GB 1998-18989	A	19980829		
	GB 1998-28433	A	19981224		
	WO 1999-GB2790	W	19990824		
	US 2001-763705	B1	20010226		
OS	MARPAT 132:194385				
AB	The title compds. (I) [wherein R1 = H or (un)substituted alkyl, alkenyl or alkynyl; Q1 and Q2 = independently (un)substituted Ph, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, and one or both of Q1 and Q2 is substituted with -X(CH2)nCHY(CH2)mZ; X = CH2, O, S, or NH; Y = H or as defined for Z; Z = OH, SH, NH2, alkoxy, alkylthio, (cyclo)alkylamino, or dialkylamino; n = 1-3; m = 1-3] were prepared as cyclin dependent kinase (CDK) and focal adhesion kinase (FAK) inhibitors. Examples include over 100 syntheses, descriptions of a number of biol. assays with some data, and 7 pharmaceutical formulations. For instance, 2-chloro-4-(2-bromo-4-methylanilino)pyrimidine (preparation given) was coupled with 4-[3-(N,N-dimethylamino)-2-hydroxypropoxy]aniline (preparation given) in BuOH to give II. The latter inhibited CDK4 with IC50 = 0.6 $\mu$ M and FAK with IC50 = 3.3 $\mu$ M. Typical IC50 values for compds. of the invention when tested in the Sulforhodamine B (SRB) cell growth inhibition assay were in the range of 1 mM to 1 nM. I and their pharmaceutically-acceptable salts and in-vivo-hydrolyzable esters are useful as anticancer agents, antiproliferatives, cell migration inhibitors, and apoptotic agents.				
IT	260045-55-4P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT				

(Reactant or reagent)

(intermediate; preparation of bis(arylamino)pyrimidine derivs. as anticancer agents, antiproliferatives, cell migration inhibitors, and apoptotic agents)

RN 260045-55-4 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[4-(2-oxiranylmethoxy)phenyl]-N4-phenyl- (CA INDEX NAME)




IT 260044-97-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of bis(arylamino)pyrimidine derivs. as anticancer agents, antiproliferatives, cell migration inhibitors, and apoptotic agents)

RN 260044-97-1 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[4-[[4-(phenylamino)-2-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)



OSC.G 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS RECORD (32 CITINGS)  
 RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 62 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 1997:457074 CAPLUS  
 DN 127:81461  
 OREF 127:15621a,15624a  
 TI Preparation of substituted 2-anilinopyrimidines as protein kinase inhibitors  
 IN Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive  
 PA Celltech Therapeutics Limited, UK; Davis, Peter David; Moffat, David Festus Charles; Davis, Jeremy Martin; Hutchings, Martin Clive  
 SO PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9719065	A1	19970529	WO 1996-GB2854	19961120
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5958935	A	19990928	US 1996-753041	19961119
	AU 9676314	A	19970611	AU 1996-76314	19961120
	EP 862560	A1	19980909	EP 1996-939171	19961120
	EP 862560	B1	20030402		
	R: CH, DE, ES, FR, GB, IT, LI				
	ES 2195020	T3	20031201	ES 1996-939171	19961120
	US 6235746	B1	20010522	US 1999-249760	19990216
PRAI	GB 1995-23675	A	19951120		
	US 1996-753041	A3	19961119		
	WO 1996-GB2854	W	19961120		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 127:81461

AB The title compds. [I; R1 = H, halo, (un)substituted alkyl, etc.; R2, R3 = (un)substituted alkyl, alkenyl, alkynyl; R4 = H, alkyl; R5 = H, (un)substituted alkyl, alkenyl, alkynyl; R6 = H, halo, (un)substituted NH2, etc.; X = a direct bond, a linker atom, group; R7 = (un)substituted aliphatic, cycloaliph., heteroaliph., heterocycloaliph., aromatic or heteroarom.

group], selective protein kinase inhibitors, particularly the kinases p56lck, p59fyn, ZAP-70 and protein kinase C, and useful in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role, were prepared Thus, treatment of 4-[3-(3-phthalimidopropoxy)phenyl]-N-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine with N2H4.H2O in EtOH afforded I.2HCl [R1 = MeO; R2, R3 = Me; R4-R6 = H; R7 = H2N(CH2)3; X = O] which showed IC50 of 22 nM in the protein kinase assay.

IT 191728-29-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted 2-anilinopyrimidines as protein kinase

inhibitors)


RN 191728-29-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-phenyl-N2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)




OSC.G 87 THERE ARE 87 CAPLUS RECORDS THAT CITE THIS RECORD (97 CITINGS)  
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 63 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 1973:97592 CAPLUS  
 DN 78:97592  
 OREF 78:15663a,15666a  
 TI The 2-and 4-substituted 5-fluoropyrimidines  
 AU Kuz'menko, I. I.; Protsenko, L. D.  
 CS Kiev. Nauchno-Issled. Inst. Farmakol. Toksikol., Kiev, USSR  
 SO Khimiya Geterotsiklicheskikh Soedinenii (1973), (1), 117-19  
 CODEN: KGSSAQ; ISSN: 0132-6244  
 DT Journal  
 LA Russian  
 AB 5-Fluoropyrimidines (I; R = Cl, MeO, EtO, PrO, BuO, PhO, o-, m-,  
 p-MeC<sub>6</sub>H<sub>4</sub>O, o-, p-FC<sub>6</sub>H<sub>4</sub>O, PhNH, o-MeC<sub>6</sub>H<sub>4</sub>NH, p-FC<sub>6</sub>H<sub>4</sub>NH, piperidino; R1 =  
 MeO, EtO, PrO, BuO, o-, m-, p-MeC<sub>6</sub>H<sub>4</sub>O, o-, p-FC<sub>6</sub>H<sub>4</sub>O, PhNH, o-MeC<sub>6</sub>H<sub>4</sub>NH,  
 p-FC<sub>6</sub>H<sub>4</sub>NH, piperidino) were prepared in 70-99% yields by treatment of  
 2,4-dichloro-5-fluoropyrimidine with the appropriate alcoholates,  
 phenolates, aromatic, aliphatic, and heterocyclic amines.  
 IT 40423-76-5P 40423-83-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 40423-76-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-fluoro-N2,N4-bis(2-methylphenyl)- (CA INDEX  
 NAME)



RN 40423-83-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-fluoro-N2,N4-bis(2-methylphenyl)-, hydrochloride  
 (1:?) (CA INDEX NAME)



●x HCl

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

L7 ANSWER 64 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN

AN 1909:238 CAPLUS

DN 3:238

OREF 3:50e-i,51a-b

TI Researches on Pyrimidines, XXXV. The Action of Potassium Thiocyanate on Some Imide Chlorides

AU Johnson, T. B.; Storey, W. F.

CS Sheffield Laboratory of Yale Univ.

SO American Chemical Journal (1909), 40, 131-47

CODEN: ACJOAZ; ISSN: 0096-4085

DT Journal

LA Unavailable

AB A continuation of the study of the action of KSCN on some chlorpyrimidines which shows definitely that in some cases the intermediate thiocyanate can be easily isolated and by heating the dry substance converted into its isomeric form, and, secondly, that certain chlorpyrimidines do not act with KSCN. 2-Ethylmercapto-6-thiocyanpyrimidine, m. 81-2°, is obtained from KSCN in EtOH and 2-ethylmercapto-6-chlorpyrimidine. At ordinary temperatures it does not rearrange into the isothiocyanate (previously described, Am. Chemical J., 36, 136). Rearrangement does take place at 80-90°. Yellow oil, b45-50 200-5°. 2-Ethylmercapto-5-methyl-6-thiocyanpyrimidine is produced by the similar action of KSCN on the analogous chlorpyrimidine, m. 95°. 2-Ethylmercapto-5-brom-6-thiocyanpyrimidine was similarly obtained from the chlorpyrimidine in EtOH, m. 81-2°. It was rearranged into the isothiocyanate by heating to 150-60°, m. 75-80°. 2-o-Toluidino-6-oxypyrimidine was made by heating 2-ethylmercapto-6-oxypyrimidine with o-toluidine, m. 119-20°. The corresponding chlorpyrimidine was produced by heating with POC13, m. 178°. Unacted upon by boiling for 2 hours with KSCN in EtOH. 2-o-Toluidino-6-aminopyrimidine from the chlorpyrimidine and alcoholic NH3 at 140-50°. Yield 100%, m. 124°. 2-Ortho-toluidino-6-anilino-pyrimidine hydrochloride was produced similarly by the action of aniline in C6H6, m. 126°. Base, m. 128°. 2-p-Toluidino-6-oxypyrimidine was produced in the same manner as the corresponding substance given above, m. 270-1°. Its 6-chlorpyrimidine, m. 112-3°, does not act with KSCN when heated for 2 1/2 h. in Me2CO solution. 6-Anilino-pyrimidine-hydrochloride decomposes at 134°. Base, m. 135°. 2-β-Naphthylamino-6-oxypyrimidine, m. 270°. 2-p-Tolyl-4-methyl-6-chlorpyrimidine from the oxypyrimidine and PC15 + POC13, m. 107°. 2-p-Tolyl-4-methyl-6-thiocyan-pyrimidine results from heating the above chlorpyrimidine with KSCN in EtOH, m. 123°. Heated to 130-5° it rearranges into the isothiocyanate, m. 207-8. Probably a polymeric form, since it did not react with NH3. The product obtained from a second experiment, in which the substance was not isolated in pure condition but instead treated with NH4OH for 2 days, gave what is probably 6-thiourea-pyrimidine, m. 145-6°. The corresponding aminopyrimidine from NH3 in EtOH and the chlorpyrimidine, m. 178-9°. The analogous anilino-pyrimidine hydrochloride from PhNH2, m. 269-70°. Base, m. 120-1°. By heating the thiocyanpyrimidine (1 m.) with thiobenzoic acid (1 m.), the thiopyrimidine is produced, m. 114°.

IT 859957-34-9P, Pyrimidine, 4-anilino-2-o-toluino-

860760-71-0P, Pyrimidine, 4-anilino-2-p-toluino-, hydrochloride


860760-72-1P, Pyrimidine, 4-anilino-2-p-toluino-

860760-73-2P, Pyrimidine, 4-anilino-2-o-toluino-, hydrochloride

RL: PREP (Preparation)  
(preparation of)


RN 859957-34-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(2-methylphenyl)-N4-phenyl- (CA INDEX NAME)



RN 860760-71-0 CAPLUS


CN 2,4-Pyrimidinediamine, N2-(4-methylphenyl)-N4-phenyl-, hydrochloride (1:1)  
(CA INDEX NAME)



● HCl


RN 860760-72-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(4-methylphenyl)-N4-phenyl- (CA INDEX NAME)



RN 860760-73-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(2-methylphenyl)-N4-phenyl-, hydrochloride (1:1)  
(CA INDEX NAME)



● HCl

10/568,367

10/568,367

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

367.46

555.96

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-52.48

-52.48

STN INTERNATIONAL LOGOFF AT 11:59:18 ON 22 OCT 2009